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CHAPTER 1 INTRODUCTION
1.1.

Parkinson’s disease
Parkinson’s disease (PD), which was first described by Dr. James

Parkinson in 1817 (Parkinson 2002), is an age-related neurodegenerative
disease that mainly affects the motor system. It has four cardinal symptoms,
namely, bradykinesia, rigidity, resting tremor, and postural instability (Moustafa et
al. 2016, Jankovic 2008). In addition, this disease affects the non-motor system
as well and gives rise to symptoms such as mood changes, cognitive decline,
pain, sleep disturbance, and autonomic dysfunction (Politis et al. 2010). The
severity of both motor and non-motor symptoms progresses during the course of
the disease (Alves, Forsaa, Pedersen, Gjerstad, et al. 2008).
Two pathological hallmarks of PD have been described in literature. One
is the progressive loss of dopaminergic neurons in the substantia nigra cons
compacta (SNpc); the other is the presence of intraneuronal proteinaceous
deposits named Lewy bodies (LBs) or Lewy neurites (LNs) (Dauer and
Przedborski 2003). The neuropathological-clinical correlations based on multiple
studies have suggested that the initial motor signs in PD may occur when
experiencing around 30% of total substantia nigra neurons loss (Grosch, Winkler,
and Kohl 2016).
1.2.

Statistics about PD
PD is the second most common neurodegenerative disorder following

Alzheimer’s disease and affects around ten million people worldwide (Parkinson's
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Disease Foundation). In the industrialized countries, the prevalence of PD is
estimated to be approximately 0.3% in the entire population or 1% of the
population over the age 60 (de Lau and Breteler 2006).
According to the World Health Organization, the age-adjusted incidence
rate of PD ranges from 9.7 to 13.8 per 100,000 population per year (World Health
Organization 2006). This rate in the developed countries is estimated to be
approximately 14 per 100,000 population per year in the total population or about
160 per 100,000 population per year for the population aged 65 years or over
(Ascherio and Schwarzschild 2016). It has also been suggested that the
incidence rate of PD increases with age (Hirsch et al. 2016).
The economic burden of PD in the United States has been estimated to be
15.5 billion per year, which covers direct medical costs and indirect costs
including reduced employment, workdays lost due to illness, reduced household
income, higher disability payments (Gooch, Pracht, and Borenstein 2017).
Moreover, the economic burden of PD is expected to escalate further in the
coming decades (Kowal et al. 2013).
1.3.

Pathogenesis of PD
This section reviews the studies on PD pathogenesis as they serve as the

foundation of rational drug design and development. Although the etiology of PD
is still not well-understood, multiple pathological factors including oxidative stress,
mitochondrial dysfunction, α-synuclein (αSN) protein aggregation, as well as
genetic and environmental aspects are strongly implicated in the disease
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progression (Hwang 2013, Bose and Beal 2016, Stefanis 2012, Corti, Lesage,
and Brice 2011, Goldman 2014).
1.3.1. Oxidative stress

Oxidative stress refers to the redox imbalance due to excess reactive
oxygen species (ROS) production over the capability of antioxidant response

(Ray, Huang, and Tsuji 2012). Under physiological conditions, the endogenous
generation of ROS in general involves direct interactions with redox-active metals
and oxygen species through reactions including the Fenton and Haber-Weiss
reactions, in combination with indirect pathways that are mediated by both
mitochondrial and non-mitochondrial ROS-generating enzymes, including
monoamine oxidase (MAO) and nicotinamide adenine dinucleotide phosphate
(NADPH) oxidase (NOX) (Dias, Junn, and Mouradian 2013, Kim et al. 2015).
The consumption of oxygen by brain comprises approximately 20% of the
oxygen supply of the whole body, a large portion of which is converted to ROS
(Johnson, Wilson-Delfosse, and Mieyal 2012). Both the ROS-generating
enzymes and dopamine (DA), an autoxidizable neurotransmitter, render the
dopaminergic neurons more susceptible to oxidative stress (Hwang 2013,
Halliwell 2006). DA itself has been suggested to be a possible source of oxidative
stress due to the fact that excess cytosolic DA can be readily metabolized and
generate ROS (Blesa et al. 2015). Under normal conditions, the vesicular
monoamine transporter (VMAT) sequesters more than 90% of intracellular DA
into storage vesicles and prevent it from excessive accumulation and subsequent
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degradation in the intracellular compartment, which produces neurotoxic species
(Eisenhofer, Kopin, and Goldstein 2004, Caudle et al. 2008). However, in the
presence of insults such as αSN protofibrils, oxidative stress, and certain weak
base compounds, disruption of vesicular DA storage may cause the exposure of
dopamine and promote its metabolism through two pathways leading to the ROS
production (Hastings 2009) (Figure 1). The autoxidation of DA, which may be
facilitated by the presence of transition metal ions, can generate electrondeficient DA quinone species that can react readily with cellular nucleophiles
(Lotharius and Brundin 2002, Hastings 2009). It has been suggested that the
covalent modification of proteins by DA quinones often results in inactivation of
protein functions (Hastings 2009). Moreover, the enzymatic degradation of DA by
MAO-B

enzyme

produces

the

reactive

3,4-dihydroxyphenylacetaldehyde

(DOPAL), which undergoes further inactivation, and hydrogen peroxide (Meiser,
Weindl, and Hiller 2013). The generated hydrogen peroxide can be further
converted to hydroxyl radical by the Fenton reaction mediated by iron leading to
cytotoxicity (Lotharius and Brundin 2002). Additionally, the level of iron in SN has
been reported to be significantly higher than in other brain regions due to its
binding affinity to neuromelanin, and it was further elevated in the SN of PD
patients (Lotharius and Brundin 2002).
In addition to mechanisms involving DA metabolism, several studies have
suggested a role for NOX enzymes, which mainly reside on the cellular
membrane and can generate superoxide anions by coupling NADPH-derived
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electrons with oxygen (Sorce, Krause, and Jaquet 2012, Zhao et al. 2017). It has
also been proposed that the elevation of NOX1 and NOX2 may contribute to the
dopaminergic neuronal loss in PD brain via NOX-derived ROS (Ma et al. 2017).

Figure 1. Non-enzymatic and enzymatic metabolism of DA (modified based on
Lotharius and Brundin 2002). DA can undergo autoxidation and lead to the
formation of ROS, including dopamine quinone species (SQ•), superoxide anion
(O2•-), and hydrogen peroxide (H2O2). It can also be metabolized by MAO-B
enzyme and produce hydrogen peroxide that can be further converted by the
Fenton reaction.

As for the ROS removal, several postmortem studies have revealed a
decrease in the amount of reduced glutathione (GSH), which is a major
component of cellular antioxidant defenses, relative to glutathione disulfide
(GSSG) (GSH:GSSG ratio) in the SN of the PD brain compared to the controls
(Dias, Junn, and Mouradian 2013, Martin and Teismann 2009). Furthermore,
altered GSH-dependent enzyme activity caused by the mutations that correlate
with PD has also been reported, such as the mutation of Glutathione STransferases P1 (GSTP1), an enzyme that has an important role in dopaminergic
nerve cell survival (Johnson, Wilson-Delfosse, and Mieyal 2012). The effect of
GSH depletion includes the inhibition of mitochondrial complex I, E1 ubiquitin
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ligase, and proteasome activity and also the activation of the JNK pathway,
leading to an inflammatory response (Martin and Teismann 2009).
As a consequence of oxidative stress, increased levels of oxidized protein,
lipid, and DNA have been observed in the SN of PD subjects (Limongi and
Baldelli 2016). Furthermore, the structures and functions of macromolecules
have been proposed to be altered by ROS through direct or indirect oxidative
modifications of small molecules that either comprise or interact with the
macromolecules, which can disturb nucleic acid stability, protein homeostasis,
the functionality of ion channels, and cellular self-defenses leading to the
neurodegeneration of PD (Zhao et al. 2017).
1.3.2. Mitochondrial dysfunction
Mitochondria is where oxidative phosphorylation takes place (Winklhofer
and Haass 2010). A reduced activity of mitochondrial complex I has been
observed in the SN, platelets, and skeletal muscle of PD subjects (Schapira 2006,
Hauser and Hastings 2013). A number of observations, including defects in the
activity of the mitochondrial electron transport complex, a reduction of
mitochondria movement, and an increase in the mitochondrial permeability
transition have been reported in the toxin models of mitochondrial dysfunction
(Bose and Beal 2016). Studies have also suggested that defects in mitochondria,
especially

complex I, can lead to neurodegeneration as they result in an

elevated ROS level and a decreased ATP level (Moore et al. 2005, Winklhofer
and Haass 2010).
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Certain gene mutations that can cause mitochondrial dysfunction are
known to play a role in familial forms of PD (Bose and Beal 2016). Point
mutations and deletions in gene Parkin, PINK1, and DJ-1 have been reported to
cause familial/early-onset PD (Subramaniam and Chesselet 2013, Hauser and
Hastings 2013).
1.3.3. Protein aggregation
In addition to oxidative stress and mitochondrial dysfunction, protein
aggregation has also been suggested to be critically involved in PD pathogenesis
(Stefanis 2012). As a part of neurodegenerative process, the accumulation of
proteins will result in the formation of proteinaceous inclusions (LBs or LNs),
whose presence is one of the pathological hallmarks of PD (Dauer and
Przedborski 2003). The main component of these inclusions has been identified
to be αSN through immunohistochemical staining in the early studies (Spillantini
et al. 1997, Spillantini et al. 1998). Furthermore, to date six N-terminal missense
mutations (A30P, E46K, H50Q, G51D, A53E, A53T) in the α-synuclein gene
(SNCA) as well as duplication and triplication of the SNCA locus have been
linked to the autosomal dominant forms of familial PD (Kruger et al. 1998,
Zarranz et al. 2004, Proukakis et al. 2013, Lesage et al. 2013, Pasanen et al.
2014, Polymeropoulos et al. 1997, Chartier-Harlin et al. 2004, Singleton et al.
2003, Wong and Krainc 2017). While the penetrance of SNCA duplication has
been estimated to be approximately 40%, it has been reported to be close to 100%
for triplications and missense mutations (Schulte and Gasser 2011, Goedert
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2015). In addition, the genome-wide association studies (GWAS) on the sporadic
PD patients have revealed a strong association of the SNCA locus and the
sporadic form of PD (Venda et al. 2010). These findings indicate the important
role of αSN in the disease pathogenesis.
1.3.3.1.

Structure and physiological function of αSN

αSN, encoded by the SNCA gene that resides on chromosome 4q21.3q22, is a 14.5 kDa presynaptic protein (Chen et al. 1995, Siddiqui, Pervaiz, and
Abbasi 2016). It consists of 140 amino acids and can be structurally divided into
three domains (Figure 2a). The amphipathic N-terminal domain (from residue 1
to 60) and the hydrophobic non-amyloid component (NAC) domain (from residue
61 to 95) contain seven imperfect 11-residue repeats with a consensus motif
(KTKEGV), which share structural similarity with the class A2 apolipoproteins and
are capable of lipid binding through the formation of helical structures (Jo et al.
2000). The NAC domain can form β-sheets and is believed to be responsible for
the protein aggregation (Giasson et al. 2001, Tuttle et al. 2016). The acidic Cterminal domain (from residue 96 to 140) is rich in glutamate, aspartate, and
proline residues and is highly charged (Barrett and Timothy Greenamyre 2015).
This region has been suggested to have a critical role in interaction with other
proteins and small molecules (Mor et al. 2016). During the interaction with
membranes, the N-terminus helical structure can serve as a membrane anchor,
while the central region has the capacity to modulate the affinity to the
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membranes through acting as a sensor for the lipid properties; however, the Cterminal domain will remain unstructured (Figure 2b) (Fusco et al. 2014).

Figure 2. αSN structure and domains. a) Schematic depiction of the primary
structure of αSN. The N-terminal domain and the non-amyloid component (NAC)
domain are illustrated in light green; the C-terminal domain is shown in grey. The
11-mer imperfect repeats with a consensus motif (KTKEGV) are depicted as
green boxes, and their sequences are listed below as well. Currently identified
disease-associated point mutations are highlighted in yellow. A common spot for
post translational modification (PTM) is indicated. b) Schematic drawing of αSN
bond to the negatively charged membrane.

αSN is traditionally viewed as an intrinsically disordered protein (IDP),
which does not possess defined three-dimensional structures, based on the
biophysical characterization of recombinant αSN purified from E. coli using
techniques such as circular dichroism (CD) spectroscopy and Fourier-transform
infrared (FTIR) spectroscopy (Weinreb et al. 1996, Wang et al. 2016). This
disordered monomeric structure has been reported to be independent of cell lysis
method and heating/acidification for protein purification (Coelho-Cerqueira et al.
2013), and it is also able to adopt α-helical secondary structure upon lipid binding
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(Davidson et al. 1998). In addition, the native αSN purified from mouse brain
without boiling or detergents has been shown as a largely unstructured monomer
that is prone to aggregation (Burre et al. 2013). However, in recent years an
ongoing debate on the native conformation of αSN started. Endogenous αSN
isolated from cell lines, brain tissue and living human cells under non-denaturing
conditions has been proposed to exist mainly as a folded tetramer that resists
aggregation (Bartels, Choi, and Selkoe 2011). Other evidence has demonstrated
that αSN forms physiological multimers, principally tetramers, that have α-helical
conformation (Wang et al. 2011, Dettmer et al. 2015). In another study, αSN has
been observed to exist in a stable monomeric form, in which the NAC domain is
shielded to prevent spontaneous aggregation (Theillet et al. 2016). These
contradicting observations have led to the current postulation that αSN with great
structural flexibility may exist in a dynamic equilibrium between multiple forms
depending on the cellular localization, environment and binding partners (Jain et
al. 2013, Wang et al. 2016, Wong and Krainc 2017).
Although the physiological role of αSN, which predominantly exists in the
presynaptic terminals, is still not fully understood (Calo et al. 2016), it has been
suggested that αSN is importantly involved in synaptic maintenance (Mor et al.
2016). It can participate in synaptic vesicle trafficking (Esposito, Ana Clara, and
Verstreken 2012). αSN may also act as molecular chaperones by cooperating
with Cysteine-string protein α (CSPα). This idea is further supported by the
observation of sequence homology between αSN and 14-3-3 protein chaperones
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and its ability to prevent denatured protein aggregation in vitro (Mor et al. 2016).
Moreover, modulatory role of αSN in dopamine neurotransmission through the
function of soluble NSF attachment protein receptor (SNARE) complex assembly
has been reported (Mor et al. 2016, Gallegos et al. 2015). In addition, αSN may
have a putative role in neurotransmitter synthesis and reuptake through the
modulation of tyrosine hydroxylase (TH), vesicular monoamine transporter 2
(VMAT2),

dopamine

transporter

(DAT)

trafficking

(Butler,

Sambo,

and

Khoshbouei 2016, Mor et al. 2016).
1.3.3.2.

Misfolding and aggregation of αSN

As stated earlier, αSN possesses a great degree of structural flexibility,
which can adopt various conformations in different conditions and exert versatile
functions (Wang et al. 2016). Due to the presence of central hydrophobic region,
αSN can be misfolded into β-sheet enriched αSN assembly that varies in size,
stability, morphology, and potential for further aggregation; this process can be
influenced by factors including the interactions with lipids, small molecules such
as dopamine, or metals such as iron, mutations, post-translational modification
(PTM), oxidative stress and truncation (Lashuel et al. 2013, Majd, Power, and
Grantham 2015, Breydo, Wu, and Uversky 2012) (Figure 3).
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Figure 3. Schematic drawing of αSN misfolding and aggregation (modified based
on Wong and Krainc 2017). Drawings are not to scale. The native protein is
depicted as circles, and the aberrant form is indicated by rectangular shape. The
native αSN may exist in a dynamic equilibrium between multiple conformations.
Under the conditions such as oxidative stress or the presence of metals, αSN can
be misfolded into abnormal β-sheets and tends to aggregate.

Redox-active metal ions can affect the αSN misfolding and aggregation
either through direct interaction that leads to conformational change or via
oxidation (Breydo, Wu, and Uversky 2012). Mutations in the imperfect repeats
extending to the hydrophobic domain may reduce the membrane binding and
cause αSN dissociation, which can subsequently lead to the accumulation of
unfolding forms that favors the formation of oligomeric and/or fibrillar species
(Luna and Luk 2015). Among various PTMs in αSN, phosphorylation of Serine
129 (Figure 2a) is the most well studied, and has been suggested to be the most
pathologically relevant to PD (Barrett and Timothy Greenamyre 2015). Autopsy
of PD brains revealed that about 90% of αSN found in LB is phosphorylated at
S129 in contrast to 4% or less in the normal brain, which suggests a link between
phosphorylation and aggregation (Majd, Power, and Grantham 2015, Tyson,
Steiner, and Brundin 2016, Xu, Deng, and Qing 2015). It has also been
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suggested that phosphorylation of αSN may act as a signal for degradation
(Tyson, Steiner, and Brundin 2016).
1.3.3.3.

Propagation of αSN

The progression of αSN pathology in sporadic PD adopts a distinct pattern,
which can be characterized into six stages and is termed as “Braak staging”
(Braak et al. 2003). This pathology starts from olfactory bulb, the anterior
olfactory

nucleus

and/or

the

dorsal

motor

nuclei

of

the

vagal

and

glossopharyngeal nerves in the brainstem and gradually expands to less
vulnerable nuclear grays and cortical areas (Braak et al. 2003, Goedert et al.
2013). Continuing study based on the “Braak staging” proposed that this
spreading is caused by a neurotropic pathogen that enters the central nervous
system (CNS) through retrograde axonal and transneuronal transport (Hawkes,
Del Tredici, and Braak 2007).
Following these findings, the observation of LB like inclusions in the
grafted neurons in the PD brain years after implantation by two independent
studies suggested “host-to-graft” transmission of αSN pathology (Li et al. 2008,
Kordower et al. 2008). In addition, based on the initial clinical observations,
various in vitro and in vivo models have been developed to simulate αSN
propagation (Rey, George, and Brundin 2016, Gallegos et al. 2015, Hasegawa,
Nonaka, and Masuda-Suzukake 2017). These studies indicated that in addition
to the traditional cell-autonomous mechanism, which means independent
occurrence of protein misfolding and assemblies in many cells, cell non-
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autonomous mechanism may also exist in αSN propagation. (Goedert,
Clavaguera, and Tolnay 2010, Goedert 2015). Moreover, the “prion-like”
propagation has been hypothesized, which suggested that the aberrant αSN has
prion-like properties to convert the normal proteins into abnormal forms and
spread throughout the brain via cell-to-cell transmission (Hasegawa, Nonaka,
and Masuda-Suzukake 2017).
The early in vitro studies and recent models in αSN propagation gave rise
to the “seeding” concept, which was first used to describe Prion protein (PrP)
(Oueslati, Ximerakis, and Vekrellis 2014). As illustrated in Figure 4a, seeding is
a nucleation-dependent mechanism, in which the seeds (the pathogenic species)
generated from rate-limiting nucleation step can recruit adjacent soluble
monomers and serve as a template to accelerate the assembly (Oueslati,
Ximerakis, and Vekrellis 2014).
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Figure 4. Schematic drawing of αSN seeding and propagation mechanism.
Drawings are not to scale. The native protein is depicted as circle, and the
aberrant form is indicated by rectangular shape. a) Seeding of αSN is a
nucleation-dependent mechanism. b) Propagation of αSN via cell-to-cell
transmission (adapted from Oueslati, Ximerakis, and Vekrellis 2014). The donor
cell can release seeds through non-classic secretory pathway or direct release,
and the acceptor cell can internalize them by mechanisms including classical
endocytosis, exosomal transport, receptor-mediated internalization, and direct
membrane penetration.

The transmission of αSN from donor cells to acceptor cells involves
multiple molecular mechanisms (Figure 4b). Studies have shown that αSN can
be released via non-classic secretory pathway, including exocytotic vesicles and
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exosomes, and direct release from injured/dying neurons (Recasens and Dehay
2014, Oueslati, Ximerakis, and Vekrellis 2014). Failure of intracellular clearance
pathways may further exacerbate the pathological release (Recasens and Dehay
2014, Gallegos et al. 2015). Moreover, the uptake of αSN can be achieved
through

classical

endocytosis,

exosomal

transport,

receptor-mediated

internalization, and direct membrane penetration (Gallegos et al. 2015, Recasens
and Dehay 2014, Oueslati, Ximerakis, and Vekrellis 2014).
1.3.3.4.

Toxicity of αSN

The removal of abnormal proteins is critical for the cell survival and
cellular function (Tyson, Steiner, and Brundin 2016). However, A30P and A53T
mutations have been reported to inhibit chaperone-mediated autophagy (CMA);
familial mutations and overexpression of αSN as well as LB-like αSN inclusions
have been shown to inhibit macro autophagy (Tyson, Steiner, and Brundin 2016).
Moreover, defects in quality control and protein degradation machinery may
result in an elevated intracellular αSN concentration, an increase in cell
autonomous aggregation and the chance of seeding by exogenous αSN (Luna
and Luk 2015). In addition, in compromised cells or in cells expressing
aggregation-prone familial forms of αSN, the overwhelmed protein degradation
system may lead to a cascade of pathological events that cause cellular
dysfunction and cell death (Tyson, Steiner, and Brundin 2016).
There is an ongoing debate on whether oligomeric species or fibrils are
the toxic form of αSN. Studies have suggested that PD-linked A53T and A30P
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mutations can accelerate oligomerization rather than fibrillization, and an
increased level of soluble, lipid-dependent oligomers has been observed in both
αSN transgenic mice and PD brains comparing to the controls (Wong and Krainc
2017). The annular protofibrils have been shown to alter membrane permeability
and increase influx of calcium from the extracellular to intracellular space, leading
to cell death (Lashuel et al. 2013). Other studies have demonstrated that fibrils,
when injected into rat SNpc, can significantly induce motor impairment,
dopaminergic cell loss and synaptic impairment, suggesting they might be more
toxic than their precursors (Wong and Krainc 2017).
Both toxic gain-of-function and loss-of-function mechanisms have been
proposed to play a significant role in αSN pathology (Collier et al. 2016,
Winklhofer, Tatzelt, and Haass 2008). The misfolding of αSN caused by
conformational changes can reduce the capacity of αSN in vesicular trafficking
and modulating neurotransmission (Majd, Power, and Grantham 2015).
Furthermore, αSN overexpression can contribute to the impairment of
mitochondrial homeostasis leading to oxidative stress and dopamine oxidation
(Majd, Power, and Grantham 2015). Studies have suggested that oligomers and
aggregates spanning through the cell body and neurites, may cause disruption of
cellular function, including organelle dysfunction, defects in interorganelle
contacts and dysfunctional organelle dynamics (Figure 5) (Wong and Krainc
2017).
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Figure 5. Pathways implicated in α-synuclein toxicity (Wong and Krainc 2017).

1.3.4. Genetic factors
Compared to sporadic PD, familial/early-onset PD, which constitutes less
than 10% of total PD cases, is more tightly associated with genetic factors
(Schapira 2006, Wirdefeldt et al. 2011, Alves, Forsaa, Pedersen, Gjerstad, et al.
2008, Lesage and Brice 2009). Till this decade, more than 16 loci and 11 genes
including aforementioned Parkin, PINK1, DJ-1, and SNCA have been associated
with PD (Corti, Lesage, and Brice 2011, Hernandez, Reed, and Singleton 2016,
Ferreira and Massano 2017).
1.3.5. Environmental factors
The environmental factors include rural living, drinking well water, farming,
and using herbicides or pesticides (Priyadarshi et al. 2001, Schapira 2006,
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Goldman 2014). These risk factors may lead to an increased exposure to
exogenic toxins, many of which are known to have neurotoxicity and can produce
Parkinsonian syndromes in animals (Burbulla and Kruger 2011, Schapira 2006).
It needs to be emphasized that the pathogenesis of PD is multifactorial. As
shown above, all these pathogenic factors are interrelated. A single pathogenic
event may lead to another and initiate a vicious cycle. This provides a great
challenge in PD treatment, which is discussed briefly in the next section.
1.4.

PD treatments
This section reviews the current status of anti-parkinsonian agents in use.

The present treatments available for PD generally fall into four major categories,
namely dopamine replacement therapy, MAO-B inhibitors, catechol-O-methyl
transferase (COMT) inhibitors, and dopamine agonists (Figure 6, 7) (Schapira
2009, Factor 2008).
1.4.1. Dopamine replacement therapy
Levodopa, an orally active precursor of DA, remains the gold standard of
PD treatment (Mercuri and Bernardi 2005, Poewe et al. 2010). Due to the
peripherrial levodopa decarboxylation, which causes limited bioavailability and
poor tolerability, levodopa is commonly admistrated with carbidopa, a DOPA
decarboxylase (DDC) inhibitor (Gershanik 2015). However, the long-term use of
levodopa may induce motor complications, such as motor fluctuations and
dyskinesia, due to the erratic stimulation of DA receptors (Jankovic and Aguilar
2008, Blandini and Armentero 2014). Over the years, interventions, including the
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use of oral, transdermal, and subcutaneous DA agonists, MAO-B or COMT
inhibitors, have been developed to manage motor complications by extending the
duration of striatal DA receptors stimulation (Rascol, Perez-Lloret, and Ferreira
2015).
1.4.2. MAO-B inhibitors
MAO-B is a mitochondrial enzyme that catalyzes the oxidative
deamination of a group of monoamines including DA (Youdim, Edmondson, and
Tipton 2006). MAO-B inhibitors have been suggested to be a class of medication
that is relatively safe and well tolerated (Robakis and Fahn 2015). The first FDA
approved selective irreversible MAO-B inhibitor, selegiline, is commonly used as
either monotherapy or an adjunct in moderately advanced PD; however, its Lamphetamine-like metabolic products can cause sympathomimetic side effects
such as insomnia (Robakis and Fahn 2015, Teo and Ho 2013). Rasagiline, a
second generation propargylamine-based selective irreversible MAO-B inhibitor,
in contrast to selegiline, is free from generating such metabolic products (Teo
and Ho 2013). It is usually used alone or with other PD medications in early-tolate stages of PD (Robakis and Fahn 2015). They function by delaying the
metabolism of DA and reducing the generation of ROS (Jankovic and Aguilar
2008). In March 2017, safinamide, a selective reversible MAO-B inhibitor with
additional pharmacologic properties including blocking of voltage-dependent
sodium channels and inhibiting glutamate release, has been approved by FDA as
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an adjuvant therapy to levodopa/carbidopa for PD patients experiencing “off”
episodes (Stocchi and Torti 2016, The Food and Drug Administration).
1.4.3. COMT inhibitors
Agents such as entacapone and tolcapone have been used as adjuvants
to increase levodopa bioavailability and prolong DA response by inhibiting COMT,
which is an enzyme involved in DA degradation (Jankovic and Aguilar 2008,
Bonifacio et al. 2007). When levodopa/DDC inhibitor formulations used in
combination with COMT inhibitors, more continuous plasma behaviour and
weakening in levodopa/DDC inhibitor related homocysteine increase, a
biomarker for an impaired methylation capacity, have been observed (Muller
2015).
1.4.4. Dopamine agonists
Dopamine agonists, which mimic DA, can directly activate dopaminergic
receptors (Lev, Djaldetti, and Melamed 2007). They can be used as monotherapy
mainly in the early stage of PD in order to delay

levodopa-induced motor

complications or combined with levodopa in advanced PD (Jankovic and Aguilar
2008, Blandini and Armentero 2014). Currently, the clinical use of ergot
dopamine agonists has been drastically reduced due to side effects (Factor 2008,
Blandini and Armentero 2014). Non-ergot dopamine agonists, such as
pramipexole (PPX) and ropinirole, have been shown to be effective in the early
stage of PD (Jankovic and Aguilar 2008). Furthermore, in addition to being
effective for treating drug-resistant tremor in PD, studies have also suggested
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that PPX is able to inhibit the phosphorylation of αSN induced by inhibition of the
ubiquitin proteasomal system through a machnism independent of DA receptor
activation (Constantinescu 2008, Chau, Cooper, and Schapira 2013).

Figure 6. Chemical structures of pharmacological treatments for PD.
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Figure 7. Mechanism of treatments available for PD (adapted based on Jankovic
and Aguilar 2008). Abbreviations: COMT, catechol-O-methyl-transferase; 3-OMD,
3-O-methyldopa; DDC: DOPA decarboxylase; DA, dopamine; BBB, blood-brain
barrier; 3-MT, 3-methoxytramine; MAO, monoamine oxidase; ALDH, aldehyde
dehydrogenase; HVA, homovanillic acid; DOPAC, 3,4-dihydroxyphenylacetic
acid.

Although great progress has been made in PD research throughout the
years, the benefits provided by these current treatments are mostly symptom
relieving and there are still no curative treatments for PD (Jones, Moussaud, and
McLean 2014). Furthermore, these anti-parkinsonian agents suffer from the loss
of efficacy as the disease progresses (Jankovic and Aguilar 2008, Blandini and
Armentero 2014). Thus, there is still a great unmet need for the development of
neuroprotective and disease-modifying therapeutics, which can delay or halt the
disease progression. Rationally designed anti-parkinsonian agents that target the
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aforementioned pathogenic factors are desirable in terms of providing more
effective and safe treatment for PD.
1.5.

Potential therapeutic targets and treatments under development
This section reviews the potential therapeutic targets that have been

identified and proposed for PD treatment as well as the development of newer
generation of therapeutic agents. Events such as oxidative stress, mitochondrial
dysfunction, and αSN protein aggregation have been proposed as major potential
therapeutic targets to combat PD due to their significant involvement in the PD
pathogenesis (Jiang, Sun, and Chen 2016, Moreira et al. 2010, Dehay et al. 2015,
Lee and Trojanowski 2006, Hwang 2013, Bose and Beal 2016, Stefanis 2012).
For targeting oxidative stress, the use of antioxidants, which scavenge
reactive species, has been suggested, and both direct-acting or indirect-acting
methods have been explored (Jiang, Sun, and Chen 2016, Tarazi et al. 2014,
Patel 2016). Moreover, the mitochondrial dysfunction has been targeted by
mechanisms including the modulations of PD-related genetic mutants,
mitochondrial proteins, and the consequences of mitochondrial dysfunction (Luo
et al. 2015). Here, the therapeutic development strategies and rationale for
targeting αSN aggregation and MAO-B enzyme are discussed in detail below.
1.5.1. Therapeutic development targeting αSN aggregation
As described previously, the identification of αSN as the main component
in LBs or LNs and the genetic association of αSN with familial PD have
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suggested the critical involvement of αSN in PD pathogenesis and thus, a highly
relevant target for therapeutic development (Stefanis 2012, Dehay et al. 2015).
In general, the strategies that have been proposed to combat αSN toxicity
include reducing αSN production, increasing αSN clearance, modulating αSN
aggregation either directly or indirectly via small molecules (Yacoubian and
Standaert 2009, Dehay et al. 2015). The reducing αSN production approach has
been proposed by applying techniques such as small interfering RNA (siRNA) or
microRNA (miRNA) (Lashuel et al. 2013). Furthermore, activation of proteosomal
or lysosomal pathways, promotion of chaperone function, and vaccine-based
therapies have been commonly proposed for increasing αSN clearance
(Yacoubian and Standaert 2009). Here, only the αSN aggregation modulation
strategy is discussed, and the molecules targeting αSN aggregation, especially
the polyphenolic compounds and derivatives, are focused on.
1.5.1.1.

Polyphenolic compounds as αSN aggregation modulators

Over the years, naturally occurring polyphenolic compounds and their
derivatives, such as epigallocatechin gallate (EGCG), baicalein, curcumin, gallic
acid, and resveratrol (Figure 8), have been substantially investigated for their
modulatory effect on αSN aggregation. It has been proposed that polyphenolic
compounds, such as EGCG, baicalein, and curcumin, in general may function by
inducing the formation of soluble non-toxic oligomers (Ardah et al. 2014).
However, there are still variations in their effects. Baicalein has been found to
inhibit oligomer formation and disaggregate existing oligomers (Hu et al. 2016).
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Studies have suggested that EGCG may function by immobilizing the Cterminal region of αSN and moderately reducing the binding of oligomers to
membranes, and gallic acid may function by stabilizing the non-toxic oligomeric
αSN through oligomer binding (Lorenzen et al. 2014, Ardah et al. 2014). Recently,
the optimized cocktail of curcumin and β-cyclodextrin (β-CD) has been shown to
inhibit aggregation and greatly disaggregate preformed aggregates (Gautam et al.
2014). In addition, the similar effect has been reported for the polyphenol–β-CD
combinations formed by baicalein, EGCG, and resveratrol (Gautam et al. 2017).
Furthermore, rifampicin (Figure 8), an antibiotic, has also demonstrated to
preferentially stabilize the non-toxic monomeric and soluble oligomeric forms of
αSN (Li et al. 2004).

Figure 8. Examples of known αSN aggregation modulators

The mechanism of action (Figure 9) of these polyphenolic compounds
has been speculated to be that they can be readily converted into quinone

27

structure to interact with αSN and alter the aggregation pathway (Ardah et al.
2014). Further analysis has suggested that the lysine (Lys) residues on αSN can
undergo nucleophilic attack towards the electrophilic center of the quinone group
(Li et al. 2005, Labenski et al. 2009). In addition, these polyphenolic compounds
may be viewed as candidates of pathologically activated therapeutic, as they can
be activated in response to oxidative stress, which plays a crucial role in the
pathogenesis of PD (Figure 10) (Lipton 2007).

Figure 9. Possible interaction between Lys residue and quinone moiety (Li et al.
2005).

Figure 10. Schematic drawing of pathologically activated therapeutics design
(modified based on Lipton 2007).

1.5.1.2.

Other molecules as αSN aggregation modulators
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In addition to the polyphenolic moiety, other molecules have also been
studied on. A molecular tweezer, CLR01, has been developed to directly bind to
the αSN monomer near the N terminus, which alters its charge distribution,
swells the chain, and increases protein reconfiguration rate (Figure 11b)
(Acharya et al. 2014). In addition, cyclic peptides (CPs), such as CP1 and CP2,
and their derivatives have been reported as a new class of αSN aggregation
modulators to prevent fibrillation and decrease the cytotoxicity of aggregates
(Figure 11a) (Luo and Abrahams 2014). In another study, a class of binding
proteins termed β-wrapins with affinity for αSN has been engineered and has
been demonstrated to inhibits αSN aggregation and toxicity by interfering with the
nucleation phase of aggregation (Mirecka et al. 2014).

Figure 11. Examples of other type of αSN aggregation modulators a) scaffold of
cyclic peptides (CPs) (Luo and Abrahams 2014); b) molecular tweezer, CLR01
(Acharya et al. 2014).

1.5.2. Therapeutic development targeting MAO-B
The two isoforms of MAO, which are the major neurotransmitter-degrading
enzymes in the central nervous system (CNS), are tightly associated with the
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mitochondrial outer membrane (Binda et al. 2002, Youdim, Edmondson, and
Tipton 2006). Despite of approximately 70% identity of amino acid sequence,
they differ in substrate specificities and tissue distribution (Youdim, Edmondson,
and Tipton 2006). While neurotransmitters such as serotonin and norepinephrine
are preferentially metabolized by the MAO-A isoform, phenylethylamine is mainly
metabolized by the MAO-B isoform (Youdim and Riederer 2004). In addition, it
has been suggested that the level of MAO-B is near 6-fold higher than the MAOA in the human SNpc, and both isoforms appear to equally metabolize DA (Tong
et al. 2013, O'Carroll et al. 1983).
As displayed in Figure 12a, the crystal structure of human MAO-B is
dimeric with extensive monomer-monomer interactions, and the C-terminal tail
region is responsible for the membrane attachment (Binda et al. 2002). The
structure of a single monomer is shown in Figure 12b: the side chain of
isoleucine199 functions as a gate separating the hydrophobic entrance cavity
and substrate cavity, and the flavin adenine dinucleotide (FAD) coenzyme is
covalently bound in an 8α-thioether linkage to cysteine397 at the distal end of the
substrate cavity (Edmondson, Binda, and Mattevi 2007).
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Figure 12. Structure of human MAO-B enzyme. a) Ribbon diagram of the MAO-B
dimer, which has monomer A displayed on the right and monomer B on the left
(Binda et al. 2002). The flavin moiety is shown in yellow in a ball and stick model.
The flavin binding domain and the substrate domain are colored in red, and the
C-terminal membrane binding domain is shown in green. b) Ribbon diagram of
human MAO-B monomer (Edmondson, Binda, and Mattevi 2007). The flavin
moiety is shown in yellow in a ball and stick model. The flavin binding domain is
shown in blue, the substrate domain in red and the C-terminal membrane binding
domain in green.

1.5.2.1.

Rationale for targeting MAO-B

As mentioned previously, MAO-B catalyzes the deamination of DA and
generates reactive aldehyde, hydrogen peroxide, and ammonia (Figure 1)
(Meiser, Weindl, and Hiller 2013). While the reactive aldehyde derived from
dopamine degradation does not appear to accumulate in the healthy brain, a
great reduction in the level of aldehyde dehydrogenase observed in the PD brain
may cause the aldehydes to adduct with amine groups and generate toxic
species (Youdim, Edmondson, and Tipton 2006). In addition, neurotoxicity may
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also derive from Fenton reaction that involves iron and hydrogen peroxide,
another product from DA metabolism by MAO-B (Youdim and Bakhle 2006).
It has been reported that MAO-B level adopts a distinct developmental
pattern: its activity remains constant during early childhood and rise during
advanced age (Nicotra et al. 2004). Multiple studies have suggested that both the
content and activity of MAO-B increase with aging in mammalian species,
including humans (Nicotra et al. 2004). Moreover, increased level of MAO-B in
PD subjects has been observed as a consequence of gliosis (Youdim,
Edmondson, and Tipton 2006). Subsequently, increased level of the catalytic
reaction products, DOPAL and hydrogen peroxide, which may promote apoptotic
signaling events resulting in the dopaminergic cell loss, and reduced level of
dopamine may take place (Edmondson et al. 2009). In addition to the age-related
increase of brain MAO-B level, increase of brain iron with aging may further the
Fenton reaction and hydroxyl radical generation (Youdim and Bakhle 2006).
Thus, when targeting the MAO-B with enzyme inhibitors, increased level
of monoamine that is available to the membrane receptors and decreased level
of toxic products may be achieved, which may have a beneficial effect on the
treatment of PD (Youdim and Bakhle 2006). Although DA is also metabolized by
MAO-A isoform, due to the “cheese effect”, which refers to a hypertensive crisis
caused by the hindered metabolism of tyramine and other sympathomimetic
amines by MAO-A, the use of non-selective MAO inhibitors requires dietary
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restrictions (Youdim and Riederer 2004, Youdim, Edmondson, and Tipton 2006).
Therefore, selective MAO-B inhibitors are preferred.
1.5.2.2.

MAO-B inhibitors under development

The common molecular scaffolds of MAO-B inhibitors under development
can be categorized into propargylamines and oxygen or nitrogen heterocycles
(Finberg 2014, Helguera et al. 2012, Reis et al. 2012). These heterocyclic
scaffolds are usually originated from privileged structures, including coumarins,
chalcones, chromones, pyrazoles, xanthines, and isatins (Reis et al. 2012,
Carradori and Silvestri 2015). Here, only the propargyl-based MAO-B inhibitors
are briefly reviewed.
Following the development and clinical application of neuroprotective
MAO-B inhibitors, selegiline and rasagiline, various compounds with propargyl
functional moiety have been studied. One of the most well-known examples is
compound M30, a multi-target drug functioning by iron chelation and MAO-B
inhibition, and its analog, VAR10303, has also been studied in details (Figure 13)
(Gal et al. 2006, Bar-Am et al. 2015). Furthermore, other highly potent and
selective MAO-B inhibitors have also been developed through templates shown
in Figure 13 (Huleatt et al. 2015, Can et al. 2017).
In addition to the MAO-B inhibition, studies have revealed the
neuroprotective effect of the propargylamine derivatives in cellular and animal
models; however, this effect is independent from MAO-B inhibition but probably
mediated through apoptosis signaling pathways (Tatton, Chalmers-Redman, and
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Tatton 2003). Rasagiline, the FDA approved MAO-B inhibitor, for example, has
been shown to maintain mitochondrial integrity and up-regulate neurotrophic
factors (Weinreb et al. 2010). The multi-target compound M30 has shown
neuroprotective effect in neuronal cell culture, and similar to rasagiline, its
mechanism has been suggested to be by regulating the anti-apoptotic Bcl-family
proteins and PKC activation (Gal et al. 2006). Moreover, both M30 and its analog
VAR10303 have displayed neuroprotective effect in PD animal models (Gal et al.
2006, Bar-Am et al. 2015).

Figure 13. Examples of MAO-B inhibitors.
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CHAPTER 2 HYPOTHESIS AND SPECIFIC AIMS
Parkinson’s disease (PD), the second most common neurodegenerative
disorder, gives rise to a wide array of clinical features ranging from motor to nonmotor symptoms. In addition to levodopa, the gold standard treatment, various
therapeutic treatments have been explored and developed over the years,
including dopamine receptor agonists, monoamine oxidase (MAO) inhibitors, and
catechol-O-methyltransferase (COMT) inhibitors (Factor 2008). However, these
current available clinical treatments are only able to provide symptomatic relief
and fail to delay the disease progression (Tarazi et al. 2014). Furthermore, the
long-term use of levodopa leads to motor complications including dyskinesia
(Jankovic and Aguilar 2008). Thus, there is still a great unmet need for effective
PD treatment.
2.1.

Hypothesis

PD is a chronic and progressive disease, and its pathogenesis has been
identified to be multifactorial (Alves, Forsaa, Pedersen, Dreetz Gjerstad, et al.
2008). Due to the complexity observed in the disease pathogenesis, treatments
that address the pathogenic factors involved in PD might offer an advantage in
combating the disease by delaying the disease progression. The hypothesis of
this project is that the incorporation of dopamine D2/D3 agonistic component with
accessory moieties targeting α-synuclein (αSN) aggregation or MAO enzyme has
the potential to provide both symptom relieving and disease modifying effects as
a promising approach for new generation PD treatment.
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2.2.

General aim
The general aim of this work is to develop a library of compounds that link

the dopamine D2/D3 agonistic moiety with additional functional moieties targeting
either αSN aggregation or MAO enzyme based on the previously established
hybrid structure approach to conduct a structure-activity relationship (SAR) study
and discover possible lead compounds through both in vitro and in vivo
evaluations.
2.3.

Specific aims

2.3.1. Ligand design and synthesis
a) Design and synthesize of novel dopamine D2/D3 receptor agonists that
can potentially modulate αSN aggregation by incorporating dihydroxy
or hydroxyl-methoxy component with D2/D3 agonist fragment through a
linker based on the hybrid molecular template. A SAR study has been
carried out to assess the effect of linker and dihydroxy or monohydroxy
phenolic structure modifications.
b) Design and synthesize of novel dopamine D2/D3 receptor agonists that
can potentially inhibit MAO-B enzyme activity by incorporating the
propargyl group with D2/D3 agonist fragment based on the hybrid
molecular template. An initial SAR study has been conducted based on
the generated compound library.
2.3.2. In vitro radioligand binding assay using [3H]-spiperone
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The synthesized compounds have been evaluated for their in vitro affinity
towards the D2 and D3 dopamine receptors by using radioligand binding assays.
2.3.3. In vitro functional assay using [35S]-GTPγS
Based on the binding affinity, compounds were selected and further
evaluated for their functional activity through an in vitro functional assay.
2.3.4. In vitro neuroprotection study
In addition to the receptor assays, selected lead compounds have been
assessed for their potential neuroprotective effect through the neurotoxin-based
in vitro models, 6-hydroxydopamine (6-OHDA) or rotenone model in PC12 cells.
2.3.5. In vitro αSN aggregation study
Selected lead compounds containing the dihydroxy phenolic moiety has
been tested for their ability to modulate αSN aggregation through in vitro studies,
including shaking and seeding assays.
2.3.6. In vitro MAO inhibition assay
Selected lead compounds containing the propargyl group has been
evaluated for their ability to inhibit MAO enzyme activity through in vitro
enzymatic assay experiments.
2.3.7. In vivo assays with rat model of PD
Selected lead compounds have been examined further for their in vivo
potency in a PD animal model, the reserpine-induced hypolocomotion rat model.
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* CHAPTER 3 & 4 CONTAIN MATERIAL FROM PUBLISHED WORK IN
WHICH I WAS THE FIRST AUTHOR. THE CO-AUTHORS OF THESE
PUBLICATIONS AGREE TO THE USE OF THE PUBLISHED DATA IN THIS
DISSERTATION.

CHAPTER 3 RESULTS AND DISCUSSION
3.1.

Overview
The first main objective is to design and develop a series of novel

dopamine D2/D3 receptor agonists that can potentially modulate α-synuclein
(αSN) aggregation by combining the dihydroxy or hydroxy-methoxy component
with D2/D3 agonist fragment through various linkers according to the hybrid
molecular template. Based on the results of in vitro receptor assays, compounds
were selected and further evaluated to determine their potential αSN aggregation
modulatory

properties

and

neuroprotective

effect.

Subsequently,

lead

compounds were identified by using a well-established Parkinson’s disease (PD)
animal model. The second main objective is to design and synthesize a series of
novel dopamine D2/D3 receptor agonists that may potentially inhibit monoamine
oxidase B (MAO-B) activity by introducing the propargyl group into the hybrid
molecular template. An initial structure-activity relationship (SAR) study was
conducted based on the generated compound library through in vitro receptor
assays and enzymatic studies. Moreover, in vitro neuroprotection models and a
PD animal model were also used to further evaluate potential candidates. Thus,
this chapter will describe the following:
1) Chemistry involved in generating compound libraries
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2) In vitro binding data for all the compounds and functional activity data
for selected compounds
3) In vitro αSN aggregation modulation data for selected compounds
4) In vitro MAO inhibition data for selected compounds
5) In vitro neuroprotection data for selected compounds
6) In vivo efficacy data for selected compounds
All the experimental details, including synthesis procedures, spectral data,
and protocols for in vitro and in vivo biological evaluations will be described in
Chapter 4.
3.2.

Design, synthesis, and the initial SAR study of novel multifunctional
dopamine D2/D3 receptors agonists with potential neuroprotection
and anti-αSN aggregation properties
In continuation of our work for the development of multifunctional

dopamine D2/D3 receptor agonists for the symptom-relieving and diseasemodifying treatment of PD based on the hybrid structure strategy, which has led
to the successful identification of several potent and promising lead compounds
including D-520 and D-512 (Figure 14) early on, a modified hybrid molecule
template has been developed. This molecular template (Figure 15) joined the
headgroups derived from the known dopamine D2/D3 receptor agonists,
pramipexole and 5-hydroxy-N,N-dipropyl-2-aminotetralin (5-OH-DPAT), with the
dihydroxy or hydroxy-methoxy component, which has been demonstrated to
modulate αSN aggregation, through an alkyl linker, which replaced the piperazine
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ring linker in the previous template design as seen in the lead compounds D-520
and D-512. In the current study, the influence of various linkers along with the
introduction of dihydroxy or hydroxy-methoxy functionalities has been explored to
evaluate the effect of linker length, the saturation state of linker, and hydroxy or
methoxy substitutions on D2/D3 agonist potencies. In addition to these alkyl linker
compounds, a para-dihydroxy substituted analog of a previously developed lead
compound D-520, (−)-49 (D-670), was also designed and synthesized. In the
previous studies, lead compound D-520 has shown a great effect in the αSN
aggregation inhibition and neuroprotection against 6-OHDA-induced toxicity in
addition to its potent and efficacious D2/D3 receptor agonistic activities seen in
both in vitro and in vivo studies (Modi et al. 2014). Thus, it is interesting to
include its para-substituted analog (−)-49 (D-670) in this study to briefly assess
the effect of ortho- vs. para- dihydroxy substitution.
Following the initial characterization via in vitro binding assay and GTPγS
binding functional assay, compounds were selected for further in vitro biological
evaluation to assess their neuroprotective effect and their ability to modulate αSN
aggregation. Finally, selected compounds were tested in vivo in a wellestablished PD animal model.
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Figure 14. Molecular structures of dopamine D2/D3 receptor agonists.

Figure 15. The hybrid molecule template for multifunctional dopamine D2/D3
receptor agonists that may potentially modulate αSN aggregation.

3.2.1. Synthesis of multifunctional αSN modulators

41

Scheme 1 describes the synthesis of a series of compounds where the 2aminothiazole head group is attached to various diphenol- or methoxyphenol
fragments via five-carbon alkyl linkers. One 5-hydroxy aminotetralin analog is
also included in this scheme. Commercially available ethyl 4-bromobutyrate (1)
was reacted with triphenylphosphine (TPP) to give phosphonium bromide 2,
which was subjected to the Wittig olefination with aldehydes 3a or 3b using
sodium hexamethyldisilazide (NaHMDS) to obtain preferentially (Z:E > 20:1) (Z)alkene products 4a and 4b, respectively. Their stereochemistry was confirmed by
a smaller coupling constant (J = 11.2 Hz) observed for the Z-isomers as opposed
to a larger vicinal coupling (J = 16 Hz) obtained for the corresponding (E)isomers. Pd/C-catalyzed hydrogenation of 4a and 4b yielded corresponding
saturated intermediates 5a and 5b. Then these esters were reduced to
aldehydes 6a and 6b by using diisobutylaluminium hydride (DIBALH). Reductive
amination with sodium triacetoxyborohydride was used to couple 6a and 6b with
(±)- or (−)-pramipexole to give (±)-7a (D-548), (−)-7a (D-591), (±)-7b, and (−)-7b,
respectively, which were then reacted with boron tribromide to yield
corresponding dihydroxy-compounds (±)-8a (D-575), (−)-8a (D-593), (±)-8b (D584), and (−)-8b (D-601). The (Z)-isomer of 4a was separated by normal phase
silica gel chromatography and used to synthesize target compound (±)-12 (D567). tert-Butyldimethylsilyl (TBS) protection of 4a yielded intermediate 9, which
was reduced to alcohol 10 by DIBALH and then oxidized to aldehyde
intermediate 11 by pyridinium chlorochromate (PCC) oxidation. Deprotection of
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the TBS group and subsequent reductive amination gave the final compound (±)12 (D-567). Compound (−)-14 (D-644), the aminotetralin analog of (−)-8a (D-593),
was synthesized by coupling aldehyde 6a with (−)-5-methoxy-N-propyl-2aminotetralin through reductive amination followed by demethylation using
hydrobromic acid.

Scheme 1. Synthesis of compounds (±)-7a (D-548), (−)-7a (D-591), (±)-8a (D575), (−)-8a (D-593), (±)-8b (D-584), (−)-8b (D-601), (±)-12 (D-567), and (−)-14
(D-644). Reaction and Conditions: (a) TPP, toluene, reflux, 16 h; (b) NaHMDS,
THF, −78 °C to rt, 48 h; (c) 10% Pd/C, H2, EtOH, rt, 2 h; (d) DIBALH, toluene,
−78 °C, 2 h; (e) (±), (−)-pramipexole or (−)-5-methoxy-N-propyl-2-aminotetralin,
NaBH(OAc)3, CH2Cl2, rt, 36 h; (f) BBr3, CH2Cl2, −78 °C to rt, 6 h; (g) TBDMSCl,
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imidazole, DMF, rt, 2 h; (h) DIBALH, THF, −10 °C to rt, 6 h; (i) PCC, CH2Cl2, 0 °C
to rt, 9h; (j) TBAF, THF, 0 °C, 1.5 h; (k) 48% HBr, reflux, 6 h.

Scheme 2. Synthesis of compounds (±)-20 (D-604) and (−)-20 (D-618). Reaction
and Conditions: (a) TPP, toluene, reflux, 16 h; (b) HMDS, n-BuLi, THF, 0 °C, 15
min; (c) vanillin, LiHMDS, THF, rt, 24 h; (d) CH3COCl, MeOH, 0 °C to rt, 4 h; (e)
DIBALH, toluene, −78 °C, 2 h; (f) (±) or (−)-pramipexole, NaBH(OAc)3, CH2Cl2, rt,
36-48 h.

Scheme 2 depicts the synthesis of additional five-carbon linker containing
compounds, (±)-20 (D-604) and (−)-20 (D-618), where the unsaturated linker
fragment is in the (E)-conformation. Phosphonium salt 16 was first prepared by
reacting 4-bromobutyric acid (15) with TPP. Then the Wittig olefination of 16 with
vanillin (3a) using freshly prepared lithium hexamethyldisilazide (LiHMDS) gave
preferentially (E:Z > 10:1) (E)-alkene intermediate 17. 17 was converted to its
corresponding methyl ester 18, and its (E)-isomer (J = 15.6 Hz) was separated
by column chromatography. Reduction to aldehyde followed by reductive
amination with (±)- or (−)-pramipexole gave target compounds (±)-20 (D-604) and
(−)-20 (D-618).

44

Scheme 3. Synthesis of compound (±)-26 (D-606). Reaction and Conditions: (a)
HMDS, n-BuLi, THF, 0 °C, 15 min; (b) vanillin, LiHMDS, THF, rt, 24 h; (c) 10%
Pd/C, H2, EtOH, rt, 2 h; (d) CH3COCl, MeOH, 0 °C to rt, 4 h; (e) DIBALH, toluene,
−78 °C, 2 h; (f) (±)-pramipexole, NaBH(OAc)3, CH2Cl2, rt, 48 h.

Scheme 3 describes the synthesis of target compound (±)-26 (D-606),
which

contains

a

saturated

six-carbon

linker.

Commercially

available

phosphonium salt 21 was reacted with vanillin (3a) in the presence of freshly
prepared LiHMDS resulting preferentially in (E)-alkene product 22. This
unsaturated carboxylic acid precursor was reduced through Pd/C-catalyzed
hydrogenation and converted to corresponding methyl ester 24. Final compound
(±)-26 (D-606) was obtained by the reduction of ester intermediate 24 to
aldehyde 25 followed by the reductive amination of 25 with (±)-pramipexole.
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Scheme 4. Synthesis of compounds (±)-32 (D-547), (±)-33 (D-573), and (±)-38
(D-570). Reaction and Conditions: (a) TPP, toluene, reflux, 16 h; (b) 1 M NaOH
aq., 15 min; (c) vanillin, CHCl3, reflux, 5 h; (d) 10% Pd/C, H2, EtOH, rt, 2 h; (e)
DIBALH, toluene, −78 °C, 2 h; (f) (±)-pramipexole, NaBH(OAc)3, CH2Cl2, rt, 36-48
h; (g) BBr3, CH2Cl2, −78 °C to rt, 6 h; (h) TBDMSCl, imidazole, DMF, rt, 2 h; (i)
DIBALH, THF, −10 °C to rt, 6 h; (j) MnO2, CH2Cl2, rt, 24h; (k) TBAF, THF, 0 °C, 1
h.

Scheme 4 shows the synthesis of another series of compounds with
three-carbon linkers connecting the tetrahydrobenzo 2-aminothiazole head group
to a diphenol- or methoxyphenol fragment. (E)-alkene intermediate 29 was
prepared via the Wittig reaction. Pd/C-catalyzed hydrogenation was used to
generate saturated ester precursor 30, which was then converted to aldehyde 31
by DIBALH. Target compound (±)-32 (D-547) was prepared by the reductive
amination of aldehyde 31 with (±)-pramipexole. Demethylation was then
achieved to obtain target compound (±)-33 (D-573). To prepare compound (±)-38
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(D-570), intermediate 29 was first protected and reduced to alcohol 35. Then
aldehyde 37 was synthesized by the oxidation of alcohol intermediate 35 using
manganese dioxide followed by the deprotection of TBS group in intermediate 36.
The aldehyde intermediate 37 was then reacted with (±)-pramipexole to yield
final compound (±)-38 (D-570).

Scheme 5. Synthesis of compounds (±)-44&45 (D-592). Reaction and Conditions:
(a) BBr3, CH2Cl2, −78 °C to rt, 6 h; (b) TBDMSCl, imidazole, DMF, rt, 2 h; (c)
phosphonium bromide 2, NaHMDS, THF, −78 °C to rt, 48 h; (d) DIBALH, toluene,
−78 °C, 2 h; (e) (±)-pramipexole, NaBH(OAc)3, CH2Cl2, rt, 36 h; (f) TBAF, THF,
0 °C, 1.5 h.

Scheme 5 outlines synthesis of D-592, a mixture of compounds (±)-44, 45
as deduced from NMR and mass spectroscopy (m/z [M + H]+: major 388.46,
minor 386.44). Air oxidation of the catechol to the corresponding dione could be
a result of stabilization from an extended conjugation in the dione state. Prior to
coupling to the phosphonium salt through Wittig reaction, aldehyde 3a was first
demethylated and TBS-protected by tert-butyldimethylsilyl chloride (TBDMSCl) to
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give intermediate 40. After the Wittig olefination with phosphonium bromide 2,
reduction to aldehyde intermediate 42 was achieved by chemistry described
above. Subsequent reductive amination of 42 with (±)-pramipexole resulted in
intermediate (±)-43, which was deprotected to give D-592 as a mixture of
compounds (±)-44 and 45.

Scheme 6. Synthesis of compound (−)-49 (D-670). Reaction and Conditions: (a)
oxalyl chloride, DMSO, CH2Cl2, Et3N, −78 °C to rt, 2 h; (b) (−)-5-methoxy-Npropyl-2-aminotetralin, NaBH(OAc)3, CH2Cl2, rt, 40 h; (c) 48% HBr, reflux, 6.5 h.

Scheme 6 describes the synthesis of compound (−)-49 (D-670), which is
the analog of D-520. Alcohol intermediate 46 (Modi et al. 2014) was oxidized to
its corresponding aldehyde 47 using the Swern oxidation, and the subsequent
reductive amination with (−)-5-methoxy-N-propyl-2-aminotetralin was conducted
in the presence of sodium triacetoxyborohydride. Then the demethylation by
hydrobromic acid was used to produce the final compound (−)-49 (D-670).
3.2.2. In vitro receptor assays with multifunctional αSN modulators
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In the current SAR study to explore the effect of structural variations in the
linker region that connects the D2/D3 agonistic head group with accessory binding
site moiety, the replacement of the piperazine ring in the lead compounds, such
as D-520, with saturated and unsaturated alkyl linkers was pursued. By varying
the alkyl chain length, compounds with three to six carbon linkers were designed.
The effect of linker length on the D2/D3 binding affinity can be inferred from
compounds in the saturated series, which includes (±)-32 (D-547), (±)-7a (D-548),
and (±)-26 (D-606). Among them, compound (±)-26 (D-606) with a six-carbon
linker exhibited the highest affinity for both D2/D3 receptors (Ki, D2=58.5 nM,
D3=0.675 nM, Table 1). Compound (±)-7a (D-548), which has a five-carbon linker,
also displayed potent binding affinity at D3 receptor (Ki, D3=3.62 nM) and
moderate affinity for D2 receptor (Ki, D2=175 nM). However, the three-carbon
linker compound (±)-32 (D-547) gave much weaker binding, especially for D2
receptor (Ki, D2=2,404 nM, D3=15.8 nM). These results suggest that linker length
has a considerable effect on the binding affinity of these compounds: lengthening
the linker chain from three-carbon to six-carbon greatly improves the affinity for
both D2 receptor (by 41-fold) and D3 receptor (by 23-fold). The high activity of the
six-carbon linker compound (±)-26 (D-606) could be because of better
accessibility and/or interactions of the tetrahydrobenzo 2-aminothiazole head
group moiety at the D2/D3 receptors binding sites. The binding data of (±)-32 (D547) also suggests that a greater selectivity for D3 receptor could be achieved by
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connecting the head group and the accessory binding fragment through a linker
with appropriate length.
The increasing trend of receptor binding affinity may indicate lesser steric
hindrance occurred between the phenyl ring in the designed molecules and the
binding pocket of receptors when extended linkers were incorporated. It may also
be reasoned that a six- or a five-carbon linker could confer more flexibility; thus,
(±)-26 (D-606) and (±)-7a (D-548) may adopt different conformations than the
corresponding three-carbon linker compound (±)-32 (D-547). Towards this end,
conformational restrictions were introduced in the linker portion through insertion
of a double bond. Further, with an aim to impart potential neuroprotective
property, a conjugated double bond, as in curcumin, was particularly envisaged
resulting in substituted styrene accessory binding fragments. The effect of
introducing a double bond in the linker portion is more complicated. For
compounds containing three-carbon linkers, the incorporation of an (E)-double
bond in compound (±)-38 (D-570) greatly reduced the binding affinity for both D2
and D3 receptors in comparison to its corresponding saturated linker analog (±)32 (D-547) (Ki, D2= 4,634 vs. 2,404 nM, D3= 39.1 vs. 15.8 nM, Table 1). For a
five-carbon linker saturated analog (±)-7a (D-548) (Table 1), the introduction of
an (E)-double bond as in (±)-20 (D-604) improved binding affinity at D2 receptor
(Ki, D2=150 nM) and was also tolerated at D3 receptor (Ki, D3=4.24 nM). To
determine the effect of stereochemistry, corresponding (Z)-isomer analog,
compound (±)-12 (D-567), was also synthesized. As predicted, stereochemistry
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did influence the binding affinity as the (Z)-isomer analog (±)-12 (D-567)
displayed reduced affinity at both D2 and D3 receptors (Ki, D2=233 nM, D3=23.3
nM) when compared to its saturated (±)-7a (D-548) and the (E)-isomer
counterpart (±)-20 (D-604). These results suggest that the length along with the
stereochemistry of linkers influences the binding of compounds at both D2 and D3
receptors. Overall, this SAR study demonstrates that the piperazine ring present
in the previous lead compounds could be replaced by an appropriate alkyl linker
in the present series of compounds while maintaining affinity and potency.
Next, the focus was placed on the terminal accessory binding fragment
that is designed to impart multifunctional properties to the designed compounds
for combating neurodegeneration in PD. Structural motifs present in naturallyoccurring compounds including polyphenols and curcumin, were substituted as
the accessory binding fragments. Effects of various hydroxyl or methoxy
substitutions on the phenyl ring were investigated through compounds (±)-7a (D548), (±)-8a (D-575), (±)-32 (D-547), and (±)-33 (D-573). Compounds with either
an ortho- or a para-substitution on the aromatic ring were explored, as such
substitution has a potential of forming a quinone/semiquinone moiety for αSN
aggregation. Compound (±)-7a (D-548), with a hydroxyl at the p-position and a
methoxy at the m-position, exhibited potent binding affinity for D3 receptor (Ki,
D3=3.62 nM) and moderate affinity for the D2 receptor (Ki, D2=175 nM). The
replacement of m-methoxy group in (±)-7a (D-548) with a hydroxyl group
resulting in (±)-8a (D-575) exhibited a moderate improvement for both D2 and D3
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binding (Ki, D2=116 nM, D3=2.59 nM, Table 1). Among the three-carbon linker
analogs, the dihydroxyl analog (±)-33 (D-573) showed a significant increase in
affinity for D2 receptor (Ki, D2=499 nM) as compared to the hydroxy-methoxy
substituted analog (±)-32 (D-547) (Ki, D2= 2,404 nM); however, for D3 binding,
(±)-33 (D-573) (Ki, D3=11.9 nM) showed little or no enhancement over (±)-32 (D547) (Ki, D3=15.8 nM). These results demonstrate that the dihydroxy-compounds
(±)-8a (D-575) and (±)-32 (D-547) exhibited better binding profiles. Next, to briefly
assess the effect of substituent position, compound (±)-8b (D-584), having
hydroxyls at the 2′- and 5′-positions, was synthesized. This compound exhibited
comparable binding affinity for D2 receptor and a slightly improved binding for D3
receptor compared to its counterpart (±)-8a (D-575) (Ki, D2= 117 vs. 116 nM, D3=
1.01 vs. 2.59 nM). Thereafter, to investigate the effect of a dihydroxyl substituent
in the presence of an unsaturated linker, compound (±)-44 was designed and
synthesized. However, probably as a result of air oxidation, the resulting
compound was obtained as an inseparable mixture of (±)-44 and dione (±)-45
which showed moderate affinity for both D2 and D3 receptors (Ki, D2=121 nM,
D3=25.0 nM).
Our previous studies have demonstrated that compounds with (−)-(S)isomer of pramipexole as the head group generally resulted in greater binding
affinity than their (+)-(R)- isomer counterparts (Das et al. 2015). Thus, (−)isomers of selected compounds 7a, 8a, 8b, 20 were synthesized. Compounds
(−)-7a (D-591) (Ki, D2=68.3 nM, D3=1.57 nM) and (−)-8a (D-593) (Ki, D2=65.7 nM,
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D3=1.42 nM) demonstrated improved binding profile, particularly for the D2
receptor, in comparison to their racemic counterparts (±)-7a (D-548) and (±)-8a
(D-575), respectively. Compound (−)-8b (D-601) exhibited a binding Ki, for D3
(0.78 nM) that was among the higher affinity values observed in this series of
compounds. In general, (S)-isomers displayed somewhat higher binding affinities
for both D2/D3 receptors than their racemic counterparts except for (−)-20 (D-618)
(Ki, D2=123 nM, D3=22.3 nM), where a decrease of D3 binding and little or no
change in D2 binding were observed.
A bioisosteric replacement of the 2-aminothiazole head group in
compound (−)-8a (D-593) with an aminotetralin moiety to give (−)-14 (D-644) was
performed. In consistence with our previous data, the aminotetralin analog (−)-14
(D-644) (Ki, D2=4.67 nM, D3=0.493 nM) showed much better binding affinity at
both D2 and D3 receptors compared to the 2-aminothiazole derivative (−)-8a (D593) (Ki, D2=65.7 nM, D3=1.42 nM).
In addition to these alkyl linker compounds, (−)-49 (D-670), the paradihydroxy analog, was studied in pair with its ortho-substituted parent compound
D-520. Comparing to D-520, the newly developed para-substituted analog
exerted a visible reduction in affinity towards both D2/D3 receptors with a
comparable D2/D3 receptor selectivity (Ki, D2= 79.5 vs. 41.8 nM, D3= 0.643 vs.
0.350 nM, D2/D3 = 124 vs. 119, for (−)-49 (D-670) and D-520, respectively, Table
1), suggesting a modest effect of the ortho- to para- dihydroxy substitutions on
receptor binding in the current scaffold.
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Table 1. Ki values (nM) for inhibition of [3H] spiroperidol binding (HEK - D2,3
cells)a (cLogP and tPSA values are calculated using ChemDraw)

Compound

Ki (nM), [3H]spiperone

D2L/D3 cLogP tPSA

dopamineb

D2L
990 ± 198

D3
101 ± 14.9

10

(−)-5-OH-DPAT

153 ± 32

2.07 ± 0.38

74

(±)-7a, D-548

175 ± 8

3.62 ± 0.78

48

4.42

71.08

(−)-7a, D-591

68.3 ± 12.0

1.57 ± 0.41

43

4.42

71.08

(±)-8a, D-575

116 ± 8

2.59 ± 0.31

45

3.97

82.08

(−)-8a, D-593

65.7 ± 11.7

1.42 ± 0.14

46

3.97

82.08

(±)-8b, D-584

117 ± 17

1.01 ± 0.28

116

3.85

82.08

(−)-8b, D-601

112 ± 8

0.78 ± 0.20

143

3.85

82.08

(±)-12, D-567

233 ± 8

23.3 ± 4.0

10

4.12

71.08

(−)-14, D-644

4.67 ± 0.65

0.493 ± 0.067

9

5.22

63.93

(±)-20, D-604

150 ± 20

4.24 ± 0.74

35

4.12

71.08

(−)-20, D-618

123 ± 18

22.3 ± 2.2

6

4.12

71.08
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(±)-26, D-606

58.5 ± 7.3

0.675 ± 0.178

87

4.95

71.08

(±)-32, D-547

2,404 ± 29

15.8 ± 2.0

153

3.36

71.08

(±)-33, D-573

499 ± 16

11.9 ± 1.9

42

2.92

80.08

(±)-38, D-570

4,634 ± 325

39.1 ± 5.4

119

3.26

71.08

(±)-44&45, D-592

121 ± 21

25.0 ± 1.96

5

N/A

N/A

(−)-49, D-670

79.5 ± 7.7

0.643 ± 0.089

124

5.72

70.41

D-520b

41.8 ± 11.2

0.350 ± 0.101

119

6.09

70.41

a

Results are expressed as means ± SEM for three to four experiments, each
performed in triplicate.
b Data was obtained under almost identical assay conditions (Zhen et al. 2015,
Modi et al. 2014).

The optically active compounds 7a, 8a, 8b, 14 and 20 were also assessed
by measuring the stimulation of [35S]GTPγS binding in comparison to dopamine,
the full agonist, to evaluate their ability of activating human dopamine hD2 and
hD3 receptors expressed in CHO cells. Compounds (−)-7a (D-591), (−)-8a (D593), (−)-8b (D-601), (−)-14 (D-644), and (−)-20 (D-618) exerted high functional
potency and efficacy at both D2/D3 receptors (Table 2). In contrast to the more
selective binding affinity observed for D3 receptor, all tested compounds turned
out to be comparably potent and full agonist at both D2 and D3 receptors.
Compound (−)-7a (D-591) was the most potent among the 2-aminothiazole
derivatives with a very high functional potency (EC50 (GTPγS); D2 =2.09 nM and
D3 =0.78 nM) and full agonist activity (%Emax, D2=96.2, D3=94.4) at both D2 and
D3 receptors. Similarly, compound (−)-8b (D-601) also turned out to be an
agonist with comparable potency (EC50 (GTPγS); D2=9.3 nM and D3=1.22 nM).
On the other hand, the aminotetralin analog (−)-14 (D-644), showed a non-
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selective profile (D2/D3=0.82). When compared to its 2-aminothiazole derivative
counterpart (−)-8a (D-593), a great improvement in potency at both D2/D3
receptors (EC50 (GTPγS); D2 =0.27 vs. 22.9 nM and D3 =0.33 vs. 2.62 nM for (−)14 (D-644) and (−)-8a (D-593), respectively) was observed. As for the efficacy, a
decrease at D2 receptor and an increase at the D3 receptor were observed when
comparing compound (−)-14 (D-644) to (−)-8a (D-593) (%Emax, D2= 88.8 vs.
97.4, D3=90.9 vs. 83.4) (Luo et al. 2016).
When comparing the para-dihydroxy substituted compound (−)-49 (D-670)
to its ortho-substituted counterpart D-520, it was interesting to notice a modest
increase in the potency to both D2/D3 receptors in contrast to the decrease in the
binding affinity from the aforementioned binding assay (EC50 (GTPγS); D2 =2.75
vs. 4.73 nM and D3 =0.0827 vs. 2.18 nM, for (−)-49 (D-670) and D-520,
respectively, Table 2). In addition, compound (−)-49 (D-670) became more
selective for D3 receptor (D2/D3 = 33.25 vs. 2.17, Table 2). On the other hand,
while the efficacy of compound (−)-49 (D-670) to the D2 receptor remained the
same when compared to D-520, it was found to be enhanced for D-670 in the
case of the D3 receptor (%Emax, D2= 81.8 vs. 80.9, D3=86.4 vs. 58.3, for (−)-49
(D-670) and D-520, respectively, Table 2).

Table 2. Stimulation of [35S]GTPγS Binding to hD2 and hD3 receptors expressed
in CHO cellsa
Compound

CHO-D2

CHO-D3

D2/D3
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[35S]GTPγS
EC50 (nM)

%Emax

[35S]GTPγS

%Emax

EC50 (nM)

Dopamine

376 ± 39

100

7.26 ± 0.21

100

51.79

(−)-7a, D-591

2.09 ± 0.22

96.2 ± 2.3

0.78 ± 0.10

94.4 ± 4.2

2.68

(−)-8a, D-593

22.9 ± 1.6

97.4 ± 3.6

2.62 ± 0.49

83.4 ± 8.2

8.74

(−)-8b, D-601

9.3 ± 2.49

88.0 ± 3.6

1.22 ± 0.30

90.9 ± 5.5

7.62

(−)-14, D-644

0.27 ± 0.62

88.8 ± 3.5

0.33 ± 0.09

90.9 ± 2.6

0.82

(−)-20, D-618

37.7 ± 5.6

84.3 ± 3.6

20.4 ± 5.8

87.5 ± 6.2

1.85

(−)-49, D-670

2.75 ± 0.10

81.8 ± 7.2 0.0827 ± 0.0048 86.4 ± 4.5 33.25

D-520b

4.73 ± 0.44

80.9 ± 6.6

2.18 ± 0.30

58.3 ± 9.6

2.17

a

Results are expressed as means ± SEM for three to five experiments, each
performed in triplicate.
b Data was obtained under almost identical assay conditions (Modi et al. 2014)

3.2.3. In vitro anti-aggregation study
So far the effects of structural variations in the designed compounds on
the receptor activities have been studied and discussed. In this section, focus will
be cast on the ability of selected compounds to modulate αSN aggregation,
which was tested through both the shaking and seeding studies.
3.2.3.1.

Shaking study

In this experiment, αSN was continuously shaken at aggregation-prone
conditions for six days to produce β-sheet-positive fibrillar structures, which can
be detected by thioflavin T (ThT). Aliquots were taken in the beginning (day 0)
and the end (day 6) of this experiment, and they were characterized through both
transmission

electron

microscope

(TEM)

and

circular

dichroism

(CD)

spectroscopy. As shown in Figure 16, the morphology of αSN transferred from
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the initial spherical look (day 0) to fibrillar structure at the endpoint of the study
(day 6). Further protein secondary structure analysis through far-UV CD spectra
revealed a significant reduction in the intensity of the negative shoulder around
203 nm, suggesting a more structured state (Figure 17).

Figure 16. TEM analysis of samples collected in the αSN (60 µM) shaking
experiment. (a) aliquot at day 0, (b) aliquot at day 6; Scale bar = 100 nm.

10

w a v e le n g th (n m )

C D (m D e g )

0

-1 0

200

220

240

260

0 D S h a k in g
6 D S h a k in g

-2 0

-3 0

Figure 17. Circular dichroism spectra analysis of samples collected in the αSN
(60 µM) shaking experiment.
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The potential candidate compound (−)-8a (D-593) was first evaluated
through this shaking experiment in comparison to the reference compound D-520:
αSN was shaken in the presence or absence of the tested compound (1:2 ratio)
at aggregation-prone conditions for six days. Aliquots collected at day 0 and day
6 were analyzed by both ThT and cell viability assay. When tested for cell
viability, the collected aliquots were diluted with cell medium for the treatment
with the PC12 cells. The final concentrations resulted from the dilution were 10
µM for αSN and 20 µM for the compounds.
A significant inhibition of ThT activity was observed at day 6 in the
presence of the test compound (−)-8a (D-593) or reference compound D-520
compared to αSN alone, indicating alteration of the aggregation process in the
presence of these drugs (Figure 18a). However, while D-520 increased the cell
viability by 24%, this new compound failed to generated a similar effect to reduce
the cytotoxicity induced by αSN in the current assay condition: only a statistically
non-significant 9% increase in cell viability was detected (Figure 18b).
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Figure 18. Modulation of compound (−)-8a (D-593) on the aggregation of αSN
induced by shaking. Tested compound (−)-8a (D-593) and reference compound
D-520 (120 µM) were incubated with αSN (60 µM) over a period of 6 days. Drugs
were also tested alone to show any direct effect on assays. a) Fibrillation was
measured by ThT assay. Readings from ThT assay were normalized by
assigning the reading of αSN alone day 0 sample as 100%. The data are shown
as means ± SEM of three independent experiments. One-way ANOVA followed
by Tukey’s multiple comparison post hoc test was performed (#### p ≤ 0.0001
compared to the αSN-0D, **** p ≤ 0.0001 compared to the αSN sample at
corresponding time points). b) Cell viability was measured by MTT assay.
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Readings were normalized to the untreated control. The data are shown as
means ± SEM of three independent experiments. One-way ANOVA followed by
Tukey’s multiple comparison post hoc test was performed (## p ≤ 0.01, #### p ≤
0.0001 compared to the untreated control, **** p ≤ 0.0001 compared to the αSN
sample at corresponding time points).
3.2.3.2.

Seeding study

The shaking assay has been widely accepted and applied in the screening
for αSN aggregation modulators, and the continuous agitation considerably
shorten the experimental time span. However, the fact that it was done in
aggressive agitation conditions renders it relatively artificial in terms of mimicking
the actual αSN aggregation process in the PD brain. An in vitro seeding assay
without any shaking has been developed recently to overcome this drawback
while trying to maintain a relatively short experimental time span (Yedlapudi et al.
2016).
In this experiment, ThT-positive preformed fibrils (PFF), the αSN seeds,
were first generated by shaking at aggregation-prone condition, which were
subsequently added to and incubated with αSN monomers over the time.
Aliquots were taken in the beginning (day 0) and every 10 days throughout this
assay, and they were characterized via both transmission electron microscope
(TEM) and circular dichroism (CD) spectroscopy. As shown in Figure 19a, the
seeds generated through a shaking procedure adopted the morphology similar to
what was observed in the shaking day 6 sample. When the seeding reaction was
initiated (day 0) by the addition of PFF to the αSN monomers pool, the PFF
served as a template or scaffold to recruit adjacent monomers (Figure 19b) and
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αSN aggregation continued (Figure 19c). Unlike the relatively uniformed mixture
of fibrils observed in the shaking day 6 samples (Figure 16b), the product of the
seeding reaction is rather heterogenous: a considerable amount of monomers or
small order aggregates were still visible in the same view with the meshed fibrils
(Figure 19d).
Furthermore, the far-UV CD spectra revealed an incubation timedependent patent. A clear reduction in the intensity of the negative shoulder
around 203 nm and an increase in the intensity of the negative shoulder around
220 nm suggest a gradual conversion to more structured states over the time
(Figure 20). However, the extent of these alterations was much less comparing
to the observation made in the shaking assay, which could be due to the
heterogenicity of the finial protein mixture obtained from the seeding process.

62

Figure 19. TEM analysis of samples collected in the αSN (1.25 mg/mL = 86.45
µM) 0.5% seeding experiment. (a) PFF, (b) seeding aliquot at day 0, (c) seeding
aliquot at day 10, (d) seeding aliquot at day 30; Scale bar = 100 nm.

63

10

w a v e le n g th (n m )

C D (m D e g )

0

200

220

240

260

-1 0
0 D S e e d in g
1 0 D S e e d in g
-2 0

2 0 D S e e d in g
3 0 D S e e d in g

-3 0

Figure 20. Circular dichroism spectra analysis of samples collected in the αSN
(86.45 µM) 0.5% seeding experiment.

Three representative compounds (−)-8a (D-593), (−)-20 (D-618), and (−)14 (D-644) were selected and tested in this assay in comparison to the reference
compound D-520. αSN was seeded with 0.5% (v/v) PFF and incubated in the
presence or absence of the tested compound (1:2 ratio) for 10 days, while αSN
alone and compounds alone were also included. Aliquots collected at day 0 and
day 10 were analyzed by both ThT and cell viability assay. When tested for cell
viability, the collected aliquots were diluted with cell medium and treated to the
PC12 cells, resulting a final concentration of 10 µM for αSN and 20 µM for
compounds.
As seen in Figure 21a, the reference compound D-520 and compound
(−)-14 (D-644) significantly reduced the ThT activity by either 289% or 303% at
day 10 comparing to the 10 day αSN seeding sample. However, only 105% and
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185% decrease of ThT signals were observed for compound (−)-8a (D-593) and
(−)-20 (D-618), respectively. The less extent of ThT signal reduction by (−)-8a (D593) in this assay could result from the autofluorescence generated through the
incubation of compound itself.
When the PC12 cells were exposed to the 10 day αSN seeding sample, a
43% cell death was observed. While the reference compound D-520 was able to
enhance the cell viability tremendously by 27%, compounds (−)-8a (D-593) and
(−)-14 (D-644) moderately raised the viability by 16% and 18%, respectively
(Figure 21b). As for compound (−)-20 (D-618), the increase in cell viability was
limited to only 9% (Figure 21b). This cell viability data as well as the ThT data
suggest that the methoxy-hydroxy compound is less potent in modulating seeded
αSN aggregation.
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Figure 21. Modulation of the aggregation of αSN induced by 0.5% (v/v) seeding
by compounds (−)-8a (D-593), (−)-20 (D-618), and (−)-14 (D-644). Test
compounds (−)-8a (D-593), (−)-20 (D-618), and (−)-14 (D-644) and the reference
compound D-520 (172.9 µM) were incubated with αSN (86.45 µM) for 10 days.
Drugs were also tested alone as controls to show any direct effect on assays. a)
Fibrillation was measured by ThT assay. Readings from ThT assays were
normalized by assigning the data of αSN alone from day 0 sample as 100%. The
data are shown as means ± SEM of three independent experiments. Data and
statistics of D-520 were taken from Yedlapudi et al. 2016. One-way ANOVA
followed by Tukey’s multiple comparison post hoc test was performed (#### p ≤
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0.0001 compared to the αSN-0D, * p ≤ 0.05, **** p ≤ 0.0001 compared to the
seeded αSN sample at day 10). b) Cell viability was measured by MTT assay.
Readings were normalized to the untreated control. The data are shown as
means ± SEM of three independent experiments. Data and statistics of D-520
were taken from Yedlapudi et al. 2016. One-way ANOVA followed by Tukey’s
multiple comparison post hoc test was performed (#### p ≤ 0.0001 compared to
the untreated control, * p ≤ 0.05, **** p ≤ 0.0001 compared to the seeded αSN
sample at day 10).

To gain more information on the effect of para- and ortho-dihydroxy
substitution on seeded αSN aggregation, compound (−)-49 (D-670) was studied
along with its ortho-substituted analog D-520 for a prolonged period of 30 days.
As seen in Figure 22a, a gradual increased ThT signal as an indication of
fibrilization was found throughout the seeding process, and both pare- and orthocompounds significantly reduced this signal, which suggests a significant
inhibition to the PFF induced aggregation. When the PC12 cells were treated
with 10 day to 30 day αSN PFF seeded samples, about 48% cell death were
induced. However, when the seeded samples were incubated with either
compound (−)-49 (D-670) or D-520, the samples became much less toxic to the
cells in contrast to PFF induced untreated seeded samples at the corresponding
time points. Both compounds were able to improve the cell viability considerably
by approximately 30-40% (Figure 22b). Thus, both para- and ortho-dihydroxy
substitutions exerted comparable anti-aggregation activity.
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Figure 22. Modulation of compound (−)-49 (D-670) on the aggregation of αSN
induced by 0.5% (v/v) PFF seeding. Test compound (−)-49 (D-670) and the
reference compound D-520 (172.9 µM) were incubated with αSN (86.45 µM) in
presence of 0.5% PFF for 30 days. Drugs were also tested alone to show any
direct effect on assays. a) Fibrillation was measured by ThT assay. Readings
from ThT assay were normalized by assigning the reading of αSN alone at day 0
sample as 100%. The data are shown as means ± SEM of three independent
experiments. One-way ANOVA followed by Tukey’s multiple comparison post
hoc test was performed (## p ≤ 0.01, #### p ≤ 0.0001 compared to the αSN-0D,
**** p ≤ 0.0001 compared to the seeded αSN sample at corresponding time
points). b) Cell viability was measured by MTT assay. Readings were normalized
to the untreated control. The data are shown as means ± SEM of three
independent experiments. One-way ANOVA followed by Tukey’s multiple
comparison post hoc test was performed (#### p ≤ 0.0001 compared to the
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untreated control, **** p ≤ 0.0001 compared to the seeded αSN sample at
corresponding time points).

3.2.4. Neuroprotection against 6-OHDA induced toxicity in PC12 cell line
with multifunctional αSN modulators
Following the screening through the in vitro receptor assays and αSN antiaggregation study, three representative alkyl linker compounds (−)-8a (D-593),
(−)-20 (D-618), and (−)-14 (D-644) were selected based on their structural
diversity on the terminal aromatic substitutions and the agonist head groups to
evaluate

their

protective

effect

in

reversing

toxicity

induced

by

6-

hydroxydopamine (6-OHDA). This dopaminergic neurotoxin is widely used in PD
study because of its known effect in causing cell death via the production of
reactive oxygen species in a dose dependent manner (Blum et al. 2000, SotoOtero et al. 2000).
First, these selected compounds were assessed for toxicity to the PC12
cells, for which the cells received treatments with the compounds at various
doses for 24 h. As shown in Figure 23 a) and b), compounds (−)-8a (D-593),
(0.1-30 µM) and (−)-20 (D-618) (1-50 µM) had no noticeable effect on cell
viability compared to the untreated control. In contrast, compound (−)-14 (D-644)
(0.1-30 µM) slightly induced cell proliferation at higher concentrations (Figure
23c).
Then, the effect of compounds on 6-OHDA induced toxicity was examined.
PC12 cells were first pretreated 24 h with increasing doses of compounds (−)-8a
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(D-593) (0.1-30 µM), (−)-14 (D-644) (0.1-30 µM), or (−)-20 (D-618) (1-50 µM),
followed by the single treatment of 6-OHDA for additional 24 h. The dose of toxin
was set to 75 µM to produce a significant reduction of cell viability based on the
previously published data (Das et al. 2015). Cell viability was assessed by MTT
assay. As shown in Figure 23 d-f), compounds (−)-8a (D-593), (−)-20 (D-618),
and (−)-14 (D-644) were able to protect cells against 6-OHDA-induced toxicity in
a dose-dependent manner. The greatest protection (18-25%) was seen at 30 µM
dose point for all the three compounds (Figure 23).
In addition, compound (−)-49 (D-670) was also tested in the same fashion
for its ability to reverse the cytotoxicity induced by 6-OHDA. Unlike those alkyl
linker compounds, compound (−)-49 (D-670) demonstrated toxicity at higher
doses and caused up to 38% cell death at the highest dose tested (Figure 24a).
Due to the inherent toxicity of compound (−)-49 (D-670) in the current assay
conditions, the greatest protection (16%) was seen at 5 µM dose point (Figure
24b).
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Figure 23. a-c) Dose-dependent effect of compounds (−)-8a (D-593) (a), (−)-20
(D-618) (b), and (−)-14 (D-644) (c) on the viability of PC12 cells in 24 h treatment.
The results shown are mean ± SEM of three independent experiments performed
in six to eight replicates. One-way ANOVA followed by Tukey’s multiple
comparison post hoc test was performed (* p ≤ 0.05, ** p ≤ 0.01 compared to the
control). d-e) Dose-dependent effect on the viability of PC12 cells by 24 h
pretreatment with compounds (−)-8a (D-593) (d), (−)-20 (D-618) (e), and (−)-14
(D-644) (f) followed by single treatment with 75 µM 6-OHDA for another 24 h.
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The results shown are mean ± SEM of three independent experiments performed
in six to eight replicates. One-way ANOVA followed by Tukey’s multiple
comparison post hoc test was performed (#### p ≤ 0.0001 compared to the
control; * p ≤ 0.05, ** p ≤ 0.01, **** p ≤ 0.0001 compared to the 6-OHDA control).
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Figure 24. a) Dose-dependent effect of compound (−)-49 (D-670) on the viability
of PC12 cells by 24 h treatment. The results shown are mean ± SEM of three
independent experiments performed in six to eight replicates. One-way ANOVA
followed by Tukey’s multiple comparison post hoc test was performed (**** p ≤
0.0001 compared to the control). b) Dose-dependent effect on the viability of
PC12 cells by 24 h pretreatment with compound (−)-49 (D-670) at various
concentrations (0.1-30 µM) followed by single treatment with 75 µM 6-OHDA for
another 24 h. The results shown are mean ± SEM of three independent
experiments performed in six to eight replicates. One-way ANOVA followed by
Tukey’s multiple comparison post hoc test was performed (#### p ≤ 0.0001
compared to the control; **** p ≤ 0.0001 compared to the 6-OHDA control).
3.2.5. Reversal

of

reserpine-induced

hypolocomotion

in

rats

with

multifunctional αSN modulators
Catalepsy was induced in rats by administrating reserpine, which can
block the vesicular monoamine transporter (VMAT) and subsequently lead to the
depletion of monoamines in the synapse of the peripheral sympathetic nerve
terminals (Fernandes et al. 2012, Duty and Jenner 2011, Leao et al. 2015). In
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this well-established PD model, significant inhibition of locomotion of rats, which
indicates the development of akinesia, was observed 18 h after administrating
reserpine (5 mg/kg, s.c.) (Figure 25). The ability of compounds (−)-8a (D-593)
and (−)-20 (D-618) to reverse the reserpine-induced hypolocomotion was
investigated in this assay because of their high affinity and efficacy at D2 and D3
receptors in the in vitro receptor assays. At the dose of 10 µmol/kg i.p.,
compound (−)-8a (D-593) effectively reversed akinesia induced by reserpine
treatment and displayed a steady continuous effect in comparison to the peak
effect from reference drug ropinirole (Figure 25). This significant locomotor
stimulation is likely to be mediated by postsynaptic D2/D3 receptor activation,
which suggested that compound (−)-8a (D-593) can cross the blood-brain barrier
effectively and function as a potent agonist. However, despite the similarity
between the compounds (−)-8a (D-593) and (−)-20 (D-618) in structure,
predicted chemical properties, and in vitro receptor activities, the latter displayed
only a slight activity in reversing the induced hypolocomotion (Figure 25). The
reduced agonist efficacy may be due to a potential difference in compound
metabolism.
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Figure 25. Effect of compounds (−)-8a (D-593), (−)-20 (D-618), and ropinirole on
reserpine-induced (5.0 mg/kg, s.c.) hypolocomotion in rats. Results are
expressed as means ± SEM; n=2-3 rats per value. Horizontal activity (HACTV),
which is the total number of beam interruptions that occurred in the horizontal
sensor during a given sample period, was measured as described in Chapter 4.
Locomotor data during each 30-min interval after the administration of
compounds (−)-8a (D-593) (i.p.), (−)-20 (D-618) (i.p.) or ropinirole (i.p.) at the
dose of 10 µmol/kg compared to control reserpine treated rats in 18 h post
reserpine treatment was plotted. Differences among treatments were significant
by one-way ANOVA analysis (F (3, 48) = 32.27; p< 0.0001). Dunnett’s analysis
following ANOVA revealed that the effects of compounds (−)-8a (D-593) (p<
0.0001) and (−)-20 (D-618) (p< 0.05) were significantly different when compared
to reserpine control.

Besides these alkyl linker compounds, (−)-49 (D-670), the para-dihydroxy
analog of a highly potent and efficacious D2/D3 receptor agonist D-520, was also
evaluated in the same PD animal model. However, this newly developed analog
exhibited no in vivo agonistic activity when compared to the reserpine model
(Figure 26). The loss of agonistic activity could be due to a faster phenol-
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quinone conversion of the para-dihydroxy substitution or the interference of
unpredicted compound metabolism.

H A C T V c o u n ts

2000

1500

1000

500

0
0

100

200

300

400

T im e ( M in )
R e s e r p in e C o n tro l

R o p in ir o le , 1 0  m o l/k g

D - 6 7 0 , 1 0  m o l/k g

D - 5 2 0 , 1 0  m o l/k g

Figure 26. Effect of compounds (−)-49 (D-670), D-520, and ropinirole on
reserpine-induced (5.0 mg/kg, s.c.) hypolocomotion in rats. Results are
expressed as means ± SEM; n=3-5 rats per value. Horizontal activity (HACTV),
which is the total number of beam interruptions that occurred in the horizontal
sensor during a given sample period, was measured as described in Chapter 4.
Locomotor data during each 30-min interval after the administration of
compounds (−)-49 (D-670) (i.p.), D-520 (i.p.), or ropinirole (i.p.) at the dose of 10
µmol/kg compared to control reserpine treated rats in 18 h post reserpine
treatment was plotted. Differences among treatments were significant by oneway ANOVA analysis (F (3, 48) = 19.99; p < 0.0001). Dunnett’s analysis following
ANOVA revealed that the effects of compound (−)-49 (D-670) was not significant
when compared to reserpine control.

3.3.

Design, synthesis, and the initial SAR study of novel multifunctional
dopamine D2/D3 receptors agonists containing an propargyl moiety
for potential MAO-B inhibitory activity
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In this section, results from the initial SAR study on a group of novel
dopamine D2/D3 receptor agonists that incorporates the N-propargylamine moiety,
which has been reported to exert MAO-B inhibitory activity, will be shown and
discussed. The hybrid molecule template (Figure 27) was modified from the
previously established model that had resulted in the discovery of multiple
promising lead compounds including D-512 and D-616 (Figure 28). In the current
template, the propyl group was replaced by the propargyl group in the head
group derived from pramipexole or 5-OH-DPAT. The dopamine D2/D3 receptors
targeting head group was attached with various accessory binding site moieties,
which originated from previously published lead compounds, through a linker,
usually a piperazine ring. In addition, a pentynyl analog was also included in this
series of compounds to provide further information of the effect of propargyl
group replacement.

Figure 27. The hybrid molecule template for multifunctional dopamine D2/D3
receptor agonists that may potentially inhibit the MAO-B activity.
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Figure 28. Structure of compounds in the initial brief SAR study. Compounds
labeled as black were designed and synthesized, whose corresponding propyl
containing parent molecules are labeled as grey.

3.3.1. Synthesis of multifunctional MAO-B inhibitors
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Scheme 7. Synthesis of compounds 62a (D-674), 62b (D-629), 62c (D-676), 62d
(D-680), 62e (D-664), and 63 (D-649). Reaction and Conditions: (a) 2nitrobenzenesulfonyl chloride, Et3N, THF, −10 °C to rt, 1.5 h; (b) K2CO3, CH3CN,
50 °C, 24h or 85 °C, 36 h; (c) thioglycolic acid, K2CO3, DMF, 0 °C to rt to 55 °C,
18-21 h; (d) Et3N, 4-DMAP, TsCl, CH2Cl2, 0°C to rt, overnight; (e) 2bromoethanol, K2CO3, CH3CN or EtOH, reflux, 4-20 h; (f) SO3·Py or oxalyl
chloride, DMSO, Et3N, CH2Cl2, 0 or −78 °C to rt, 2 h; (g) Na(OAc)3BH, CH2Cl2, rt,
40-48 h.

Scheme 7 describes the synthesis of four N-propargyl compounds and
one N-pentynyl analog, all of which have a piperazine ring as the linker
connecting a phenyl ring to the head group. Another propargyl containing
compound that derived from (−)-20 (D-618) mentioned in section 3.2 is also
included. The common N-propargyl intermediate 54 and the N-pentynyl
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intermediate 58 were synthesized by using the Fukuyama nosyl strategy adapted
based on literature (Zivec, Anzic, and Gobec 2010). The starting diamine 50
(Brown et al. 2009) was first selectively protected by 2-nitrobenzenesulfonyl
chloride to give the common sulfonamide intermediate 51. For the N-propargyl
intermediate 53, commercially available propargyl bromide (52) was used to
react with nitrobenzenesulfonamide 51. And for the N-pentynyl intermediate 57,
commercially available pent-4-yn-1-ol (55) was first converted to corresponding
tosylate 56, which was then reacted with nitrobenzenesulfonamide 51 to produce
tertiary amine 57. Thioglycolic acid was used to deprotect tertiary amine 53 or 57
to generate secondary amine 54 or 58, respectively. Amine intermediates 59a,
59b, 59c, and 59d were coupled with 2-bromoethanol to form the alcohol
intermediates 60a, 60b, 60c, and 60d, respectively, which were subsequently
oxidized by either the Parikh–Doering oxidation or the Swern oxidation to give
corresponding aldehyde intermediates 61a, 61b, 61c, and 61d. These aldehyde
intermediates were then coupled with either amine 54 or 58 to yield the final
compounds 62a (D-674), 62b (D-629), 62c (D-676), 62d (D-680) and 62e (D664). The final compound 63 (D-649) was synthesized by reacting the (E)-alkene
intermediate 19 described in section 3.2 with the common intermediate 53 in the
presence of sodium triacetoxyborohydride.
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Scheme 8. Synthesis of compounds 73 (D-635) and 76 (D-614). Reaction and
Conditions: (a) K2CO3, CH3CN, reflux, 15 h; (b) (Boc)2O, 4-DMAP, THF, rt, 12 h;
(c) Pd(OAc)2, BINAP, Cs2CO3, toluene, reflux, 24 h; (d) TBAF, THF, 0 °C to rt, 2
h; (e) oxalyl chloride, DMSO, Et3N, CH2Cl2, −78 °C to rt, 2 h; (f) Na(OAc)3BH,
CH2Cl2, rt, 40-65 h; (g) CF3COOH, CH2Cl2,0 °C to rt, 2 h.
Scheme 8 depicts the synthesis of a pair of compounds, 73 (D-635) and
76 (D-614), which have the indole rings as the accessory binding site moiety.
The linker is synthesized by refluxing piperazine (64) with (2-bromoethoxy)-tertbutyl-dimethylsilane (65) in the presence of K2CO3. Following the N-protection of
6-bromoindole (67) with di-tert-butyl decarbonate, palladium-catalyzed cross
coupling was used to combine the protected intermediate 68 with the linker
fragment 66 in the presence of Cs2CO3 and BINAP to generate intermediate 69,
which was subsequently deprotected by tetra-n-butylammonium fluoride (TBAF)
to produce alcohol intermediate 70. Through the Swern oxidation, alcohol 70 was
converted to its corresponding aldehyde 71 and further reacted with the common
intermediate 54 in the presence of sodium triacetoxyborohydride to give the
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intermediate 72. In the same fashion, the aldehyde intermediate 74, which was
obtained following the procedure reported in literature (Johnson et al. 2012,
2013), was used first to couple with the common intermediate 54 to yield
intermediate 75. Finally, the deprotection of the Boc group was achieved by
using trifluoroacetic acid to generate the final compound 73 (D-635) and 76 (D614), respectively.

Scheme 9. Synthesis of compound 84 (D-675). Reaction and Conditions: (a)
Me2SO4, K2CO3, acetone, reflux, 4 h; (b) Na, EtOH, reflux, 2 h; aqueous HCl,
reflux, 1 h; (c) MeONH2·HCl, AcONa, 60% MeOH/H2O, rt, 2 h; (d) H2 (2 bar), 10%
Pd/C, HCl, MeOH, rt, 2.5 h; (e) 2N NaOH aq; (f) Na(OAc)3BH, CH2Cl2, rt, 40 h; (g)
propargyl bromide, K2CO3, CH3CN, 50-60 °C, 4 h; (h) BBr3, CH2Cl2, −40 °C to rt,
4 h.
Scheme 9 shows the synthesis of final compound 84 (D-675), which is a
racemic DPAT analog of compound 62b (D-629). The amine intermediate 81 was
synthesized

following

a

published

procedure

(Hirayama,

Ikunaka,

and

Matsumoto 2005). The starting material 1,6-dihydroxynaphthalene (77) went
through bis-O-methylation and the Birch reduction to give tetralone intermediate
79. Then it was converted to its corresponding oxime O-methyl ether 80, and
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further hydrogenation was used to produce the HCl salt of intermediate 81. The
free base of 81 was liberated by 2N NaOH aqueous solution and extracted with
ethyl acetate. After coupling it to aldehyde 61b through reductive amination, Npropargylation was applied to yield intermediate 83, which was further
demethylated by boron tribromide to produce the final compound 84 (D-675).
3.3.2. In vitro receptor assays with multifunctional MAO-B inhibitors
In this study, a small library of nine compounds was generated according
to the hybrid molecule template, and in vitro binding and functional assays were
conducted to gain information for the initial SAR study.
A radioligand competition assay was carried out with the rat D2L and D3
receptors expressed in HEK-293 cells to evaluate the receptor binding properties
of the synthesized compounds. The newly synthesized compounds were first
studied in pairs with their corresponding propyl containing parent compounds that
had been developed and analyzed previously.
In general, a noticeable decrease in D2 binding affinity due to the
replacement of the propyl group with the propargyl group was observed. The D2
binding affinity of compounds 76 (D-614) and 84 (D-675) decreased moderately
compared to their propyl parent molecules, D-512 and D-238 (Ki, D2= 86.5 vs. 39
nM; 89.4 vs. 14.6 nM, Table 3). Moreover, compounds 62a (D-674) and 73 (D635) have exhibited great reduction in D2 binding affinity when compared to their
propyl counterparts D-258 and D-616, respectively (Ki, D2= 661 vs. 243 nM; 172
vs. 16.4 nM, Table 3). This trend reached an extreme in the case of compound
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63 (D-649), which exerted no binding affinity for D2 receptor while the propyl
containing molecule (−)-20 (D-618) exhibited a good binding affinity (Ki, D2= 123
nM, Table 3). However, there was only a slight to no effect of the propargyl
replacement in D2 binding affinity for compound 62b (D-629) in comparison to D260 (Ki, D2= 75 vs. 56.8 nM, Table 3). And in the case of compound 62c (D-676),
an exception was found, which showed an increase in D2 binding when
compared to its corresponding propyl analog D-259 (Ki, D2= 160 vs. 288 nM,
Table 3).
A similar trend caused by the propargyl replacement has also been
noticed in the change of D3 binding affinity. As shown in Table 3, the D3 binding
affinity of compounds 62a (D-674), 62b (D-629), 62c (D-676), 64 (D-649), 76 (D614), and 84 (D-675) was reduced moderately to largely when compared to their
propyl parent compounds D-258, D-260, D-259, (−)-20 (D-618), D-512, and D238, respectively (Ki, D3= 171 vs. 4.15 nM; 11.8 vs. 1.8 nM; 81.6 vs. 7.01 nM;
141 vs. 22.3 nM; 14.4 vs. 2.19 nM; 32.3 vs. 0.45 nM, Table 3). Nevertheless,
compound 73 (D-635) has displayed a near 8-fold enhancement in D3 binding
affinity in comparison to its propyl counterpart D-616 (Ki, D3= 0.145 vs. 1.15 nM,
Table 3).
These trends suggest a generally reduced binding interaction between the
propargyl group and the “propyl cleft” in the D2 and D3 receptors, which could be
a result of either an increased rigidity or a slight change of conformation in the
headgroup fragment induced by the propargyl replacement. In addition, the
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abolishment of the D2 receptor binding of compound 63 (D-649), which
possesses a linear linker and a styrene moiety in the accessory binding site,
could result from the induced conformational change of this compound that is not
tolerated by receptor binding pocket.
Furthermore, it is interesting to notice in Table 3 that in general these
newly synthesized propargyl compounds 62a (D-674), 62b (D-629), 62c (D-676),
76 (D-614), and 84 (D-675) are much less selective (D2/D3 ratio ranging from 2 to
6) for the dopamine D2/D3 receptors in contrast to their propyl parent molecules
D-258, D-260, D-259, D-512, and D-238 (D2/D3 ratio ranging from 18 to 59).
However, the exceptions took place in the case of compounds 73 (D-635) and 63
(D-649) when compared to their propyl analogs D-616 and (−)-20 (D-618), which
is due to either the uneven change between D2/D3 receptors binding or the
complete loss of D2 binding affinity, respectively (D2/D3, 1186 vs. 14; N/A vs. 6,
Table 3). This suggests an important role of the interaction to propyl cleft in
tuning the dopamine D2/D3 receptors selectivity.
To gain more insight into the role of the propargyl group in receptor
binding, a 4-pentynyl analog 62e (D-664), which has a more extended
substituent in the headgroup fragment, was synthesized and tested. Comparing
to the original propargyl compound 62b (D-629), this analog exhibited a slight
decrease in D2 binding and a moderate decrease in D3 binding (Ki, D2 = 91.3 vs.
75.0 nM, D3 = 24.2 vs. 11.8 nM, Table 3). The D2/D3 selectivity also showed a
slight reduction accordingly (D2/D3, 3.8 vs. 6.3, Table 3). This suggests that the
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size of N-substituents in the headgroup may have a limited effect on the binding
to the propyl cleft of dopamine D2/D3 receptors.
Moreover, additional information on the effect of accessory binding site
moieties can be gained from analyzing the D2/D3 receptors binding profile of the
synthesized compounds. By introducing 2,3-dichloro or 2-methoxy group to the
phenyl ring in the accessory binding site moiety, compounds 62b (D-629) and
62c (D-676) showed a great increase in the binding affinity for both D2 and D3
receptors when compared to the non-substituted compound 62a (D-674) (Ki, D2 =
75.0 or 160 vs. 661 nM, D3 = 11.8 or 81.6 vs. 171 nM, Table 3). However, the 4fluoro substitution in compound 62d (D-680) led to a reduction in the binding
affinity for D2 receptor and an improvement for D3 receptor (Ki, D2 = 1,014 nM, D3
= 93.9 nM, Table 3). In the case of 73 (D-635) and 76 (D-614), which only differ
at the indole substituents, a great difference in both D2/D3 receptors binding
especially the D2/D3 selectivity was found (Ki, D2 = 172 vs. 86.5 nM, D3 = 0.145 vs.
14.4 nM, D2/D3, 1186 vs. 6, Table 3). This indicates that a proper modification at
the accessory binding site may largely improve the binding property.

Table 3. Ki values (nM) for inhibition of [3H] spiroperidol binding (HEK - D2,3
cells)a (cLogP and tPSA values are calculated using ChemDraw)

Compound

Ki (nM), [3H]spiperone

D2L/D3 cLogP tPSA

dopamineb

D2L
990 ± 198

D3
101 ± 14.9

10

(−)-5-OH-DPAT

153 ± 32

2.07 ± 0.38

74
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62a, D-674

661 ± 51

171 ± 8

4

3.58

48.1

62b, D-629

75 ± 10.3

11.8 ± 2.0

6

5.12

48.1

62c, D-676

160 ± 22

81.6 ± 5.8

2

3.52

57.33

62d, D-680

1,014 ± 92

93.9 ± 14.2

11

3.90

48.1

62e, D-664

91.3 ± 6.4

24.6 ± 2.6

4

6.05

48.1

63, D-649

no binding

141 ± 32

N/A

3.92

71.08

73, D-635

172 ± 16

0.145 ± 0.035

1186

4.51

60.13

76, D-614

86.5 ± 15

14.4 ± 1.0

6

4.51

60.13

84, D-675

89.4 ± 14.7

32.3 ± 2.0

3

6.36

29.95

D-258b

243 ± 65

4.15 ± 0.76

59

4.22

48.1

D-260b

56.8 ± 15.4

1.80 ± 0.32

32

5.76

48.1

D-259b

288 ± 86

7.01 ± 1.16

41

4.24

57.33

(−)-20, D-618

123 ± 18

22.3 ± 2.2

6

4.56

71.08

D-616b

16.4 ± 2.8

1.15 ± 0.19

14

5.14

60.13

D-512b

39 ± 5

2.19 ± 0.39

18

5.14

60.13

D-238b

14.6 ± 1.7

0.45 ± 0.16

32

7.00

29.95

a

Results are expressed as means ± SEM for three to four experiments, each
performed in triplicate.
b Data was obtained under almost identical assay conditions (Zhen et al. 2015,
Biswas, Hazeldine, et al. 2008, Biswas, Zhang, et al. 2008, Das et al. 2015,
Johnson et al. 2012).
Based on the binding results, compounds were selected and further
assessed for their ability to activate human dopamine hD2 and hD3 receptors
expressed in CHO cells by measuring the stimulation of [35S]GTPγS binding.
Dopamine (DA), the endogenous full agonist, was included for comparison. It is
easy to notice that the propargyl replacement in compounds (−)-62b (D-629), (−)73 (D-635), and (−)-76 (D-614) resulted in a moderate to large decrease in the
potency at the D2 receptor in comparison to their propyl counterparts D-260, D-
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616, and D-512 (EC50 (GTPγS); D2 = 62.8 vs. 13.4 nM; 39.4 vs. 3.23 nM; 21.6 vs.
2.96 nM, Table 4). As for the efficacy, the propargyl replacement rendered both
62b (D-629) and 76 (D-614) into partial agonists category for the D2 receptor
(Emax=17.4% and 26.7%, Table 4). However, compound 73 (D-635) still retained
nearly full agonistic activity at D2 receptor (Emax=86.8%, Table 4). On the other
hand, while the propargyl replacement caused a noticeable reduction of potency
to the D3 receptor for compounds 62b (D-629) and 76 (D-614) comparing to the
propyl parent molecules D-260 and D-512 (EC50 (GTPγS); D3 = 1.40 vs. 0.06 nM;
10.9 vs.1.26 nM, Table 4), compound 73 (D-635) exhibited a slight improvement
in the potency at the D3 receptor when compared to D-616 (EC50 (GTPγS); D3 =
0.84 vs.1.41 nM, Table 4). It is interesting to find that all these propargyl
compounds 62b (D-629), 74 (D-635), and 76 (D-614) remained full agonists at
the D3 receptor (Emax=106%; 93.0%; 94%, Table 4). These findings indicate that
the propargyl replacement in the head group moiety may not be well-tolerated for
the D2 receptor activity; however, its effect on D3 receptor activity is much less.
In addition, the pentynyl analog 62e (D-664) was tested and compared
with its propargyl version 62b (D-629) to understand the effect of propargyl group.
Unlike what was found in the binding assay, the extended pentynyl chain totally
lost the agonistic activity at both D2 and D3 receptors. This could result from the
steric interference of the head group interact with the D2 and D3 receptors, and it
also suggests a great significance of the interaction between the head group to
the propyl cleft.
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Table 4. Stimulation of [35S]GTPγS Binding to hD2 and hD3 receptors expressed
in CHO cellsa
CHO-D2
Compound [35S]GTPγS
EC50 (nM)

CHO-D3

%Emax

[35S]GTPγS
EC50 (nM)

%Emax

D2/D3

dopamine

376 ± 39

100

7.26 ± 0.21

100

51.8

62b, D-629

62.8 ± 15.0

17.4 ± 2.3

1.40 ± 0.50

106 ± 4

44.8

62e, D-664

no stimulation

no stimulation

N/A

74, D-635

39.4 ± 6.31

86.8 ± 3.8

0.84 ± 0.05

93.9 ± 3.6

46.9

77, D-614

21.6 ± 9.6

26.7 ± 6.4

10.9 ± 2.4

94 ± 3.5

2.0

D-260b

13.4 ± 2.4

78.8 ± 0.8

0.06 ± 0.02

D-616c

3.23 ± 0.78

101 ± 4

1.41 ± 0.08

113 ± 7

2.3

D-512c

2.96 ± 0.3

107 ± 3

1.26 ± 0.2

93.1 ± 4.4

2.4

95.7 ± 10.7 223.3

a

Results are expressed as means ± SEM for three to five experiments, each
performed in triplicate.
b Data was obtained under similar assay conditions (Biswas, Hazeldine, et al.
2008).
c Data was obtained under almost identical assay conditions (Das et al. 2015,
Johnson et al. 2012).
3.3.3. MAO inhibition assay with multifunctional MAO-B inhibitors
To further evaluate the effect of structural changes on the inhibition of
MAO-B activity by selected compounds, a fluorescence-based enzymatic assay
was carried out. Test compounds (25 µM) were incubated with the MAO-B
enzyme (15 µg/mL) along with its substrate, kynuramine (25 µM), and the
fluorescence of the product, 4-hydroxyquinoline (4-HQ), was measured.
Pargyline, a potent and selective MAO-B inhibitor, was included as the reference
compound, and it induced a 98.6% reduction of the MAO-B activity in the assay
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conditions (Figure 29). Among all the test molecules, compounds 62b (D-629),
63 (D-649), and 76 (D-614) were the most active and reduced the MAO-B activity
by 53.5, 49.1%, and 43.1%, respectively (Figure 29). However, the inhibitory
activity (100% - Activity%) was much less for the rest of test compounds.
Comparisons could be drawn from compounds 62a (D-674), 62b (D-629), 62c
(D-676), and 62d (D-680) to briefly assess the effect of substituents on the
phenyl ring in the accessory binding site moiety on MAO-B inhibition. It seems
while the non-substituted compound 62a (D-674) and its electron donating 2methoxy substituted counterpart 62c (D-676) shared similar inhibitory activity, the
electron withdrawing 2,3-dichloro substitution in compound 62b (D-629) largely
increased its MAO-B inhibitory effect (MAO-B inhibition% = 12.6%, 14.1% vs.
53.5%, Figure 29). Similarly, the electron withdrawing 4-fluoro substitution in
compound 62d (D-680) resulted in a moderate improvement in MAO-B inhibition
when compared to the non-substituted parent molecule 62a (D-674) (MAO-B
inhibition% = 29.5% vs. 12.6%, Figure 29). These findings suggest that electron
withdrawing substitutions in the phenyl ring may potentially enhance the MAO-B
enzyme inhibitory activity; however, the position of the substitutions may also
play a role in altering this effect.
In addition to the accessory binding site, alterations at the head group
have also been briefly explored. Compound 84 (D-675), the racemic 5-OH-DPAT
analog of compound 62b (D-629), showed a reduced inhibitory activity (MAO-B
inhibition% = 17% vs. 55%, Figure 29). Furthermore, the extension of the N-
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substituent in the headgroup fragment rendered the N-pentynyl analog 62e (D664) much less effective in comparison to its parent compound 62b (D-629)
(MAO-B inhibition% = 26.9% vs. 53.5%, Figure 29). This reduced inhibition could
be a result from a change of electron distribution or an increase in the steric
hindrance.
Interestingly, although compound 63 (D-649) has an undesirable receptor
binding profile, it showed a comparable enzyme inhibition to 62b (D-629) (MAOB inhibition% = 53.5% vs. 49.1%, Figure 29). In contrast, compound 73 (D-635)
displayed promising D2/D3 receptor activities in the receptor assays, but its
inhibitory effect is less potent (MAO-B inhibition% = 17.4%, Figure 29). This data
suggests that there is no direct correlation between the D2/D3 receptor activities
and enzyme inhibitory activity. This also indicates that the structural preference
and conformational requirement for dopamine D2/D3 receptors binding and MAOB enzyme interaction may have a relatively low compatibility in the current
molecular template that requires further modifications.
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Figure 29. Initial screening of the synthesized compounds through MAO-B
inhibition assay. All the compounds were tested at 25 µM. The results shown are
means ± SEM from three independent experiments performed in triplicates. Oneway ANOVA followed by Tukey’s analysis was performed (*** p ≤ 0.001, **** p ≤
0.0001 compared to the control).

Based on the data obtained from MAO-B inhibition assay, compounds 62b
(D-629) and 76 (D-614) were selected to be tested further. To gain additional
information on the selectivity of compounds towards two isoforms of MAO, IC50
values for both MAO-A and MAO-B were determined by constructing doseresponse curve with seven dose points. As displayed in Table 5, while
compound 62b (D-629) has only a slight selectivity for MAO-B (SI = 2.2),
compound 76 (D-614) is non-selective towards both MAO isoforms (SI = 1.2).
These results suggest further expanded SAR study with more structural
modifications is required to gain a better MAO-B inhibitory profile.
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Table 5. The IC50 values for the inhibition of recombinant human MAO-A and
MAO-B by compoundsa
MAO-B

MAO-A

IC50 (µM)

IC50 (µM)

0.28 ± 0.02

10.54 ± 0.79

37.6

62b (D-629) 31.67 ± 1.61 71.04 ± 10.30

2.2

Compound
Pargyline
76 (D-614)

32.34 ± 2.41

39.71 ± 3.95

SIb

1.2

a Results

are expressed as means ± SEM for three experiments, each performed
in triplicate.
b Selectivity index = IC
50 (MAO-A)/IC50 (MAO-B)
3.3.4. Neuroprotection against neurotoxin-induced toxicity in PC12 cell line
with multifunctional MAO-B inhibitors
Based on the results obtained from the in vitro receptor assays and
enzymatic assay, compounds 76 (D-614) and 62b (D-629) were selected for
further testing.
These two compounds were first tested for cytotoxicity. As shown in
Figure 30 a) and b), both compounds displayed a non-toxic profile when treated
alone to the PC12 cells and induced cell proliferation at higher doses tested:
compound 76 (D-614) slightly increased cell viability at 20 and 30 µM, and
compound 62b (D-629) largely increased cell viability at 50 µM.
Then, they were examined for their ability to reverse the toxicity induced
by 6-OHDA in PC12 cells. After the PC12 cells were pretreated with increasing
doses (1-50 µM) of compound 76 (D-614) or 62b (D-629) for 24 h, a single
treatment of 75 µM 6-OHDA was given for another 24 h. Cell viability was
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assessed by MTT assay. Despite that these two compounds demonstrated
comparable results in both in vitro receptor assays and MAO inhibition assays,
they behaved differently in reversing the 6-OHDA induced cytotoxicity. As shown
in Figure 30, in contrast to compound 62b (D-629) (d), which showed no effect
on the 6-OHDA-induced toxicity, compound 76 (D-614) (c) exerted a dosedependent neuroprotective effect with the greatest protection (17%) seen at 20
µM dose point. As these two compounds differ only at the accessory binding site
moiety, it seems safe to assume that the indole ring could have a critical role in
conferring neuroprotective effect.
Following this, compound 76 (D-614) was also tested in another
neurotoxin induced cytotoxicity model in PC12 cells (Figure 31). When the PC12
cells were pre-treated 1 h with 76 (D-614) and co-treated with rotenone (1 µM)
for additional 24 h, unlike its propyl counterpart D-512 (unpublished work in lab),
this compound failed to exhibit any protective effect. This could result from the
increased reactivity of the molecule due to the propargyl replacement in
combination with the difference resided in the mechanisms of cytotoxicity
between neurotoxins 6-OHDA and rotenone.
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Figure 30. a-b) Dose-dependent effect of compounds 76 (D-614) (a) and 62b (D629) (b) at various concentrations on the viability of PC12 cells by 24 h treatment.
The results shown are means ± SEM of three independent experiments
performed in six to eight replicates. One-way ANOVA followed by Tukey’s
multiple comparison post hoc test was performed (* p ≤ 0.05, ** p ≤ 0.01, **** p ≤
0.0001 compared to the control). c-d) Dose-dependent effect on the viability of
PC12 cells by 24 h pretreatment of compounds 76 (D-614) (c) and 62b (D-629)
(d) at various concentrations (1-50 µM) followed by the single treatment of 75 µM
6-OHDA. The results shown are means ± SEM of three independent experiments
performed in six to eight replicates. One-way ANOVA followed by Tukey’s
multiple comparison post hoc test was performed (#### p ≤ 0.0001 compared to
the control; * p ≤ 0.05, *** p ≤ 0.001, **** p ≤ 0.0001 compared to the 6-OHDA
control).
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Figure 31. Dose-dependent effect on the viability of PC12 cells by 1 h
pretreatment of compound 76 (D-614) at various concentrations (1-50 µM)
followed by the co-treatment of 1 µM rotenone for 24 h. The results shown are
means ± SEM of three independent experiments performed in six to eight
replicates. One-way ANOVA followed by Tukey’s multiple comparison post hoc
test was performed (#### p ≤ 0.0001 compared to the control).

3.3.5. Reversal

of

reserpine-induced

hypolocomotion

in

rats

with

multifunctional MAO-B inhibitors
As mentioned previously, the administration of reserpine, a vesicular
monoamine transporter (VMAT) blocker, can generate a hypolocomotion model
in rat by inducing the exposure and depletion of monoamines in the synapse of
the peripheral sympathetic nerve terminals (Fernandes et al. 2012, Duty and
Jenner 2011, Leao et al. 2015). Compound 76 (D-614) was selected to assess its
ability to reverse the reserpine-induced hypolocomotion, which was established
18 h after administrating reserpine (5 mg/kg, s.c.). At the dose of 10 µmol/kg i.p.,
compound 76 (D-614) has effectively reversed akinesia induced by reserpine
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treatment, which is comparable to the reference drug ropinirole and has more
continuous effect throughout the assay (Figure 32). The observed moderate
locomotor stimulation of 76 (D-614) is likely to be mediated by the postsynaptic
D2/D3 receptor activation, which suggests a decent blood-brain barrier
penetration profile.
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Figure 32. Effect of compound 76 (D-614) and ropinirole on reserpine-induced
(5.0 mg/kg, s.c.) hypolocomotion in rats. Results are expressed as means ± SEM;
n=3 rats per value. Horizontal activity (HACTV), which is the total number of
beam interruptions that occurred in the horizontal sensor during a given sample
period, was measured as described in Chapter 4. Locomotor data during each
30-min interval after the administration of compound 76 (D-614) (i.p.) or ropinirole
(i.p.) at the dose of 10 µmol/kg compared to control reserpine treated rats in 18 h
post reserpine treatment was plotted. Differences among treatments were
significant by one-way ANOVA analysis (F (2, 36) = 10.57; p= 0.0002). Dunnett’s
analysis following ANOVA revealed that the effect of compound 76 (D-614) (p<
0.001) was significantly different when compared to reserpine control (Das et al.
2015).
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CHAPTER 4 MATERIALS AND METHODS
4.1.

Chemistry
All reagents and solvents were purchased from commercial suppliers and

used as received unless otherwise stated. Dry solvents were obtained according
to the standard procedure. All reactions were performed under inert atmosphere
(N2) unless otherwise indicated. Analytical silica gel 60 F254-coated TLC plates
were obtained from EMD Chemicals, Inc. and were visualized with UV light or by
treatment with phosphomolybdic acid (PMA), Dragendorff’s reagent, or ninhydrin.
Flash column chromatographic purifications were performed using Whatman
Purasil 60A silica gel 230−400 mesh. 1H NMR spectra were acquired on a Varian
400 and 600 MHz FT NMR spectrometer using tetramethylsilane (TMS) as the
internal standard. The NMR solvent used was CDCl3 or CD3OD as indicated.
Optical rotations were recorded on PerkinElmer 241 polarimeter. Melting points
were recorded using a MEL-TEMP II (Laboratory Devices Inc., Placerville, CA)
capillary melting point apparatus and were uncorrected. Elemental analyses were
performed by Atlantic Microlab, Inc.
Procedure A: (4-Ethoxy-4-oxobutyl)triphenylphosphonium bromide (2)
Triphenylphosphine (3.76 g, 14.34 mmol) and ethyl 4-bromobutyrate (2.0
g, 10.25 mmol) were added to a dried round bottom flask under argon. The
reaction mixture was heated to 120 °C under condenser for 16 h, after which the
reaction was allowed to come to room temperature. CH2Cl2 (10 mL) was added,
followed by diethyl ether until no further precipitation of product was observed.
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The precipitate was further washed with ether (100 mL) and dried in vacuo to
give pure compound 2 as a white solid (4.64 g) in quantitative yield. 1H NMR
(400 MHz, CDCl3): δ ppm 7.67-7.90 (m, 15 H), 3.98-4.12 (m, 4H), 2.86-2.89 (m,
2H), 1.88-1.94 (m, 2H), 1.22 (t, J = 7.2 Hz, 3H).
Procedure B: Ethyl 5-(4-hydroxy-3-methoxyphenyl)pent-4-enoate (4a)
Starting material 2 (6.61 g, 14.45 mmol) was added to dry THF (15 mL) in
an oven-dried round bottom flask. The resulting suspension was cooled to
−78 °C. Then a solution of NaHMDS (1M in THF, 15.77 mL, 15.77 mmol) was
added dropwise, and the reaction mixture was stirred at −78 °C for 1 h.
Thereafter, a solution of vanillin 3a (2.0 g, 13.14 mmol) in dry THF (5 mL) was
added dropwise, and reaction stirred at −78 °C for 2 h. Then it was warmed to
room temperature and stirred for 48 h. The reaction mixture was then extracted
with ethyl acetate (2 ×100 mL) and washed with brine. The combined organic
layer was dried over Na2SO4 and concentrated in vacuo. The crude thus
obtained was purified by column chromatography using 10% ethyl acetate in
hexanes to yield compound 4a (1.17 g, 36%) as colorless oil with a preferential
Z:E ratio of > 20:1. 1H NMR (400 MHz, CDCl3): δ ppm 6.88 (d, J = 8.2 Hz, 1H),
6.79-6.82 (m, 2H), 6.37 (d, J = 11.2 Hz, 1H), 5.64 (s, 1H), 5.49-5.55 (m, 1H), 4.13
(q, J = 7.2 Hz, 2H), 3.88 (s, 3H), 2.63-2.69 (m, 2H), 2.45 (t, J = 8.0 Hz, 2H), 1.24
(t, J = 7.2 Hz, 3H).
Ethyl 5-(2,5-dimethoxyphenyl)pent-4-enoate (4b)
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Starting material 2 (7.56 g, 16.53 mmol) was reacted with 2,5-dimethoxy
benzaldehyde 3b (2.5 g, 15.04 mmol) in the presence of NaHMDS 1M in THF
(18.05 mmol, 18.05 mL) according to procedure B. The crude was purified by
column chromatography using 7-10% ethyl acetate in hexanes to give compound
4b (1.71 g, 43%). 1H NMR (400 MHz, CDCl3): δ ppm 6.82 (d, J = 2.4 Hz, 1H),
6.74-6.79 (m, 2H), 6.52 (d, J = 11.2 Hz, 1H), 5.65-5.72 (m, 1H), 4.12 (q, J = 7.2
Hz, 2H), 3.78 (s, 3H), 3.77 (s, 3H), 2.55-2.60 (m, 2H), 2.41 (t, J = 7.2 Hz, 2H),
1.23 (t, J = 7.2 Hz, 3H).
Procedure C: Ethyl 5-(4-hydroxy-3-methoxyphenyl)pentanoate (5a)
Intermediate 4a (1.0 g, 4.00 mmol) was dissolved in ethanol (10 mL) in a
round bottom flask, and 10% Pd/C (0.10 g, 10 wt%) was added to it. The reaction
flask was degassed, and then the reaction mixture was stirred under hydrogen
atmosphere for 2 h at room temperature. After the completion of reaction, the
mixture was diluted with ethanol (20 mL) and passed through a short bed of
celite. The organic layer was concentrated to afford compound 5a (0.98 g) in
quantitative yield, which was pure enough for the next step. 1H NMR (400 MHz,
CDCl3): δ ppm 6.82 (d, J = 8.0 Hz, 1H), 6.65-6.67 (m, 2H), 4.12 (q, J = 7.2 Hz,
2H), 2.55 (t, J = 7.2 Hz, 2H), 3.87 (s, 3H), 2.31 (t, J = 7.2 Hz, 2H), 1.58-1.70
(m,4H), 1.24 (t, J = 7.2 Hz, 3H).
Ethyl 5-(2,5-dimethoxyphenyl)pentanoate (5b)
Intermediate 4b (1.0 g, 3.78 mmol) was dissolved in ethanol (10 mL) and
reacted with 10% Pd/C (0.1 g, 10 wt%) according to procedure C to afford
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compound 5b (0.96 g, 95%), which was used without further purification. 1H NMR
(400 MHz, CDCl3): δ ppm 6.75 (d, J = 8.8 Hz, 1H), 6.72 (d, J = 3.2 Hz, 1H), 6.68
(dd, J = 8.4, 2.4 Hz, 1H), 4.12 (q, J = 7.2 Hz, 2H), 3.76 (s, 3H), 3.75 (s, 3H), 2.60
(t, J = 7.4 Hz, 2H), 2.33 (t, J = 7.2 Hz, 2H), 1.56-1.70 (m, 4H), 1.24 (t, J = 7.2 Hz,
3H).
Procedure D: 5-(4-Hydroxy-3-methoxyphenyl)pentanal (6a)
To a solution of compound 5a (0.66 g, 2.62 mmol) in dry toluene (10 mL)
under argon was added DIBALH solution (1M in hexane, 2.87 mL, 2.87 mmol) at
−78 °C. The reaction mixture was stirred at −78 °C for 2 h. MeOH (0.20 mL) was
added to the reaction mixture, and the reaction mixture was allowed to come to
0 °C. It was then added to a separating funnel containing HCl (1N, 10 mL) and
extracted with ethyl acetate (3 × 30 mL). The combined organic layer was
washed with brine, dried over Na2SO4, and evaporated under reduced pressure.
The crude was purified by column chromatography using 11-15% ethyl acetate in
hexanes to yield compound 6a (0.23 g, 42%) as colorless oil.1H NMR (400 MHz,
CDCl3): δ ppm 9.75 (t, J = 1.6 Hz, 1H), 6.82 (d, J = 8.0 Hz, 1H), 6.65 (m, 2H),
3.87 (s, 3H), 2.56 (t, J = 7.2 Hz, 2H), 2.44 (td, J1 = 6.40 Hz, J2 = 1.60 Hz 2H),
1.59-1.68 (m, 4H).
5-(2,5-Dimethoxyphenyl)pentanal (6b)
Intermediate 5b (0.6 g, 2.25 mmol) was reduced with DIBALH solution
(1M in hexane, 2.47 mL, 2.47 mmol) in dry toluene (10 mL) using procedure D.
The crude was purified by column chromatography using 11-15% ethyl acetate in
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hexanes to give compound 6b (0.4 g, 80 %) as yellow oil. 1H NMR (400 MHz,
CDCl3): δ ppm 9.74 (d, J = 1.6 Hz, 1H), 6.76 (d, J = 8.8 Hz, 1H), 6.67-6.71 (m,
2H), 3.76 (s, 3H), 3.75 (s, 3H), 2.60 (t, J = 6.4 Hz, 2H), 2.44 (t, J = 6.8 Hz, 2H),
1.58-1.37(m, 4H).
Procedure E: 4-(5-((2-Amino-4,5,6,7-tetrahydrobenzo[d]thiazol-6yl)(propyl)amino)pentyl)-2-methoxyphenol ((±)-7a) (D-548).
Into a stirring solution of (±)-pramipexole (0.15 g, 0.71mmol) in CH2Cl2 (8
mL) was added aldehyde 6a (0.148 g, 0.71 mmol), and the mixture stirred for 1 h.
NaBH(OAc)3 (0.27 g, 1.27 mmol) was then added portion-wise followed by
MeOH (0.8 mL). The reaction was stirred for 36 h at room temperature. The
reaction mixture was quenched with a sat. NaHCO3 solution at 0 °C and
extracted with CH2Cl2 (3 × 25 mL). The combined organic layer was dried over
Na2SO4, and solvent was removed under reduced pressure. The crude product
was purified by column chromatography using 5-7% MeOH in CH2Cl2 to give
compound (±)-7a (0.2 g, 70%).1H NMR (400 MHz, DMSO-d6): δ ppm 6.64-6.72
(m, 2H), 6.58 (d, J = 8.4 Hz, 1H), 3.82 (s, 3H), 3.05 (bs, 1H), 2.50-2.67 (m, 10H),
1.59-1.70 (m, 3H), 1.48-1.53 (m, 4H), 1.28-1.36 (m, 3H), 0.89 (t, J = 7.2 Hz, 3H).
The free base was converted into its corresponding hydrochloride salt. Mp 224226 °C. Anal. (C26H43Cl2N3O4S) C, H, N.
(S)-4-(5-((2-Amino-4,5,6,7-tetrahydrobenzo[d]thiazol-6yl)(propyl)amino)pentyl)-2-methoxyphenol ((−)-7a) (D-591)
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Aldehyde 6a (0.148 g, 0.71 mmol), (−)-pramipexole (0.15 g, 0.71mmol),
and NaBH(OAc)3 (0.27 g, 1.27 mmol) in CH2Cl2 (8 mL) and MeOH (0.8 mL) were
reacted using procedure E, and the resulting crude was purified by column
chromatography using 5-7% MeOH in CH2Cl2 to give compound (−)-7a (0.19 g,
66%). 1H NMR (600 MHz, CD3OD): δ ppm 6.64-6.72 (m, 2H), 6.58 (d, J = 8.4 Hz,
1H), 3.82 (s, 3H), 3.05 (bs, 1H), 2.65-2.67 (m, 1H), 2.50-2.65 (m, 9H), 1.59-1.70
(m, 3H), 1.48-1.53 (m, 4H), 1.28-1.36 (m, 3H), 0.90 (t, J = 7.2 Hz, 3H). The free
base was converted into its corresponding hydrochloride salt. [α]D25 (salt) = −46.8
(c = 0.5 in CH3OH). Mp 196-198 °C. Anal. (C22H37Cl2N3O3S) C, H, N.
N6-(5-(2,5-Dimethoxyphenyl)pentyl)-N6-propyl-4,5,6,7tetrahydrobenzo[d]thiazole-2,6-diamine ((±)-7b)
Aldehyde 6b (0.157 g, 0.71 mmol), (±)-pramipexole (0.15 g, 0.71 mmol),
and NaBH(OAc)3 (0.27 g, 1.27 mmol) in CH2Cl2 (9 mL) and MeOH (0.8 mL) were
reacted using procedure E, and the resulting crude was purified by column
chromatography using 5-7% MeOH in CH2Cl2 to give compound (±)-7b (0.17 g,
58%). 1H NMR (400 MHz, CDCl3): δ ppm 6.75 (d, J = 8.8 Hz, 1H), 6.70 (d, J =
2.4 Hz, 1H), 6.66 (dd, J = 8.8, 2.1 Hz, 1H), 3.75 (s, 3H), 3.74 (s, 3H), 3.07 (bs,
1H), 2.69 (dd, J = 12.0, 4.04 Hz, 2H), 2.47-2.58 (m, 8H), 1.99-2.03(m, 1H), 1.681.78 (m, 1H), 1.40-1.61 (m, 6H), 1.31-1.37 (m, 2H), 0.89 (t, J = 7.2 Hz, 3H).
(S)-N6-(5-(2,5-Dimethoxyphenyl)pentyl)-N6-propyl-4,5,6,7tetrahydrobenzo[d]thiazole-2,6-diamine ((−)-7b)
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Aldehyde 6b (0.105 g, 0. 47 mmol), (−)-pramipexole (0.10 g, 0.47 mmol),
and NaBH(OAc)3 (0.18 g, 0.85 mmol) in CH2Cl2 (7 mL) and MeOH (0.6 mL) were
reacted using procedure E, and the resulting crude was purified by column
chromatography using 5-7% MeOH in CH2Cl2 to give compound (−)-7b (0.105 g,
53%). 1H NMR (600 MHz, CDCl3): δ ppm 6.76 (d, J = 8.4 Hz, 1H), 6.71 (d, J =
1.8 Hz, 1H), 6.67 (dd, J = 8.4, 3.0 Hz, 1H), 4.71 (bs, 2H), 3.77 (s, 3H), 3.76 (s,
3H), 3.04 (bs, 1H), 2.69 (d, J = 7.2 Hz, 2H), 2.4-2.6 (m, 8H), 2.0 (bs, 1H), 1.621.72 (m, 2H), 1.55-1.61 (m, 2H), 1.41-1.52 (m, 3H), 1.33-1.37 (m, 2H), 0.88 (t, J
= 7.2 Hz, 3H).
Procedure F: 4-(5-((2-Amino-4,5,6,7-tetrahydrobenzo[d]thiazol-6yl)(propyl)amino)pentyl)benzene-1,2-diol ((±)-8a) (D-575)
BBr3 1M in CH2Cl2 (2.66 mL, 2.66 mmol) was added to a solution of
compound (±)-7a (0.2 g, 0.50 mmol) in CH2Cl2 (20 mL) at −78 °C and stirred for 2
h. The reaction mixture was allowed to come to room temperature and stirred for
another 4 h. The reaction was then quenched by MeOH (20 mL) at 0 °C, and the
solvent was concentrated in vacuo. MeOH (20 mL) was added to the residue and
again evaporated. This process was repeated three times. The residue obtained
was purified by column chromatography using 10-15% MeOH in CH2Cl2 to give
pure compound (±)-8a (0.123 g, 64 %). 1H NMR (400 MHz, CD3OD): δ ppm 6.64
(d, J = 8.0 Hz, 1H), 6.60 (d, J = 2.4Hz, 1H), 6.47 (dd, J = 8.0, 2.4 Hz, 1H), 3.353.40 (m, 1H), 2.75-2.85 (m, 5H), 2.62-2.71 (m, 2H), 2.55-2.57 (m, 1H), 2.47 (t, J
= 7.2 Hz, 2H), 2.09-2.14 (m, 1H), 1.79-1.89 (m, 1H), 1.57-1.64 (m, 6H), 1.31-1.38
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(m, 2H), 0.95 (t, J = 7.6 Hz, 3H). The free base was converted into its
corresponding hydrochloride salt. Mp 196-198 °C. Anal. (C21H34Cl3N3O2S) C, H,
N.
(S)-4-(5-((2-Amino-4,5,6,7-tetrahydrobenzo[d]thiazol-6yl)(propyl)amino)pentyl)benzene-1,2-diol ((−)-8a) (D-593)
BBr3 1M in CH2Cl2 (1.61mL, 1.61 mmol) was reacted with compound (−)7a (0.132 g, 0.33 mmol) in CH2Cl2 (10 mL) according to procedure F to afford
crude, which was purified by column chromatography using 10-15% MeOH in
CH2Cl2 to give compound (−)-8a (90 mg, 71%). 1H NMR (600 MHz, CD3OD): δ
ppm 6.63 (d, J = 7.8 Hz, 1H), 6.58 (d, J = 1.8 Hz, 1H), 6.45 (dd, J = 7.8, 1.8 Hz,
1H), 2.97-3.02 (m, 1H), 2.42-2.62 (m, 10H), 1.95-1.97 (m, 1H), 1.60-1.73 (m, 1H),
1.53-1.58 (quintet, J = 7.8Hz, 2H), 1.42-1.48 (septet, J = 7.2 Hz, 4H), 1.26-1.31
(quintet, J = 7.2 Hz, 2H), 0.88 (t, J = 7.2 Hz, 3H). [α]D25 (free base) = − 51.8 (c =
1.0 in CH3OH); the free base was converted into its corresponding hydrochloride
salt. Mp 211-212 °C. Anal. (C21H35Cl2N3O3S) C, H, N.
2-(5-((2-Amino-4,5,6,7-tetrahydrobenzo[d]thiazol-6yl)(propyl)amino)pentyl)benzene-1,4-diol ((±)-8b) (D-584)
BBr3 1M in CH2Cl2 (2.27 mL, 2.27 mmol) was reacted with compound (±)7b (0.16 g, 0.38 mmol) according to procedure F to afford crude, which was
purified by column chromatography using 10-15% MeOH in CH2Cl2 to afford
compound (±)-8b (0.12 g, 80%). 1H NMR (600 MHz, CD3OD): δ ppm 6.55 (d, J =
8.4 Hz, 1H), 6.51 (d, J = 3.0 Hz, 1H), 6.41 (dd, J = 8.4, 3.0 Hz, 1H), 3.0 (m, 1H),
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2.44-2.63 61 (m, 10H), 1.98 (d, J = 10.2 Hz, 1H), 1.65-1.68 (m, 1H), 1.56-1.61 (m,
2H), 1.44-1.52 (m, 4H), 1.32-1.36 (m, 2H), 0.88 (t, J = 7.2 Hz, 3H). The free base
was converted into its corresponding hydrochloride salt. Mp 217-219 °C. Anal.
(C22H38Cl3N3O3S) C, H, N.
(S)-2-(5-((2-Amino-4,5,6,7-tetrahydrobenzo[d]thiazol-6yl)(propyl)amino)pentyl)benzene-1,4-diol ((−)-8b) (D-601)
BBr3 1M in CH2Cl2 (1.33 mL, 1.33 mmol) was reacted with compound (−)7b (93 mg, 0.22 mmol) in CH2Cl2 (6 mL) according to procedure F to afford crude,
which was purified by column chromatography using 10-15% MeOH in CH2Cl2 to
give compound (−)-8b (62 mg, 71%). 1H NMR (600 MHz, CD3OD): δ ppm 6.56
(dd, J = 8.4, 1.8 Hz, 1H), 6.52 (d, J = 2.4 Hz, 1H), 6.43 (dt, J = 8.4, 1.80 Hz, 1H),
2.98-3.03 (m, 1H), 2.44-2.64 (m, 10H), 1.99-2.00 (m, 1H), 1.63-1.71 (m, 1H),
1.57-1.62 (m, 2H), 1.46-1.52 (m, 4H), 1.32-1.37 (m, 2H), 0.90 (t, J = 7.2 Hz, 3H).
The free base was converted into its corresponding hydrochloride salt. [α]D25 (salt)
= −18.4 (c = 0.5 in CH3OH); Mp 222-224 °C. Anal. (C21H34Cl3N3O2S) C, H, N.
Procedure G: (Z)-Ethyl 5-(4-((tert-butyldimethylsilyl)oxy)-3methoxyphenyl)pent-4-enoate (9)
The (Z)-isomer of 4a was obtained by further purification of the mixture of
(E)-, (Z)-isomers through column chromatography using 10% ethyl acetate in
hexanes. Imidazole (0.35 g, 5.14 mmol) was added to a solution of intermediate
4a (0.52 g, 2.08 mmol) and tert-butyldimethylsilyl chloride (0.37 g, 2.45 mmol) in
DMF (5 mL). The solution was stirred at room temperature for 2 h. After the
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completion of reaction, sat. NaHCO3 (10 mL) was added and stirred for another
30 min. The reaction mixture was extracted with CH2Cl2 (2 x 50 mL). The
combined organic layer was dried over Na2SO4 and concentrated in vacuo. The
crude thus obtained was purified by column chromatography using 5% ethyl
acetate in hexanes to afford compound 9 (0.75 g) in quantitative yield. 1H NMR
(400 MHz, CD3OD): δ ppm 6.85 (s, 1H), 6.79 (d, J = 8.0 Hz, 1H), 6.73 (d, J = 8.4
Hz, 1H), 6.37 (d, J = 11.2 Hz, 1H), 5.47-5.55 (m, 1H), 4.10 (m, J = 7.2 Hz, 2H),
3.78 (s, 3H), 2.63 (q, J = 7.2 Hz, 2H), 2.44 (t, J = 7.2 Hz, 2H), 1.20 (t, J = 7.2 Hz,
3H), 0.99 (s, 9H), 0.13 (s, 6H).
Procedure H: (Z)-5-(4-((tert-Butyldimethylsilyl)oxy)-3-methoxyphenyl)pent4-en-1-ol (10)
Into a stirring solution of compound 9 (0.71 g, 1.95 mmol) in anhydrous
THF (15 mL) was added DIBALH solution 1 M in THF (9.73 mL, 9.73 mmol)
dropwise at −10 °C. The reaction mixture was stirred at room temperature for 6 h
and was quenched with MeOH (1 mL). The mixture was neutralized with 1N HCl
(15 mL) solution. The organic layer was separated, and the aqueous layer was
extracted with ethyl acetate (2 x 100 mL). The combined organic layer was dried
over Na2SO4 and concentrated in vacuo. The crude product was purified by
column chromatography using 11-15% ethyl acetate in hexanes to give
compound 10 (0.55 g, 88%). 1H NMR (CDCl3, 400 MHz): δ ppm 6.74-6.85 (m,
3H), 6.37 (d, J = 11.2 Hz, 1H), 5.48-5.53 (m, 1H), 3.80 (s, 3H), 2.67 (q, J = 7.2

106

Hz, 2H), 2.43 (t, J = 7.2 Hz, 2H), 1.22 (t, J = 7.2 Hz, 2H), 1.06 (s, 9H), 0.15 (s,
6H).
Procedure I: (Z)-5-(4-((tert-Butyldimethylsilyl)oxy)-3-methoxyphenyl)pent-4enal (11)
Alcohol 10 (0.9 g, 2.79 mmol) was slowly added to an ice cooled
suspension of PCC (pyridinium chlorochromate) (0.80 g, 3.71 mmol) in CH2Cl2
(90 mL), and the mixture was stirred at rt for 9 h. The reaction mixture was then
filtered over celite, and solvent was evaporated to get residue, which was purified
by column chromatography using 10-15% of ethyl acetate in hexanes to give
compound 11 (0.36 g, 40%). 1H NMR (CDCl3, 400 MHz): δ ppm 9.78 (s, 1H),
6.74-6.85 (m, 3H), 6.37 (d, J = 11.2 Hz, 1H), 5.49-5.52 (m, 1H), 3.80 (s, 3H),
2.56-2.68 (m, 4H), 0.99 (s, 9H), 0.16 (s, 6H).
Procedure J: (Z)-4-(5-((2-Amino-4,5,6,7-tetrahydrobenzo[d]thiazol-6yl)(propyl)amino)pent-1-en-1-yl)-2-methoxyphenol ((±)-12) (D-567)
Compound 11 (0.315 g, 0.98 mmol) was dissolved in THF (10 mL) and
cooled to 0 °C. TBAF (n-tetrabutylammonium fluoride) 1M in THF (1.02 mL, 1.02
mmol) was added, and reaction stirred in ice for 1.5 h. After reaction was
complete, 10% NaHCO3 solution (10 mL) was added, and reaction mixture was
extracted with CH2Cl2 (3 x 50 mL) to obtain aldehyde, which was immediately
taken to the next step without further purification. Aldehyde (0.195 g, 0.95 mmol),
(±)-pramipexole (0.20 g, 0.95 mmol), and NaBH(OAC)3 (0.36 g, 1.70 mmol) in
CH2Cl2 (7 mL) and MeOH (1.0 mL) were reacted using procedure E, and the
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resulting crude was purified by column chromatography using 5-7% MeOH in
CH2Cl2 to give compound (±)-12 (0.148 g, 39%). 1H NMR (400 MHz, CD3OD): δ
ppm 6.86 (d, J = 8.0 Hz, 1H), 6.76-6.82 (m, 2H), 6.35 (d, J = 12.4 Hz, 1H), 5.495.56 (m, 1H), 4.98 (bs, 1H), 3.86 (s, 3H), 3.1 (bs, 1H), 2.50-2.71 (m, 8H), 2.37 (q,
J = 7.2 Hz, 2H), 2.03 (bs, 1H), 1.44-1.70 (m, 5H), 0.88 (t, J = 7.2 Hz, 3H). The
free base was converted into its corresponding hydrochloride salt. Mp 212214 °C. Anal. (C22.5H36Cl3N3O2.5S) C, H, N.
(S)-2-Methoxy-4-(5-((5-methoxy-1,2,3,4-tetrahydronaphthalen-2yl)(propyl)amino)pentyl)phenol ((−)-13)
Aldehyde 6a (0.12 g, 0.58 mmol), (−)-5-methoxy-N-propyl-2-aminotetralin
(0.11 g, 0.50 mmol), and NaBH(OAc)3 (0.24 g, 1.13 mmol) in CH2Cl2 (8 mL) were
reacted using procedure E, and the resulting crude was purified by column
chromatography using 5% MeOH in CH2Cl2 to give compound (±)-13 (0.17 g,
82%). 1H NMR (600 MHz, CDCl3): δ ppm 7.08 (t, J = 7.8 Hz, 1H), 6.81 (d, J =
8.4Hz, 1H), 6.70 (d, J = 7.8Hz, 1H), 6.67-6.63 (m, 3H), 3.86 (s, 3H), 3.80 (s, 3H),
3.00-2.97 (m, 1H), 2.94-2.90 (m, 1H), 2.84-2.71 (m, 2H), 2.55-2.45 (m, 7H), 2.072.01 (m, 1H), 1.62-1.51 (m, 3H), 1.51-1.44 (m, 4H), 1.43-1.32 (m, 2H), 0.88 (t, J
= 7.2 Hz, 3H).
Procedure

K:

(S)-4-(5-((5-Hydroxy-1,2,3,4-tetrahydronaphthalen-2-

yl)(propyl)amino)pentyl)benzene-1,2-diol ((−)-14) (D-644)
Compound (−)-13 (95 mg, 0.23 mmol) was treated with 48% hydrobromic
acid (9.5 mL) and refluxed for 6 h. HBr was removed to obtain the residue, which
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was then dissolved in MeOH and filtered through cotton. The filtrate was
concentrated and washed with ether for several times followed by drying to give
the hydrobromide salt of compound (−)-14 (72 mg, 66%). 1H NMR (600 MHz,
CDCl3): δ ppm 6.96 (t, J = 7.8 Hz, 1H), 6.65-6.60 (m, 4H), 6.47 (d, J = 7.8 Hz,
1H), 3.67 (s, 1H), 3.27-3.23 (m, 2H), 3.11-3.04 (m, 5H), 2.66-2.60 (m, 1H), 2.50 (t,
J = 7.2 Hz, 2H), 2.31-2.25 (m, 1H), 1.89-1.83 (m, 1H), 1.76-1.74 (m, 4H), 1.681.63 (m, 2H), 1.43-1.39 (m, 2H), 1.03 (t, J = 7.2 Hz, 3H). [α]D25 (salt) = −29.55 (c
= 1.0 in CH3OH). Mp 151-153 °C. Anal. (C25H38BrNO4) C, H, N.
(3-Carboxypropyl)triphenylphosphonium bromide (16)
Triphenylphosphine

(7.82

g,

29.81

mmol)

was

reacted

with

4-

bromobutanoic acid 15 (4.15 g, 24.85 mmol) according to procedure A to give
compound 16 (9.5 g, 89%). 1H NMR (400 MHz, CDCl3): δ ppm 7.89-7.90 (m, 3 H),
7.82-7.85 (m, 6H), 7.76-7.79 (m, 6H), 3.45-3.49 (m, 2H), 2.59-2.61 (m, 2H), 1.92
(t, J = 6.6 Hz, 2H).
Procedure L: 5-(4-Hydroxy-3-methoxyphenyl)pent-4-enoic acid (17)
n-Butyl lithium 2.5 M in hexane (17.4 mL, 43.50 mmol) was added
dropwise to a solution of bis(trimethylsilyl)amine (9.91 mL, 47.28 mmol) in THF
(45 mL) at 0 °C, and the reaction mixture was stirred for 15 min after completion
of addition. Thereafter, the resulting LiHMDS was added to a solution of
intermediate 16 (8.46 g, 19.71 mmol) in THF (85 mL). The reaction mixture was
stirred at rt for 1 h after the last addition of base. Vanillin 3a (3.0 g, 19.72 mmol)
in THF (10 mL) was then added to the above solution, and the reaction mixture
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was stirred at rt for 24 h. After the completion of reaction, water was added, and
the layers were separated. The aqueous layer was then acidified to pH=2 with
conc. H2SO4 and extracted with ethyl acetate (3×150 mL). The combined organic
layers were dried over Na2SO4 and evaporated in vacuo. The residue obtained
was purified by column chromatography using 20 % ethyl acetate in hexanes to
yield compound 17 (3.0 g, 68%) preferentially as the E isomer. 1H NMR (600
MHz, CDCl3): δ ppm 6.92 (s, 1H), 6.76 (d, J = 7.8 Hz, 1H), 6.69 (d, J = 8.4 Hz,
1H), 6.32 (d, J = 15.6 Hz, 1H), 6.04-6.08 (m, 1H), 3.83 (s, 3H), 2.42-2.44 (m, 4H).
Procedure M: (E)-Methyl 5-(4-hydroxy-3-methoxyphenyl)pent-4-enoate (18)
To a solution of compound 17 (1.34 g, 6.03 mmol) in MeOH (20 mL) was
added acetyl chloride (0.94 mL, 13.22 mmol) at 0 °C, and the reaction mixture
was stirred for 1 h. The solution was allowed to come to room temperature and
stirred for another 3 h. The reaction was then quenched with saturated NaHCO3
solution and extracted with CH2Cl2 (3×50 mL). The organic layer was dried over
Na2SO4 and evaporated in vacuo. The (E)-isomer 18 was purified by column
chromatography using 15 % ethyl acetate in hexanes (0.72 g, 51%). 1H NMR
(600 MHz, CDCl3) δ ppm 6.82-6.86 (m, 3H), 6.34 (d, J = 15.6 Hz, 1H), 6.00-6.05
(m, 1H), 3.88 (s, 3H), 3.67 (s, 3H), 2.42-2.52 (m, 4H).
(E)-5-(4-Hydroxy-3-methoxyphenyl)pent-4-enal (19)
Intermediate 18 (0.425 g, 1.80 mmol) was reduced with DIBALH solution
1M in hexane (1.97 mL, 1.97 mmol) in dry toluene (8 mL) using procedure D. The
crude was purified by column chromatography using 15-25% ethyl acetate in
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hexanes to give compound 19 (0.14 g, 38%). 1H NMR (600 MHz, CDCl3): δ ppm
9.80(s, 1H), 6.79-6.86 (m, 3H), 6.32 (d, J = 15.6 Hz, 1H), 6.00-6.05 (m, 1H), 3.88
(s, 3H), 2.61 (t, J = 7.2 Hz, 2H), 2.52 (q, J = 7.2 Hz, 2H).
(E)-4-(5-((2-Amino-4,5,6,7-tetrahydrobenzo[d]thiazol-6yl)(propyl)amino)pent-1-en-1-yl)-2-methoxyphenol ((±)-20) (D-604)
Aldehyde 19 (0.11 g, 0.53 mmol), (±)-pramipexole (0.11 g, 0.52 mmol),
and NaBH(OAc)3 (0.2 g, 0.94 mmol) in CH2Cl2 (7 mL) and MeOH (0.7 mL) were
reacted using procedure E, and the resulting crude was purified by column
chromatography using 5-7% MeOH in CH2Cl2 to give compound (±)-20 (0.10 g,
48%).1H NMR (600 MHz, CDCl3): δ ppm 6.80-6.85 (m, 3H), 6.29 (d, J = 15.6 Hz,
1H), 6.02-6.07 (m, 1H), 4.86 (bs, 1H), 3.87 (s, 3H), 3.02 (bs, 1H), 2.62-2.69 (m,
2H), 2.38-2.54 (m, 6H), 2.17-2.21 (m, 2H), 1.96 (d, J = 10.2 Hz, 1H), 1.64-1.71
(m, 1H), 1.59 (t, J = 7.2 Hz, 2H), 1.45 (q, J = 7.2 Hz, 2H), 0.87 (t, J = 7.2 Hz, 3H).
The free base was converted into its corresponding hydrochloride salt. Mp 217219 °C. Anal. (C22H37Cl2N3O4S) C, H, N.
(S,E)-4-(5-((2-Amino-4,5,6,7-tetrahydrobenzo[d]thiazol-6yl)(propyl)amino)pent-1-en-1-yl)-2-methoxyphenol ((−)-20) (D-618)
Aldehyde 19 (55 mg, 0.27 mmol), (−)-pramipexole (56 mg, 0.26 mmol),
and NaBH(OAc)3 (0.1 g, 0.47 mmol) in CH2Cl2 (15 mL) were reacted using
procedure E, and the resulting crude was purified by column chromatography
using 10-15% MeOH in CH2Cl2 to give compound (−)-20 (57 mg, 54%). 1H NMR
(600 MHz, CDCl3): δ ppm 6.82-6.88 (m, 3H), 6.31 (d, J = 15.6 Hz), 6.04-6.09 (m,
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1H), 4.77 (bs, 2H), 3.90 (s, 3H), 3.05 (bs, 1H), 2.64-2.71 (m, 2H), 2.41-2.57 (m,
6H), 2.19-2.23 (m, 2H), 1.98 (d, J = 10.8 Hz, 1H), 1.67-1.74 (m, 1H), 1.61 (t, J =
7.2 Hz, 2H), 1.46 (q, J = 7.2 Hz, 2H), 0.89 (t, J = 7.2 Hz, 3H). The free base was
converted into its corresponding hydrochloride salt. [α]D25 (salt) = −56.00 (c = 1.0
in CH3OH). Mp 206-209 °C. Anal. (C24.8H41Cl3N3O2.7S) C, H, N.
6-(4-Hydroxy-3-methoxyphenyl)hex-5-enoic acid (22)
LiHMDS was prepared from n-butyl lithium 2.5 M in hexane (17.4 mL,
43.50 mmol) and bis(trimethylsilyl)amine (9.9 mL, 47.23 mmol) in THF (45 mL) at
0 °C for 15 min. Following procedure L, the resulting LiHMDS was added
dropwise to a solution of (4-carboxybutyl)triphenylphosphonium bromide 21 (8.7
g, 19.63 mmol) in THF (90 mL). And vanillin 3a (3 g, 19.72 mmol) in THF (10 mL)
was added after 1 h. The crude obtained was purified by column chromatography
using 30% ethyl acetate in hexanes to yield compound 22 (1.1 g, 24%). 1H NMR
(600 MHz, CDCl3): δ ppm 6.90-6.83 (m, 3H), 6.32 (d, J = 15.6 Hz, 1H), 6.01 (dt, J
= 15.6, 7.2 Hz, 1H), 3.87 (s, 3H), 2.41 (t, J = 7.2 Hz, 2H), 2.24 (q, J = 6.9 Hz, 2H),
1.82 (m, 2H).
6-(4-Hydroxy-3-methoxyphenyl)hexanoic acid (23)
Intermediate 22 (0.5 g, 2.12 mmol) was dissolved in ethanol (25 mL) and
reacted with 10% Pd/C (50 mg, 10 wt%) according to procedure C to afford
compound 23 (0.46 g, 91%), which was used without further purification. 1H NMR
(600 MHz, CDCl3): δ ppm 6.81 (d, J = 7.8 Hz, 1H), 6.65 (d, J = 7.8 Hz, 2H), 3.87
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(s, 3H), 2.53 (t, J = 7.5 Hz, 2H), 2.35 (t, J = 7.5 Hz, 2H), 1.69-1.64 (m, 2H), 1.631.58 (m, 2H), 1.40-1.35 (m, 2H).
Methyl 6-(4-hydroxy-3-methoxyphenyl)hexanoate (24)
Intermediate 23 (0.455 g, 1.91 mmol) was esterified with acetyl chloride
(0.3 mL, 4.22 mmol) in dry MeOH (12.5 mL) using procedure M. The extract was
concentrated to give compound 24 (0.450 g, 93%), which was pure enough for
the next step. 1H NMR (600 MHz, CDCl3): δ ppm 6.79 (d, J = 8.4 Hz, 1H), 6.65 (s,
1H), 6.62 (dd, J = 7.8, 1.8 Hz, 1H), 5.85 (bs, 1H), 3.81 (s, 3H),3.63 (s, 3H), 2.50
(t, J = 7.8 Hz, 2H), 2.28 (t, J = 7.8 Hz, 2H), 1.66-1.61 (m, 2H), 1.60-1.55 (m, 2H),
1.35-1.30 (m, 2H).
6-(4-Hydroxy-3-methoxyphenyl)hexanal (25)
Intermediate 24 (0.314 g, 1.24 mmol) was reduced with DIBALH solution
1M in hexane (1.45 mL, 1.45 mmol) in dry toluene (6 mL) using procedure D. The
crude was purified by column chromatography using 15% ethyl acetate in
hexanes to give compound 25 (89 mg, 32%). 1H NMR (600 MHz, CDCl3): δ ppm
9.75 (t, J = 1.5 Hz, 1H), 6.81 (d, J = 7.8 Hz, 1H), 6.66-6.64 (m, 2H), 5.49 (s, 1H),
3.86 (s, 3H), 2.53 (t, J = 7.8 Hz, 2H), 2.42 (td, J = 7.2, 1.8 Hz, 2H), 1.67-1.57 (m,
4H), 1.38-1.33 (m, 2H).
4-(6-((2-Amino-4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl)(propyl)amino)hexyl)2-methoxyphenol ((±)-26) (D-606)
Aldehyde 25 (60 mg, 0.27 mmol), (±)-pramipexole (57 mg, 0.27 mmol),
and NaBH(OAc)3 (103 mg, 0.49 mmol) in CH2Cl2 (7 mL) were reacted for 48 h
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using procedure E, and the resulting crude was purified by column
chromatography using 6% MeOH in CH2Cl2 to give compound (±)-26 (35 mg,
31%). 1H NMR (600 MHz, CDCl3): δ ppm 6.80 (d, J = 7.8 Hz, 1H), 6.66-6.64 (m,
2H), 4.79 (bs, 2H), 3.85 (s, 3H), 3.04-2.98 (m, 1H), 2.70-2.61 (m, 2H), 2.56-2.50
(m, 4H), 2.48-2.40 (m, 4H), 1.95 (d, J = 9.0 Hz, 1H), 1.71-1.65 (qd, J = 5.4, 11.4
Hz, 1H), 1.59-1.54 (m, 2H), 1.42 (t, J = 6.6 Hz, 4H), 1.31 (t, J = 3.0 Hz, 4H), 0.86
(t, J = 7.2 Hz, 3H). The free base was converted into its corresponding
hydrochloride salt. Mp 170-175 °C. Anal. (C25H45Cl2N3O4S) C, H, N.
Ethyl 2-(triphenylphosphoranylidene)acetate (28)
Ethyl bromoacetate 27 (1.98 mL, 17.86 mmol) was slowly added to a
stirring solution of triphenylphosphine (5.64 g, 21.50 mmol) in toluene (20 mL).
The reaction mixture was refluxed for 16 h and filtered. The filter cake was
washed with ethyl acetate (3 x 20 mL) to give phosphonium bromide (6.69 g,
87%). 1H NMR (CDCl3, 400 MHz): δ ppm 7.64-7.91 (m, 15H), 5.54 (d, J = 13.6
Hz, 2H), 4.01 (q, J = 7.2 Hz, 2H), 1.04 (t, J = 7.2 Hz, 3H). Into the solution of
phosphonium bromide (6 g, 13.98 mmol) in CH2Cl2 (50 mL) was added 1M
NaOH aqueous solution (50 mL, 50.00 mmol). The mixture was vigorously stirred
for 15 min, and the layers were separated. The aqueous layer was extracted with
CH2Cl2 (3 x 15 mL). The combined organic phase was dried over Na2SO4 and
concentrated to give compound 28 (4.28 g, 88%). 1H NMR (CDCl3, 400 MHz): δ
ppm 7.40-7.77 (m, 15H), (3.80, minor + 4.01, major) (q, J = 7.2 Hz, 2H), (2.70,
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minor + 2.92, major) (d, J = 22 Hz, 1H), (0.65, minor + 1.21, major) (t, J = 7.2 Hz,
3H).
(E)-Ethyl 3-(4-hydroxy-3-methoxyphenyl)acrylate (29)
A mixture of vanillin 3a (0.55 g, 3.61 mmol) and phosphonium ylide 28
(4.28 g, 12.29 mmol) was refluxed in chloroform (30 mL) for 5 h. The solvent was
removed, and the crude product was purified by column chromatography using
17% ethyl acetate in hexanes to give compound 29 (0.68 g, 85%). 1H NMR
(CDCl3, 400 MHz): δ ppm 7.49 (d, J = 15.9 Hz, 1H), 6.75-6.92 (m, 3H), 6.17 (d, J
= 15.7 Hz, 1H), 4.13 (q, J = 7.0 Hz, 2H), 3.70 (s, 3H), 1.19 (t, J = 7.2 Hz, 3H).
Ethyl 3-(4-hydroxy-3-methoxyphenyl)propanoate (30)
Intermediate 29 (1.0 g, 4.50 mmol) was dissolved in ethanol (10 mL) in a
round bottom flask, and 10% Pd/C (0.10 g, 10 wt%) was added to it. The reaction
was continued using procedure C. After the completion of reaction, the mixture
was diluted with ethanol (20 mL) and passed through a short bed of celite. The
organic layer was concentrated to afford compound 30 (0.95 g) as colorless oil in
quantitative yield which was pure enough for the next step. 1H NMR (400 MHz,
CDCl3): δ ppm 6.82 (d, J = 7.2 Hz, 1H), 6.68 (m, 2H), 4.12 (q, J = 7.2 Hz, 2H),
3.84 (s, 3H), 2.87 (t, J = 7.6 Hz, 2H), 2.58 (t, J = 8.0 Hz, 2H), 1.23 (t, J = 7.2 Hz,
3H).
3-(4-Hydroxy-3-methoxyphenyl)propanal (31)
Intermediate 30 (0.60 g, 2.68 mmol) was reduced with DIBALH solution
(1M in hexane, 2.93 mL, 2.93 mmol) in dry toluene (10 mL) using procedure D.
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The crude was purified by column chromatography using 12-15% ethyl acetate in
hexanes to give compound 31 (0.22 g, 46%) as yellow oil. 1H NMR (400 MHz,
CDCl3): δ ppm 9.81 (t, J = 1.6 Hz, 1H), 6.83 (d, J = 7.2 Hz, 1H), 6.68 (m, 2H),
3.87 (s, 3H), 2.89 (t, J = 7.6 Hz, 2H), 2.75 (t, J = 8.0 Hz, 2H).
4-(3-((2-Amino-4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl)(propyl)amino)propyl)2-methoxyphenol ((±)-32) (D-547)
Aldehyde 31 (0.30 g, 1.66 mmol), (±)-pramipexole (0.369 g, 1.75 mmol),
and NaBH(OAc)3 (0.633 g, 2.99 mmol) in CH2Cl2 (10 mL) and MeOH (1 mL)
were reacted using procedure E, and the resulting crude was purified by column
chromatography using 5-7% MeOH in CH2Cl2 to give compound (±)-32 (0.3 g,
48%).1H NMR (400 MHz, CD3OD): δ ppm 6.79 (s, 1H), 6.71 (d, J = 8.0 Hz, 1H),
6.64 (d, J = 8.0 Hz, 1H), 3.82 (s, 3H), 2.73-2.89 (m, 5H), 2.57-2.67 (m, 6H),
2.05-2.12 (m, 1H), 1.81-1.92 (m, 3H), 1.59 (m, 2H), 0.95 (t, J = 7.2 Hz, 3H). The
free base was converted into its corresponding hydrochloride salt. Mp 220222 °C. Anal. (C21H35Cl2N3O3S) C, H, N.
4-(3-((2-Amino-4,5,6,7-tetrahydrobenzo[d]thiazol-6yl)(propyl)amino)propyl)benzene-1,2-diol ((±)-33) (D-573)
BBr3 1M in CH2Cl2 (2.66 mL, 2.66 mmol) was reacted with compound (±)32 (0.2 g, 0.53 mmol) according to procedure F to afford crude, which was
purified by column chromatography using 15-20% MeOH in CH2Cl2 to provide
compound (±)-33 (0.12 g, 62%). 1H NMR (400 MHz, CD3OD) δ ppm 6.57 (d, J =
8.4 Hz, 1H), 6.53 (s, 1H), 6.41 (d, J = 8.4 Hz, 1H), 3.13 (bs, 1H), 2.39-2.66 (m,
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10H), 1.95 (m, 1H), 1.61-1.75 (m, 3H), 1.41-1.47 (m, 2H), 0.82 (t, J = 7.2 Hz, 3H).
The free base was converted into its corresponding hydrochloride salt. Mp 192194 °C. Anal. (C19H31Cl3N3O2.5S) C, H, N.
(E)-Ethyl 3-(4-((tert-butyldimethylsilyl)oxy)-3-methoxyphenyl)acrylate (34)
Compound 29 (1.78g, 8.01 mmol) was reacted with tert-butyldimethylsilyl
chloride (1.45 g, 9.62 mmol) and imidazole (1.36 g, 19.98 mmol) in DMF (6 mL)
according to procedure G. The mixture was extracted with water and diethyl
ether. The organic phase was washed with brine and dried over Na2SO4. Then it
was concentrated to give compound 34, which was pure enough for the next step
(2.42 g, 90%). 1H NMR (CDCl3, 400 MHz): δ ppm 7.62 (d, J = 15.2 Hz, 1H), 6.997.03 (m, 2H), 6.84 (d, J = 8.8 Hz, 1H), 6.30 (d, J = 16.0 Hz, 1H), 4.25 (q, J = 7.1
Hz, 2H), 3.83 (s, 3H), 1.33 (t, J = 7.2 Hz, 3H), 0.17 (s, 6H), 0.99 (s, 9H).
(E)-3-(4-((tert-Butyldimethylsilyl)oxy)-3-methoxyphenyl)prop-2-en-1-ol (35)
Compound 34 (2.4g, 7.13 mmol) in anhydrous THF (30 mL) was reacted
with DIBALH 1 M in THF (35.7 mL, 35.70 mmol) following procedure H to give
crude product, which was purified by column chromatography using 25% ethyl
acetate in hexanes to give compound 35 (1.97 g, 94%). 1H NMR (CDCl3, 400
MHz): δ ppm 6.90 (d, J = 1.6 Hz, 1H), 6.84 (dd, J = 8.0, 1.6 Hz, 1H), 6.79 (d, J =
8.0 Hz, 1H), 6.52 (d, J = 15.6 Hz, 1H), 6.22 (dt, J = 16.0, 6.0 Hz, 1H), 4.28 (d, J =
5.6 Hz, 2H), 3.81 (s, 3H), 0.99 (s, 9H), 0.15 (s, 6H).
(E)-3-(4-((tert-Butyldimethylsilyl)oxy)-3-methoxyphenyl)acrylaldehyde (36)
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MnO2 (3.54 g, 40.72 mmol) was added into a solution of compound 35
(0.8 g, 2.72 mmol) in CH2Cl2 (15 mL). The mixture was stirred at room
temperature for 24 h and was filtered through celite. The filter cake was washed
with ethyl acetate, and the filtrate was concentrated to give compound 36 (0.67 g,
84%). 1H NMR (CDCl3, 400 MHz): δ ppm 9.65 (d, J = 7.2 Hz, 1H), 7.40 (d, J =
16.0 Hz, 1H), 7.05-7.08 (m, 2H), 6.88 (d, J = 7.2 Hz, 1H), 6.60 (dd, J = 15.6, 7.6
Hz, 1H), 3.85 (s, 3H), 1.00 (s, 9H), 0.18 (s, 6H).
(E)-3-(4-Hydroxy-3-methoxyphenyl)acrylaldehyde (37)
Compound 36 (0.67 g, 2.29 mmol) in THF (10 mL) was reacted with TBAF
solution (1 M in THF, 2.52 mL, 2.52 mmol) according to procedure J to obtain the
crude, which was purified by column chromatography using 35% ethyl acetate in
hexanes to give compound 37 (0.343 g, 84%). It was immediately taken to the
next step.
(E)-4-(3-((2-Amino-4,5,6,7-tetrahydrobenzo[d]thiazol-6yl)(propyl)amino)prop-1-en-1-yl)-2-methoxyphenol ((±)-38) (D-570)
Aldehyde 37 (0.334 g, 1.87 mmol), (±)-pramipexole (0.395 g, 1.87 mmol),
and NaBH(OAc)3 (0.710 g, 3.35 mmol) in CH2Cl2 (10 mL) were reacted using
procedure E, and the resulting crude was purified by column chromatography
using 15% MeOH in CH2Cl2 to give compound 38 (0.21g, 30%). 1H NMR (CD3OD,
400 MHz): δ ppm 7.36 (d, J = 16.4 Hz, 1H), 7.20 (s, 1H), 7.10 (d, J = 8.0 Hz, 1H),
6.92 (dd, J = 15.2, 7.6 Hz, 1H), 6.81 (d, J = 8.4 Hz, 1H), 3.89 (s, 3H), 3.46 (s, 1H),
3.25 (dd, J = 15.6, 5.2 Hz, 1H), 2.99 (t, J = 7.1 Hz, 2H), 2.79-2.90 (m, 3H), 2.58-
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2.67 (m, 1H), 2.23-2.33 (m, 1H), 1.81-2.00 (m, 2H), 1.72 (q, J = 7.1 Hz, 2H), 1.03
(t, J = 7.2 Hz, 3H). The free base was converted into its corresponding
hydrochloride salt. Mp 205-207 °C. Anal. (C20H32Cl3N3O3S) C, H, N.
3,4-Dihydroxybenzaldehyde (39)
Vanillin 3a (3.0 g, 19.72 mmol) was reacted with BBr3 1M in CH2Cl2 (36.1
mL, 36.10 mmol) in CH2Cl2 (20 mL) following procedure F. The crude obtained
was purified by column chromatography using 20-25% ethyl acetate in hexanes
to afford compound 39 (2.18 g, 80%). 1H NMR (400 MHz, CDCl3): δ ppm 9.67 (s,
1H), 7.29 (m, 2H), 6.89 (d, J = 9.2 Hz, 1H).
3,4-bis((tert-Butyldimethylsilyl)oxy)benzaldehyde (40)
Imidazole (5.69 g, 83.58 mmol) was added to a solution of intermediate 39
(2.31 g, 16.72 mmol) and tert-butyldimethylsilyl chloride (6.30 g, 41.80 mmol) in
DMF (20 mL). The solution was reacted using procedure G. The crude thus
obtained was purified by column chromatography using 5% ethyl acetate in
hexanes to afford compound 40 (4.10 g, 67%). 1H NMR (400 MHz, CDCl3): δ
ppm 9.80 (s, 1H), 7.36 (m, 2H), 6.93 (d, J = 8.8 Hz, 1H), 0.99 (s, 9H), 0.98 (s,
9H), 0.24 (s, 6H), 0.22 (s, 6H).
(Z)-Ethyl 5-(3,4-bis((tert-butyldimethylsilyl)oxy)phenyl)pent-4-enoate (41)
Starting material 2 (5.48 g, 11.98 mmol) was reacted with compound 40
(4.0 g, 10.91 mmol) in the presence of NaHMDS 1M in THF (13.07 mmol, 13.07
mL) according to procedure B. The crude was then purified by column
chromatography using 5% ethyl acetate in hexanes to give compound 41 (2.0 g,
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39%). 1H NMR (400 MHz, CDCl3): δ ppm 6.81 (m, 2H), 6.73 (d, J = 8.4 Hz, 1H),
6.30 (d, J = 11.4 Hz, 1H), 5.46-5.50 (m, 1H), 4.12 (q, J = 7.3 Hz, 2H), 2.64 (q, J =
7.2 Hz, 2H), 2.41 (t, J = 7.2 Hz, 2H), 1.24 (t, J = 7.2 Hz, 3H), 0.97 (s, 18H), 0.19
(s, 6H), 0.18 (s, 6H).
(Z)-5-(3,4-bis((tert-Butyldimethylsilyl)oxy)phenyl)pent-4-enal (42)
Intermediate 41 (1.0 g, 2.15 mmol) was reduced with DIBALH solution 1M
in hexane (2.16 mL, 2.16 mmol) in dry toluene (15 mL) using procedure D. The
crude was purified by column chromatography using 10% ethyl acetate in
hexanes to give compound 42 (0.41 g, 45%) as yellow oil. 1H NMR (600 MHz,
CDCl3): δ ppm 9.76 (s, 1H), 6.77-6.79 (m, 2H), 6.73 (td, J = 7.2, 2.4 Hz, 1H), 6.33
(d, J = 11.4 Hz, 1H), 5.45-5.50 (m, 1H), 2.65 (q, J = 7.2 Hz, 2H), 2.56 (t, J = 7.2
Hz, 2H), 0.98 (s, 18H), 0.20 (s, 12H).
(Z)-N6-(5-(3,4-bis((tert-Butyldimethylsilyl)oxy)phenyl)pent-4-en-1-yl)-N6propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine ((±)-43)
Aldehyde 42 (0.3 g, 0.71 mmol), (±)-pramipexole (0.15 g, 0.71mmol), and
NaBH(OAc)3 (0.27 g, 1.27 mmol) in CH2Cl2 (10 mL) and MeOH (0.8 mL) were
reacted using procedure E, and the resulting crude was purified by column
chromatography using 5% MeOH in CH2Cl2 to give compound (±)-43 (0.22 g,
50%). 1H NMR (600 MHz, CD3OD): δ ppm 6.79 (m, 2H), 6.73 (d, J = 7.8 Hz, 1H),
6.29 (d, J = 11.4 Hz, 1H), 5.52 (m, 1H), 3.09 (bs, 1H), 2.44-2.66 (m, 8H), 2.342.37 (m, 2H), 1.96-1.99 (m, 1H), 1.60-1.72 (m, 3H), 1.44-1.51 (m, 2H), 0.97 (s,
18 H), 0.87 (t, J = 7.2 Hz, 3H), 0.18 (s, 12H).
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(Z)-4-(5-((2-Amino-4,5,6,7-tetrahydrobenzo[d]thiazol-6yl)(propyl)amino)pent-1-en-1-yl)benzene-1,2-diol and (Z)-4-(5-((2-amino4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl)(propyl)amino)pent-1-en-1yl)cyclohexa-3,5-diene-1,2-dione ( mixture of (±)-44 and (±)-45) (D-592)
Compound (±)-43 (0.21 g, 0.34 mmol) in THF (5 mL) was reacted with
TBAF 1M in THF (1.02 mL, 1.02 mmol) following procedure J. The crude was
purified by column chromatography using 15-20% MeOH in CH2Cl2 to give a
mixture of (±)-44 and (±)-45 (95 mg, 72%). 1H NMR (600 MHz, CD3OD): δ ppm
6.79 (s, 1H), 6.73 (s, 1H), 6.70 (d, J = 7.8 Hz, 1H), 6.63 (m, 2H), 6.59 (d, J = 8.4
Hz, 1H), 6.20-6.25 (m, 2H), 6.59 (dt, J = 15.6, 7.2 Hz, 1H), 5.46 (m, 1H), 3.0 (bs,
2H), 2.40-2.63(m, 16H), 2.32 (m, 2H), 2.16 (m, 2H), 1.95 (m, 2H), 1.56-1.70 (m,
6H), 1.41-1.51 (m, 4H), 0.85-0.90 (m, 6H). The free base was converted into its
corresponding hydrochloride salt. HRMS m/z [M + H]+: calcd for C21H30N3O2S,
388.2059; found 388.4567. Mp 212-214 °C. Anal. (C22H34.4N3Cl3O2.2S) C, H, N.
Procedure N: 2-(4-(2',5'-Dimethoxy-[1,1'-biphenyl]-4-yl)piperazin-1yl)acetaldehyde (47)
A solution of DMSO (0.11 mL, 1.55 mmol) in CH2Cl2 (1 mL) was added
into a round-bottom flask containing a stirring solution of oxalyl chloride (76 µL,
0.87 mmol) in CH2Cl2 (1 mL) at −78 °C. The mixture was stirred for 0.5 h at the
same temperature, and compound 46 (0.15 g, 0.44 mmol) in CH2Cl2 (1.5 mL)
was added. The stirring of the reaction mixture was continued at −78 °C for
another 0.5 h. Thereafter, Et3N (0.5 mL, 3.59 mmol) was added, and the reaction
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was allowed to warm to room temperature and continued for another 1 h. The
reaction mixture was quenched by the addition of a saturated solution of
NaHCO3 at 0 °C and was extracted with CH2Cl2 (3 × 20 mL). The combined
organic layer was dried over Na2SO4, and the solvent was removed in vacuo to
produce the crude, which was purified by column chromatography using ethyl
acetate to give compound 47 (0.11g, 0.74%). 1H NMR (600 MHz, CDCl3): δ ppm
9.75 (s, 1H), 7.45 (d, J = 9.0 Hz, 2H), 6.95 (d, J = 8.4 Hz, 2H), 6.88 (dd, J = 5.4,
3.6 Hz, 2H), 6.79 (dd, J = 9.0, 5.0 Hz, 1H), 3.30 (t, J = 4.8 Hz, 4H), 3.25 (d, J =
1.2 Hz, 2H), 2.70 (t, J = 4.8 Hz, 4H).
(S)-N-(2-(4-(2',5'-dimethoxy-[1,1'-biphenyl]-4-yl)piperazin-1-yl)ethyl)-5methoxy-N-propyl-1,2,3,4-tetrahydronaphthalen-2-amine ((−)-48)
Aldehyde 47 (0.11 g, 0.32 mmol), (−)-5-methoxy-N-propyl-2-aminotetralin
(0.071 g, 0.32 mmol), and NaBH(OAc)3 (0.137 g, 0.65 mmol) in CH2Cl2 (8 mL)
were reacted using procedure E, and the resulting crude was purified by column
chromatography using ethyl acetate to give compound (−)-48 (0.061 g, 35%). 1H
NMR (600 MHz, CDCl3): δ ppm 7.43-7.46 (m, 2H), 7.03 (t, J = 7.8 Hz, 1H), 6.94
(d, J = 9.0 Hz, 2H), 6.87-6.89 (m, 2H), 6.79 (dd, J = 8.4, 3.0 Hz, 1H), 6.70 (d, J =
7.8 Hz, 1H), 6.64 (d, J = 8.4 Hz, 1H), 3.80 (s, 3H), 3.79 (s, 3H), 3.74 (s, 3H), 3.24
(t, J = 5.4 Hz, 4H), 2.81-3.02 (m, 3H), 2.72-2.78 (m, 3H), 2. 66 (bs, 4H), 2.472.58 (m, 5H), 2.03-2.12 (m, 1H), 1.52-1.62 (m, 1H), 1.44-1.52 (m, 2H), 0.90 (t, J
= 7.2 Hz, 3H).
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(S)-4'-(4-(2-((5-hydroxy-1,2,3,4-tetrahydronaphthalen-2yl)(propyl)amino)ethyl)piperazin-1-yl)-[1,1'-biphenyl]-2,5-diol ((−)-49)
Intermediate (−)-48 (35 mg, 0.06 mmol) was treated with 48%
hydrobromic acid (4 mL) and refluxed for 6.5 h by following procedure K. The
crude was washed with ether for several times followed by drying to give the
hydrobromide salt of compound (−)-49 (42.5 mg, 84%). 1H NMR (600 MHz,
CDCl3): δ ppm 7.57 (d, J = 8.4 Hz, 2H), 7.24 (bs, 2H), 6.96 (t, J = 7.8 Hz, 1H),
6.67-6.72 (m, 3H), 6.58- 6.62 (m, 2H), 3.58-3.93 (m, 13H), 3.36-3.48 (m, 1H),
3.27-3.31 (m, 2H), 3.09-3.19 (m, 2H), 2.66-2.76 (m, 1H), 2.46-2.49 (m, 1H), 1.941.99 (m, 3H), 1.07 (t, J = 7.2 Hz, 3H). [α]D25 (salt) = −32.40 (c = 0.1 in CH3OH).
Mp 212-214 °C. Anal. (C31H47Br3N3O5.5) C, H, N.
(S)-N-(2-amino-4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl)-2nitrobenzenesulfonamide (51)
Into a stirring solution of 2-nitrobenzenesulfonyl chloride (0.488 g, 2.23
mmol) in THF (15 mL), Et3N (1.38 mL, 9.90 mmol) and (S)-4,5,6,7tetrahydrobenzo[d]thiazole-2,6-diamine 50 (0.41 g, 2.42 mmol) (Brown et al.
2009) were added at −10 °C, and the resulting suspension was then stirred at
room temperature for 1.5 h. The suspension was first filtered to remove
precipitated triethylammonium chloride, and the filtrate was concentrated in
vacuo. Water was added, and CH2Cl2 (3 × 30 mL) was used to extract the
product. The combined organic layer was dried over Na2SO4, and the solvent
was removed in vacuo to obtain sulfonamide 51 (0.7 g, 89%). 1H NMR (600 MHz,
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CD3OD): δ ppm 8.11-8.13 (m, 1H), 7.78-7.83 (m, 3H), 3.68-3.76 (m, 1H), 2.70
(dd, J = 15.6, 4.2 Hz, 1H), 2.47-2.51 (m, 3H), 1.83-1.91 (m, 1H), 1.78-1.81 (m,
1H).
Procedure O: (S)-N-(2-amino-4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl)-2-nitroN-(prop-2-yn-1-yl)benzenesulfonamide (53)
Sulfonamide 51 (0.52 g, 1.47 mmol), potassium carbonate (1.42 g, 10.27
mmol), and propargyl bromide 52 (0.22 mL, 2.78 mmol) were suspended in
acetonitrile (10 mL). The stirring mixture was heated to approximately 50 °C and
reacted for 24 h. After cooling to room temperature, the reaction mixture was
filtered, and the filtrate was condensed in vacuo. Water was added, and CH2Cl2
(3 × 20 mL) was used to extract the product. The combined organic layer was
dried over Na2SO4, and the solvent was removed in vacuo to give the crude,
which was purified by column chromatography using 1.5% MeOH in CH2Cl2 to
give intermediate 53 (0.345 g, 60%). 1H NMR (600 MHz, CDCl3): δ ppm 8.19 (dd,
J = 7.8, 1.8 Hz, 1H), 7.67-7.74 (m, 3H), 4.22-4.30 (m, 1H), 4.20 (d, J = 2.4 Hz,
2H), 3.04 (t, J = 13.2 Hz, 1H), 2.82 (dd, J = 15.6, 4.8 Hz, 1H), 2.68-2.77 (m, 2H),
2.21 (t, J = 2.4 Hz, 1H), 2.06−2.09 (m, 2H).
Procedure P: (S)-N6-(prop-2-yn-1-yl)-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6diamine (54)
Potassium carbonate (1.7 g, 12.30 mmol) was first suspended in DMF (6
mL), followed by the addition of thioglycolic acid (0.49 mL, 6.89 mmol) slowly into
the suspension at 0 °C. The mixture was stirred at room temperature for 1 h.
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Following the addition of intermediate 53 (0.54 g, 1.38 mmol) in DMF (6 mL), the
reaction mixture was heated to approximately 55 °C and stirred for another 17 h.
Then it was quenched carefully by the adding 1N NaOH at room temperature,
and CH2Cl2 (4 × 30 mL) was used to extract the product. The combined organic
layer was dried over Na2SO4, and the solvent was removed in vacuo to give the
crude, which was purified by column chromatography using 2-5% MeOH in
CH2Cl2 to give intermediate 54 (0.16 g, 56%). 1H NMR (600 MHz, CDCl3): δ ppm
4.79 (bs, 2H), 3.52 (dd, J = 4.2, 2.4 Hz, 2H), 3.23-3.27 (m, 1H), 2.85 (dd, J = 15.0,
5.4 Hz, 1H), 2.67 (dt, J = 17.4, 6.0 Hz, 1H), 2.59-2.63 (m, 1H), 2.39-2.44 (m, 1H),
2.23 (t, J = 2.4 Hz, 1H), 1.98-2.02 (m, 1H), 1.69-1.76 (m, 1H).
Pent-4-yn-1-yl 4-methylbenzenesulfonate (56)
Triethylamine (0.66 mL, 4.74 mmol), 4-(dimethylamino)pyridine (29 mg, 0.24
mmol), and toluene-4-sulfonyl chloride (0.498 g, 2.61 mmol) were added to an
ice-cooled solution of pent-4-yn-1-ol (0.11 mL, 1.18 mmol) in anhydrous CH2Cl2
(5 mL). The mixture was stirred at room temperature for overnight and then
diluted with CH2Cl2. The organic layer was then washed with water and dried
over Na2SO4. The solvent was removed in vacuo, and the residue was purified
by column chromatography using 20% ethyl acetate in hexanes to give
compound 56 (0.27 g, 96%). 1H NMR (600 MHz, CDCl3): δ ppm 7.78 (dd, J = 7.2,
1.8 Hz, 2H), 7.33 (d, J = 8.4 Hz, 2H), 4.13 (t, J = 6.0 Hz, 2H), 2.43 (s, 3H), 2.232.26 (m, 2H), 1.82-1.87 (m, 3H).
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(S)-N-(2-amino-4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl)-2-nitro-N-(pent-4-yn1-yl)benzenesulfonamide (57)
In the presence of potassium carbonate (0.257 g, 1.86 mmol),
sulfonamide 51 (0.11 g, 0.31 mmol) was reacted with intermediate 56 (0.081 g,
0.34 mmol) in acetonitrile (10 mL) at approximately 85 °C for 36 h by following
procedure O, and the resulting crude was purified by column chromatography
using 5% MeOH in CH2Cl2 to give compound 57 (0.103 g, 79%). 1H NMR (600
MHz, CDCl3): δ ppm 8.09 (dd, J = 7.2, 1.2 Hz, 1H), 7.68−7.74 (m, 2H), 7.65 (dd,
J = 7.2, 1.8 Hz, 1H), 4.71 (bs, 2H), 4.16-4.22 (m, 1H), 3.43 (ddd, J = 9.6, 6.0, 1.8
Hz, 2H), 2.67-2.85 (m, 4H), 2.23 (td, J = 6.6, 2.4 Hz, 2H), 1.84-2.01 (m, 5H).
(S)-N6-(pent-4-yn-1-yl)-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine (58)
Following procedure P, a solution of thioglycolic acid (0.083 mL, 1.17
mmol) in DMF (2 mL) was added into the suspension of potassium carbonate
(0.281 g, 2.03 mmol) in DMF (2 mL) at 0 °C and stirred at room temperature for
1h. After the addition of intermediate 57 (0.095 g, 0.23 mmol) in DMF (4 mL), the
reaction was heated to approximately 55 °C and stirred for another 20 h. The
resulting crude was purified by column chromatography using 5-20% MeOH in
CH2Cl2 to give compound 58 (0.04 g, 75%). 1H NMR (600 MHz, CDCl3): δ ppm
4.86 (bs, 2H), 3.02−3.03 (m, 1H), 2.89 (dd, J = 15.0, 4.2 Hz, 1H), 2.82 (t, J = 7.2
Hz, 2H), 2.66 (dt, J = 16.8, 5.4 Hz, 1H), 2.56-2.60 (m, 1H), 2.43 (dd, J = 15.6, 8.4
Hz, 1H), 2.29 (td, J = 6.9, 2.2 Hz, 2H), 2.02-2.05 (m, 1H), 1.96 (t, J = 2.7 Hz, 1H),
1.69-1.76 (m, 3H).
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Procedure Q: 2-(4-Phenylpiperazin-1-yl)ethan-1-ol (60a)
A suspension of 1-phenylpiperazine 59a (4.8 mL, 30.47 mmol), 2bromoethanol (4.37 mL, 61.61 mmol), and potassium carbonate (12.78 g, 92.47
mmol) in acetonitrile (100 mL) was refluxed for 4 h. The reaction mixture was
filtered, and the filtrate was evaporated in vacuo. The crude product was purified
by column chromatography using 5% MeOH in CH2Cl2 to give compound 60a
(5.36 g, 85%). 1H NMR (CDCl3, 600 MHZ): δ ppm 7.27 (t, J = 7.2 Hz, 2H), 6.93 (d,
J = 7.8 Hz, 2H), 6.87 (t, J = 7.2 Hz, 1H), 3.66 (t, J = 5.4 Hz, 2H), 3.21 (t, J = 5.4
Hz, 4H), 2.68 (t, J = 5.4 Hz, 4H), 2.61 (t, J = 5.4 Hz, 2H).
2-(4-(2,3-Dichlorophenyl)piperazin-1-yl)ethan-1-ol (60b)
1-(2,3-Dichlorophenyl)piperazine hydrochloride salt (1.5 g) was first
treated with saturated NaHCO3 solution and extracted with ethyl acetate to obtain
the corresponding free base. A solution of the free base 59b (0.54 g, 2.34 mmol),
2-bromoethanol (0.33 mL, 4.65 mmol), and potassium carbonate (0.97 g, 7.02
mmol) in acetonitrile (10 mL) was refluxed for 4 h by following procedure Q, and
the resulting crude was purified by column chromatography using 5% MeOH in
CH2Cl2 to give compound 60b (580 mg, 90%). 1H NMR (CDCl3, 400 MHZ): δ
ppm 7.14-7.16 (m, 2H), 6.94-6.97 (m, 1H), 3.67 (t, J = 5.6 Hz, 2H), 3.08 (bs, 4H),
2.71 (bs, 4H), 2.63 (t, J = 5.2 Hz, 2H).
2-(4-(2-Methoxyphenyl)piperazin-1-yl)ethan-1-ol (60c)
1-(2-methoxyphenyl)piperazine hydrochloride salt (1.6 g) was first treated
with saturated NaHCO3 solution and extracted with ethyl acetate to obtain the
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corresponding free base. A solution of the free base 59c (1.25 g, 6.50 mmol), 2bromoethanol (0.58 mL, 8.18 mmol), and potassium carbonate (2.25 g, 16.28
mmol) in ethanol (10 mL) was refluxed for 20 h by following procedure Q, and the
resulting crude was purified by column chromatography using 5% MeOH in
CH2Cl2 to give compound 60c (1.32 g, 86%). 1H NMR (CDCl3, 600 MHZ): δ ppm
7.00-7.03 (m, 1H), 6.91-6.96 (m, 2H), 6.86 (dd, J = 7.8, 1.2 Hz, 1H), 3.87 (s, 3H),
3.66 (t, J = 5.4 Hz, 2H), 3.10 (bs, 4H), 2.73 (bs, 4H), 2.63 (t, J = 5.4 Hz, 2H).
2-(4-(4-Fluorophenyl)piperazin-1-yl)ethan-1-ol (60d)
A solution of 1-(4-fluorophenyl)piperazine 59d (1.0 g, 5.55 mmol), 2bromoethanol (0.79 mL, 11.14 mmol), and potassium carbonate (2.3 g, 16.64
mmol) in acetonitrile (20 mL) was refluxed for 18 h by following procedure Q, and
the resulting crude was purified by column chromatography using 15% MeOH in
CH2Cl2 to give compound 60d (0.95 g, 77%). 1H NMR (CDCl3, 600 MHZ): δ ppm
6.95-6.98 (m, 2H), 6.87-6.89 (m, 2H), 3.66 (t, J = 5.4 Hz, 2H), 3.13 (t, J = 4.8 Hz,
4H), 2.68 (t, J = 4.8 Hz, 4H), 2.62 (t, J = 5.4 Hz, 2H).
2-(4-Phenylpiperazin-1-yl)acetaldehyde (61a)
Sulfur trioxide pyridine complex (0.7 g, 4.40 mmol) was dissolved in
DMSO (2 mL) and stirred at 0 °C for 15 min. Then this solution was added into a
solution of alcohol 60a (0.2 g, 0.97 mmol) in CH2Cl2 (4 mL) dropwise at 0 °C
followed by the addition of Et3N (1.3 mL, 9.33 mmol). The reaction mixture was
stirred at room temperature for 2 h. Later it was quenched with water and
extracted with CH2Cl2 (3 x 20 mL). The combined organic layer was dried over
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Na2SO4 and condensed in vacuo. The resulting crude was purified by column
chromatography using ethyl acetate to give compound 61a (0.12 g, 61%). 1H
NMR (CDCl3, 600 MHZ): δ ppm 9.75 (s, 1H), 7.28 (t, J = 8.4 Hz, 2H), 6.94 (d, J =
7.8 Hz, 2H), 6.88 (t, J = 7.2 Hz, 1H), 3.23-3.27 (m, 6H), 2.71 (t, J = 4.8 Hz, 4H).
2-(4-(2,3-Dichlorophenyl)piperazin-1-yl)acetaldehyde (61b)
DMSO (0.186 mL, 2.62 mmol, in 1.5 mL of CH2Cl2), oxalyl chloride (0.126
mL, 1.44 mmol in 2 mL of CH2Cl2), intermediate 60b (0.2 g, 0.73 mmol, in 1.5 mL
of CH2Cl2), and Et3N (0.8 mL, 5.74 mmol) were added in an order and reacted by
following procedure N, and the resulting crude was purified by column
chromatography using ethyl acetate to give compound 61b (0.159 g, 80%). 1H
NMR (400 MHz, CDCl3): δ ppm 9.75 (s, 1H), 7.13-7.18 (m, 2H), 6.96-6.99 (m,
1H), 3.28 (s, 2H), 3.12 (bs, 4H), 2.74 (bs, 4H).
2-(4-(2-Methoxyphenyl)piperazin-1-yl)acetaldehyde (61c)
DMSO (0.24 mL, 3.38 mmol, in 1 mL of CH2Cl2), oxalyl chloride (0.15 mL,
1.72 mmol in 4 mL of CH2Cl2), intermediate 60c (0.2 g, 0.85 mmol, in 2 mL of
CH2Cl2), and Et3N (0.7 mL, 5.02 mmol) were added in an order and reacted by
following procedure N, and the resulting crude was purified by column
chromatography using ethyl acetate to give compound 61c (0.134 g, 68%). 1H
NMR (600 MHz, CDCl3): δ ppm 9.75 (t, J = 1.8 Hz, 1H), 6.98-7.01 (m, 1H), 6.916.97 (m, 2H), 6.85-6.87 (m, 1H), 3.85 (d, J = 1.8 Hz, 3H), 3.25 (t, J = 2.4 Hz, 2H),
3.15 (bs, 4H), 2.74 (bs, 4H).
2-(4-(4-Fluorophenyl)piperazin-1-yl)acetaldehyde (61d)
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DMSO (0.25 mL, 3.52 mmol, in 2 mL of CH2Cl2), oxalyl chloride (0.155 mL,
1.78 mmol in 4 mL of CH2Cl2), intermediate 60d (0.2 g, 0.89 mmol, in 2 mL of
CH2Cl2), and Et3N (0.75 mL, 5.38 mmol) were added in an order and reacted by
following procedure N, and the resulting crude was purified by column
chromatography using ethyl acetate to give compound 61d (0.138 g, 70%). 1H
NMR (600 MHz, CDCl3): δ ppm 9.75 (t, J = 1.2 Hz, 1H), 6.95-6.97 (m, 2H), 6.876.90 (m, 2H), 3.26 (d, J = 1.2 Hz, 2H), 3.18 (t, J = 4.8 Hz, 4H), 2.71 (t, J = 4.8 Hz,
4H).
(S)-N6-(2-(4-phenylpiperazin-1-yl)ethyl)-N6-(prop-2-yn-1-yl)-4,5,6,7tetrahydrobenzo[d]thiazole-2,6-diamine (62a) (D-674)
Aldehyde 61a (69 mg, 0.34 mmol) and amine 54 (70 mg, 0. 34 mmol)
were reacted in the presence of NaBH(OAc)3 (143 mg, 0.67 mmol) in CH2Cl2 (10
mL) at room temperature for 48 h by using procedure E, and the resulting crude
was purified by column chromatography using 3-10% MeOH in CH2Cl2 to give
compound 62a (40 mg, 30%). 1H NMR (400 MHz, CDCl3): δ ppm 7.26 (t, J = 8.4
Hz, 2H), 6.92 (d, J = 8.0 Hz, 2H), 6.85 (t, J = 7.2 Hz, 1H), 4.76 (bs, 2H), 3.57 (d,
J = 2.0 Hz, 2H), 3.21 (t, J = 5.2 Hz, 4H), 3.06-3.13 (m, 1H), 2.81-2.88 (m, 3H),
2.62-2.73 (m, 6H), 2.55-2.60 (m, 3H), 2.22 (t, J = 2.4 Hz, 1H), 2.11-2.14 (m, 1H),
1.70-1.80 (m, 1H). [α]D25 (free base) = − 45.81 (c = 0.62 in CH3OH); the free base
was converted into its corresponding hydrochloride salt. Mp 158-161 °C. Anal.
(C23.5H41Cl4N5O1.5S) C, H, N.
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(S)-N6-(2-(4-(2,3-dichlorophenyl)piperazin-1-yl)ethyl)-N6-(prop-2-yn-1-yl)4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine (62b) (D-629)
Aldehyde 61b (79 mg, 0.29 mmol) and amine 54 (60 mg, 0. 29 mmol)
were reacted in the presence of NaBH(OAc)3 (123 mg, 0.58 mmol) in CH2Cl2 (10
mL) at room temperature for 48 h by using procedure E, and the resulting crude
was purified by column chromatography using 3-5% MeOH in CH2Cl2 to give
compound 62b (35 mg, 26%). 1H NMR (600 MHz, CDCl3): δ ppm 7.14 – 7.17 (m,
2H), 6.95-6.97 (dd, J = 7.2, 2.4 Hz, 1H), 4.77 (bs, 2H), 3.58 (d, J = 1.8 Hz, 2H),
3.08-3.12 (m, 5H), 2.83-2.88 (m, 3H), 2.72-2.82 (m, 4H), 2.60-2.70 (m, 5H), 2.23
(t, J = 1.8 Hz, 1H), 2.12-2.14 (m, 1H), 1.74-1.77 (m, 1H). [α]D25 (free base) = −
22.8 (c = 1.0 in CH3OH); the free base was converted into its corresponding
hydrochloride salt. Mp 170-172 °C. Anal. (C23.6H35Cl6N5O0.4S) C, H, N.
(S)-N6-(2-(4-(2-methoxyphenyl)piperazin-1-yl)ethyl)-N6-(prop-2-yn-1-yl)4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine (62c) (D-676)
Aldehyde 61c (81 mg, 0.35 mmol) and amine 54 (72 mg, 0. 35 mmol)
were reacted in the presence of NaBH(OAc)3 (147 mg, 0.69 mmol) in CH2Cl2 (10
mL) at room temperature for 48 h by using procedure E, and the resulting crude
was purified by column chromatography using 3-8% MeOH in CH2Cl2 to give
compound 62c (41 mg, 28%).1H NMR (400 MHz, CDCl3): δ ppm 6.90-7.02 (m,
3H), 6.86 (d, J = 8.0 Hz, 1H), 4.77 (bs, 2H), 3.86 (s, 3H), 3.58 (s, 2H), 3.11 (bs,
5H), 2.83-2.89 (m, 3H), 2.72 (bs, 5H), 2.57-2.62 (m, 4H), 2.21 (d, J = 2.0 Hz, 1H),
2.12-2.15 (m, 1H), 1.70-1.80 (m, 1H). [α]D25 (free base) = − 25.4 (c = 1.0 in
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CH3OH); the free base was converted into its corresponding hydrochloride salt.
Mp 163-165 °C. Anal. (C23H38Cl4N5O1.5S) C, H, N.
(S)-N6-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)-N6-(prop-2-yn-1-yl)-4,5,6,7tetrahydrobenzo[d]thiazole-2,6-diamine (62d) (D-680)
Aldehyde 61d (45 mg, 0.20 mmol) and amine 54 (42 mg, 0. 20 mmol)
were reacted in the presence of NaBH(OAc)3 (86 mg, 0.41 mmol) in CH2Cl2 (10
mL) at room temperature for 44 h by using procedure E, and the resulting crude
was purified by column chromatography using 3-10% MeOH in CH2Cl2 to give
compound 62d (23 mg, 27%). 1H NMR (600 MHz, CDCl3): δ ppm 6.94-6.97 (m,
2H), 6.86-6.88 (m, 2H), 4.87 (bs, 2H), 3.57 (d, J = 2.4 Hz, 2H), 3.07-3.14 (m, 5H),
2.82-2.88 (m, 3H), 2.55-2.71 (m, 9H), 2.22 (d, J = 2.4 Hz, 1H), 2.11-2.14 (m, 1H),
1.72-1.78 (m, 1H). [α]D25 (free base) = − 39.6 (c = 1.0 in CH3OH); the free base
was converted into its corresponding hydrochloride salt. Mp 156-159 °C. Anal.
(C24H40Cl4FN5O2S) C, H, N.
(S)-N6-(2-(4-(2,3-dichlorophenyl)piperazin-1-yl)ethyl)-N6-(pent-4-yn-1-yl)4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine (62e) (D-664)
Aldehyde 61b (58 mg, 0.21 mmol) and amine 58 (60 mg, 0.25 mmol) were
reacted in the presence of NaBH(OAc)3 (104 mg, 0.49 mmol) in CH2Cl2 (8 mL) at
room temperature for 48 h by using procedure E, and the resulting crude was
purified by column chromatography using 5-10% MeOH in CH2Cl2 to give
compound 62e (30 mg, 29%). 1H NMR (CDCl3, 600 MHz): δ ppm 7.13-7.17 (m,
2H), 6.96 (dd, J = 7.2, 2.4 Hz, 1H), 4.79 (bs, 2H), 3.01-3.07 (m, 5H), 2.51-2.74 (m,
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14H), 2.27 (td, J = 6.6, 2.4 Hz, 2H), 1.98-2.00 (m, 1H), 1.95 (t, J = 2.4 Hz, 1H),
1.64-1.77 (m, 3H). [α]D25 (free base) = − 20.93 (c = 1.0 in CH3OH); the free base
was converted into its corresponding hydrochloride salt. Mp 177-180 °C. Anal.
(C24H37Cl6N5S) C, H, N.
(S,E)-4-(5-((2-amino-4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl)(prop-2-yn-1yl)amino)pent-1-en-1-yl)-2-methoxyphenol (63) (D-649)
Aldehyde 61b (80 mg, 0.39 mmol) and amine 54 (72 mg, 0.35 mmol) were
reacted in the presence of NaBH(OAc)3 (164 mg, 0.77 mmol) in CH2Cl2 (10 mL)
at room temperature for 40 h using procedure E, and the resulting crude was
purified by column chromatography using ethyl acetate to give compound 62e
(48.4 mg, 35%). 1H NMR (CDCl3, 600 MHz): δ ppm 6.83-6.87 (m, 3H), 6.31 (d, J
= 15.6 Hz, 1H), 6.06 (dt, J = 15.6, 7.2 Hz, 1H), 4.75 (bs, 2H), 3.90 (s, 3H), 3.49
(dd, J = 13.8, 2.4 Hz, 2H), 3.06-3.10 (m, 1H), 2.80 (dd, J = 15.6, 5.4 Hz, 1H),
2.70 (t, J = 6.6 Hz, 3H), 2.56-2.65 (m, 2H), 2.22 (q, J = 6.6 Hz, 2H), 2.20 (t, J =
2.4 Hz, 1H), 2.11-2.13 (m, 1H), 1.74 (dq, J = 11.4, 5.4 Hz, 1H), 1.63-1.68 (m, 2H).
[α]D25 (free base) = − 46.25 (c = 1.0 in CH3OH); the free base was converted into
its corresponding hydrochloride salt. Mp 202-205 °C. Anal. (C24H39Cl3N3O3.5S) C,
H, N.
1-(2-((tert-Butyldimethylsilyl)oxy)ethyl)piperazine (66)
A

suspension

of

piperazine

64

(10.0

g,

116.09

mmol),

(2-

bromoethoxy)(tert-butyl)dimethylsilane 65 (11.1 g, 46.4 mmol), and potassium
carbonate (48.13 g, 348.27 mmol) in acetonitrile (100 mL) was refluxed for 15 h.
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The reaction mixture was filtered, and the filtrate was condensed in vacuo. The
residue was then diluted with ether, washed with water, dried over Na2SO4,
filtered, and concentrated to produce intermediate 66 (10.7 g, 95%). 1H NMR
(CDCl3, 600 MHz): δ ppm 3.73 (t, J = 6.0 Hz, 2H), 2.86 (t, J = 4.8 Hz, 4H),
2.46−2.50 (m, 6H), 0.86 (s, 9H), 0.03 (s, 6H).
tert-Butyl 6-bromo-1H-indole-1-carboxylate (68)
Into a stirring solution of 6-bromo-1H-indole 67 (2.0 g, 10.2 mmol) in THF
(20 mL) were added (Boc)2O (2.45 g, 11.22 mmol) and DMAP (1.37 g, 11.22
mmol) at room temperature. The reaction mixture was stirred at the same
temperature for 12 h, and then was condensed in vacuo. After the extraction with
ethyl acetate (3 × 20 mL) in water, the combined organic layer was dried over
Na2SO4, filtered, and concentrated in vacuo. The crude was purified by column
chromatography using 5% ethyl acetate in hexanes to give compound 68 (2.98 g,
99%). 1H NMR (CDCl3, 600 MHz): δ ppm 8.36 (bs, 1H), 7.55 (s, 1H), 7.40 (d, J =
8.4 Hz, 1H), 7.33 (dd, J = 7.2, 1.2 Hz, 1H), 6.52 (d, J = 4.2 Hz, 1H), 1.67 (s, 9H).
tert-Butyl 6-(4-(2-((tert-butyldimethylsilyl)oxy)ethyl)piperazin-1-yl)-1Hindole-1-carboxylate (69)
The mixture of intermediate 68 (0.382 g, 1.29 mmol), intermediate 66
(0.63 g, 2.58 mmol), BINAP (79.7 mg, 0.13 mmol), and Cs2CO3 (1.26 g, 3.87
mmol) in toluene (15 mL) was degassed by bubbling N2 for 5 min. Then
Pd(OAc)2 (21.6 mg, 0.10 mmol) was added quickly followed by degassing for
another 5 min. The reaction mixture was refluxed for 24 h under inert condition.
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Afterward, it was cooled to room temperature, filtered through a pad of celite,
washed with CH2Cl2, and concentrated in vacuo. The resulting crude was purified
by column chromatography using 30% ethyl acetate in hexanes to give
compound 69 (0.35 g, 59%). 1H NMR (CDCl3, 600 MHz): δ ppm 7.77 (bs, 1H),
7.44 (s, 1H), 7.40 (d, J = 8.4 Hz, 1H), 6.93 (dd, J = 6.6, 2.4 Hz, 1H), 6.45 (d, J =
3.6 Hz, 1H), 3.81 (t, J = 6.6 Hz, 2H), 3.25 (t, J = 4.8 Hz, 4H), 2.72 (t, J = 4.8 Hz,
4H), 2.60 (t, J = 6.0 Hz, 2H), 1.65 (s, 9H), 0.91 (s, 9H), 0.08 (s, 6H).
tert-Butyl 6-(4-(2-hydroxyethyl)piperazin-1-yl)-1H-indole-1-carboxylate (70)
Compound 69 (0.57 g, 1.24 mmol) was reacted with TBAF 1M in THF
(1.49 mL, 1.49 mmol) in THF (10 mL) following procedure J for 2 h. The crude
was purified by silica gel column chromatography using 20% MeOH in ethyl
acetate to give compound 69 (0.31 g, 72%). 1H NMR (CDCl3, 600 MHz): δ ppm
7.78 (bs, 1H), 7.45 (s, 1H), 7.41 (dd, J = 5.4, 3.0 Hz, 1H), 6.91−6.93 (m, 1H),
6.45 (d, J = 3.6 Hz, 1H), 3.68 (t, J = 6.0 Hz, 2H), 3.25−3.26 (m, 4H), 2.72−2.73
(m, 4H), 2.60−2.64 (m, 2H), 1.66 (s, 9H).
tert-Butyl 7-chloro-6-(4-(2-oxoethyl)piperazin-1-yl)-1H-indole-1-carboxylate
(71)
DMSO (0.33 mL, 4.63 mmol, in 1.5 mL of CH2Cl2), oxalyl chloride (0.22
mL, 2.55 mmol, in 2 mL of CH2Cl2), intermediate 70 (0.4 g, 1.16 mmol, in 5 mL of
CH2Cl2), and Et3N (0.97 mL, 6.95 mmol) were added in order and reacted
following procedure N, and the resulting crude was purified by column
chromatography using 40% ethyl acetate in hexanes to give compound 71 (0.21
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g, 48%). 1H NMR (CDCl3, 600 MHz): δ ppm 9.76 (s, 1H), 7.44 (d, J = 3.6 Hz, 1H),
7.41 (d, J = 8.4 Hz, 1H), 7.02 (d, J = 8.4 Hz, 1H), 6.49 (d, J = 3.6 Hz, 1H),
3.24−3.29 (m, 4H), 3.20 (m, 4H), 2.76 (m, 2H), 1.64 (s, 9H).
tert-Butyl (S)-6-(4-(2-((2-amino-4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl)(prop2-yn-1-yl)amino)ethyl)piperazin-1-yl)-7-chloro-1H-indole-1-carboxylate (72)
Aldehyde 71 (0.2 g, 0.53 mmol) and amine 54 (0.1 g, 0.48 mmol) were
reacted in the presence of NaBH(OAc)3 (0.22 g, 1.06 mmol) in CH2Cl2 (20 mL) at
room temperature for 65 h using procedure E, and the resulting crude was
purified by column chromatography using 10% MeOH in CH2Cl2 to give
compound 72 (0.06 g, 23%).1H NMR (CDCl3, 600 MHz): δ ppm 7.43 (d, J = 3.0
Hz, 1H), 7.39 (d, J = 7.8 Hz, 1H), 7.01 (d, J = 8.4 Hz, 1H), 6.48 (d, J = 3.6 Hz,
1H), 4.77 (bs, 2H), 3.58 (d, J = 2.4 Hz, 2H), 3.10-3.16 (m, 5H), 2.83-2.88 (m, 3H),
2.59-2.73 (m, 9H), 2.23 (t, J = 1.8 Hz, 1H), 2.13-2.15 (m, 1H), 1.73-1.79 (m, 1H),
1.64 (s, 9H). [α]D25 (free base) = − 28.0 (c = 1.0 in CH3OH).
Procedure R: (S)-N6-(2-(4-(7-chloro-1H-indol-6-yl)piperazin-1-yl)ethyl)-N6(prop-2-yn-1-yl)-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine (73) (D-635)
Into a stirred solution of compound 72 (0.017 g, 0.03 mmol) in CH2Cl2 (2
mL) at 0 °C, trifluoroacetic acid (TFA) (2 mL) was added slowly and the reaction
mixture was stirred for another 2 h at room temperature. Unreacted TFA and
solvent were removed in vacuo, and the obtained solid was washed with ether for
several times followed by drying to yield the TFA salt of 73 (0.017 g, 79%). 1H
NMR (CD3OD, 600 MHz): δ ppm 7.48 (d, J = 7.8 Hz, 1H), 7.26 (d, J = 3.0 Hz, 1H),
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6.95 (d, J = 8.4 Hz, 1H), 6.45 (d, J = 3.6 Hz, 1H), 3.63 (d, J = 2.4 Hz, 2H), 3.42 (t,
J = 6.0 Hz, 2H), 3.34 (s, 3H), 3.29-3.30 (m, 5H), 3.18-3.24 (m, 3H), 2.80 (dd, J =
15.6, 4.8 Hz, 1H), 2.78 (t, J = 2.4 Hz, 1H), 2.67-2.71 (m, 2H), 2.58-2.62 (m, 1H),
2.19 (d, J = 10.8 Hz, 1H), 1.84-1.91 (m, 1H). HRMS m/z [M + H]+: calcd for
C24H29ClN6SH, 469.1941; found, 469.1930. [α]D25 = −21.33 (c = 1.0 in CH3OH).
Mp 118-122 °C. Anal. (C28.8H37ClF6N6O6.2S) C, H, N.
tert-Butyl (S)-5-(4-(2-((2-amino-4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl)(prop2-yn-1-yl)amino)ethyl)piperazin-1-yl)-4-chloro-1H-indole-1-carboxylate (75)
Aldehyde 74 (0.22 g, 0.58 mmol), which was obtained according to
literature (Johnson et al. 2012, 2013), and amine 54 (0.11 g, 0.52 mmol) were
reacted in the presence of NaBH(OAc)3 (0.25 g, 1.16 mmol) in CH2Cl2 (12 mL) at
room temperature for 40 h using procedure E, and the resulting crude was
purified by column chromatography using 5% MeOH in CH2Cl2 to give compound
75 (0.08 g, 29%). 1H NMR (CDCl3, 600 MHz): δ ppm 7.98 (bs, 1H), 7.59 (s, 1H),
7.09 (dd, J = 6.6, 2.4 Hz, 1H), 6.67 (d, J = 3.6 Hz, 1H), 5.07 (bs, 2H), 3.58 (d, J =
2.4 Hz, 2H), 3.11-3.15 (m, 5H), 2.82-2.89 (m, 3H), 2.68-2.74 (m, 4H), 2.56-2.65
(m, 4H), 2.51 (s, 1H), 2.24 (t, J = 2.4 Hz, 1H), 2.12-2.14 (m, 1H), 1.71-1.78 (m,
1H), 1.66 (s, 10H). [α]D25 = −28.3 (c = 1.0 in CH2Cl2).
(S)-N6-(2-(4-(4-chloro-1H-indol-5-yl)piperazin-1-yl)ethyl)-N6-(prop-2-yn-1-yl)4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine (76) (D-614)
Compound 75 (0.07 g, 0.12 mmol) was reacted with trifluoroacetic acid (3
mL) in CH2Cl2 (3 mL) following procedure R to produce the TFA salt of 76 (0.1 g,
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90%). 1H NMR (CD3OD, 600 MHz): δ ppm 7.29 (dd, J = 6.0, 3.0 Hz, 1H), 7.24
(dd, J = 6.6, 3.0 Hz, 1H), 7.00 (q, J = 8.4 Hz, 1H), 6.47 (d, J = 3.0 Hz, 1H), 3.59
(d, J = 2.4 Hz, 2H), 3.33 (s, 1H), 3.10-3.15 (m, 5H), 2.95-2.99 (m, 5H), 2.77-2.85
(m, 3H), 2.66-2.67 (m, 1H), 2.59-2.64 (m, 2H), 2.48-2.53 (m, 2H), 2.11-2.13 (m,
1H), 1.72-1.80 (m, 1H). LRMS m/z [M + H]+: calcd for C24H29ClN6SH, 469.19;
found, 469.19. [α]D25 = −19.6 (c = 1.0 in CH3OH). Mp 165-170 °C. Anal.
(C31H34Cl3F9N6O6S) C, H, N.
1,6-Dimethoxynaphthalene (78)
Intermediates 78-81 were synthesized based on a published procedure
with slight modification (Hirayama, Ikunaka, and Matsumoto 2005). Into a stirring
suspension of 1,6-dihydroxynaphthalene 77 (20 g, 124.87 mmol) and potassium
carbonate (63.8 g, 461.62 mmol) in acetone (80 mL), dimethyl sulfate (41.5 mL,
437.60 mmol) was added slowly over 15 min at room temperature. The mixture
was refluxed for 4h and was cooled to room temperature afterwards. It was
filtered, and the filtrate was evaporated in vacuo. The resulting crude was purified
by column chromatography using 5% ethyl acetate in hexanes to give compound
78 (15.9 g, 68%). 1H NMR (CDCl3, 600 MHz): δ ppm 8. 25 (d, J = 9.6 Hz, 1H),
7.38-7.42 (m, 2H), 7.21 (dd, J = 10.8, 1.8 Hz, 1H), 7.16 (d, J = 2.4 Hz, 1H), 6.72
(d, J = 7.2 Hz, 1H), 4.01 (s, 3H), 3.94 (s, 3H).
5-Methoxy-3,4-dihydronaphthalen-2(1H)-one (79)
Slices of sodium (14.7 g, 639.41 mmol) was added into a stirring solution
of intermediate 78 (10 g, 53.13 mmol) in EtOH (250 mL) over 45 min at 40-60 °C,
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and the reaction mixture was refluxed for 2h. Then it was gradually cooled 0 °C,
and water (100 mL) was added with caution. Concentrated aqueous hydrochloric
acid (approximately 50 mL) was added drop wise into the mixture to reduce the
pH of solution to around 2, and it was refluxed for another 1 h. The solvents were
removed in vacuo, and CH2Cl2 (4 x 200 mL) was used to extract the product. The
resulting crude was purified by column chromatography using 3-4% ethyl acetate
in hexanes to give compound 79 (5.71 g, 61%). 1H NMR (CDCl3, 600 MHz): δ
ppm 7.18 (t, J = 7.8 Hz, 1H), 6.78 (d, J = 7.8 Hz, 1H), 6.74 (d, J = 7.8 Hz, 1H),
3.85 (s, 3H), 3.57 (s, 2H), 3.09 (t, J = 6.6 Hz, 2H), 2.53 (t, J = 6.6 Hz, 2H).
(E)-5-methoxy-3,4-dihydronaphthalen-2(1H)-one O-methyl oxime (80)
Methoxyamine hydrochloride (3.87 g, 46.34 mmol) was first dissolved in
60% (v/v) aqueous solution of MeOH (50 mL), and then sodium acetate (3.8 g,
46.32 mmol) was added at room temperature to render the mixture pH neutral. A
solution of 79 (4.9 f, 27.81 mmol) in the same MeOH aqueous solution (50 mL)
was added slowly, and the reaction mixture was continued to stir at room
temperature for 2 h. The solvents were evaporated to one third in vacuo, and
ethyl acetate (3 x 100 mL) was used extracted the product. The obtained crude
was purified by column chromatography using 2% ethyl acetate in hexanes to
give compound 80 (5.06 g, 89%). 1H NMR (CDCl3, 600 MHz): δ ppm 7.14 (t, J =
7.8 Hz, 1H), 6.70-6.80 (m, 2H), 3.89 and 3.84 (s, total 3H), 3.83 (s, 3H), 3.75 and
3.49 (s, total 2H), 2.87 (dt, J = 9.6, 6.6 Hz, 2H), 2.62 and 2.51 (t, J = 6.6 Hz, total
2H).
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5-Methoxy-1,2,3,4-tetrahydronaphthalen-2-amine hydrochloride (81)
Into a solution of intermediate 80 (1.28 g, 6.24 mmol) in MeOH (25 mL)
and 10% (w/v) solution of HCl in MeOH (11 mL), 10% Pd/C (128 mg, 10% of wt)
was added in portions with caution. The resultant suspension was placed at a
shaker hydrogenation apparatus and shaken under an atmosphere of hydrogen
(initial pressure 2.0 bar) at room temperature for 2.5 h. The reaction mixture was
filtered through celite to remove the catalyst and washed with MeOH (3 x 20 mL).
The combined filtrate was concentrated in vacuo, and recrystallized with ethyl
acetate (25 mL). The precipitated solid was filtered and dried to give compound
81 (0.94 g, 71%). 1H NMR (CDCl3, 600 MHz): δ ppm 7.12 (t, J = 7.8 Hz, 1H),
6.76 (d, J = 8.4 Hz, 1H), 6.70 (d, J = 7.8 Hz, 1H), 3.80 (s, 3H), 3.47-3.50 (m, 1H),
3.10 (dd, J = 15.6, 4.8 Hz, 1H), 2.95 (dt, J = 18.0, 5.4 Hz, 1H), 2.81 (dd, J = 15.6,
9.6 Hz, 1H), 2.63-2.69 (m, 1H), 2.19-2.23 (m, 1H), 1.75-1.82 (m, 1H).
N-(2-(4-(2,3-dichlorophenyl)piperazin-1-yl)ethyl)-5-methoxy-1,2,3,4tetrahydronaphthalen-2-amine (82)
Aldehyde 61b (270 mg, 0.99 mmol) and amine 81 (175 mg, 0. 99 mmol)
were reacted in the presence of NaBH(OAc)3 (419 mg, 1.98 mmol) in CH2Cl2 (15
mL) at room temperature for 40 h by using procedure E, and the resulting crude
was purified by column chromatography using 5% MeOH in CH2Cl2 to give
compound 82 (359 mg, 84%). 1H NMR (CDCl3, 600 MHz): δ ppm 7.13-7.17 (m,
2H), 7.10 (t, J = 7.8 Hz, 1H), 6.95 (dd, J = 7.2, 3.0 Hz, 1H), 6.71 (d, J = 7.8 Hz,
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1H), 6.66 (d, J = 8.4 Hz, 1H), 3.81 (s, 3H), 3.49 (t, J = 1.8 Hz, 3H), 3.01-3.04 (m,
5H), 2.87-2.96 (m, 4H), 2.56-2.68 (m, 8H), 2.10-2.12 (m, 1H), 1.16-1.65 (m, 1H).
N-(2-(4-(2,3-dichlorophenyl)piperazin-1-yl)ethyl)-5-methoxy-N-(prop-2-yn-1yl)-1,2,3,4-tetrahydronaphthalen-2-amine (83)
Intermediate 82 (57 mg, 0.13 mmol) was reacted with propargyl bromide
52 (15 µL, 0.19 mmol) in the presence of potassium carbonate (127 mg, 0.92
mmol) in acetonitrile (10 mL) at 50-60 °C for 4 h by following procedure O, and
the resulting crude was purified by column chromatography using ethyl acetate to
give compound 83 (33 mg, 53%). 1H NMR (CDCl3, 600 MHz): δ ppm 7.12-7.16
(m, 2H), 7.09 (t, J = 7.8 Hz, 1H), 6.96 (dd, J = 7.2, 2.4 Hz, 1H), 6.71 (d, J = 7.8
Hz, 1H), 6.65 (d, J = 7.8 Hz, 1H), 3.80 (s, 3H), 3.61 (d, J = 2.4 Hz, 2H), 2.94-3.04
(m, 7H), 2.89 (t, J = 7.2 Hz, 2H), 2.70-2.82 (m, 5H), 2.53-2.64 (m, 3H), 2.17-2.20
(m, 2H), 1.59-1.64 (m, 1H).
6-((2-(4-(2,3-dichlorophenyl)piperazin-1-yl)ethyl)(prop-2-yn-1-yl)amino)5,6,7,8-tetrahydronaphthalen-1-ol (84) (D-675)
Intermediate 83 (70 mg, 0.15 mmol) was reacted with BBr3 (1M in CH2Cl2)
(0.44 mL, 0.44 mmol) in CH2Cl2 (10 mL) at −40 °C for 2h and room temperature
for another 2 h by following procedure F. The crude obtained was purified by
column chromatography using ethyl acetate to afford compound 84 (57 mg, 84%).
1H

NMR (CDCl3, 600 MHz): δ ppm 7.13-7.17 (m, 2H), 6.95-7.00 (m, 2H), 6.65 (d,

J = 7.8 Hz, 1H), 6.56 (d, J = 7.8 Hz, 1H), 3.57 (d, J = 2.4 Hz, 2H), 3.10 (bs, 4H),
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2.86-2.98 (m, 5H), 2.66-2.75 (m, 5H), 2.62 (t, J = 7.2 Hz, 2H), 2.53-2.58 (m, 1H),
2.21 (t, J = 2.4 Hz, 1H), 2.14-2.18 (m, 1H), 1.55-1.60 (m, 1H).
4.2.

Dopamine D2 and D3 Receptor Assays
The binding assay was carried out to determine the inhibition constants (Ki)

of the synthesized compounds by observing the inhibition of [3H] spiroperidol (15
Ci/mmol, PerkinElmer) binding to rD2 or rD3 receptors expressed in HEK-293
cells in a buffer containing 0.9% NaCl (Ghosh et al. 2010, Zhen et al. 2010). The
Cheng–Prusoff equation was used to convert the observed IC50 into inhibition
constants (Ki) (Zhen et al. 2010). The functional activity of selected compounds
was assessed by measuring stimulation of [35S]GTPγS (1,250 Ci/mmol,
PerkinElmer) binding in comparison to dopamine, the full agonist, to evaluate
their ability of activating hD2 and hD3 receptors expressed in CHO cells as
described by us previously (Ghosh et al. 2010, Zhen et al. 2010).
4.3.

Reagents for biological evaluations
Dulbecco’s phosphate-buffered saline, thioflavin T (ThT), thiazolyl blue

tetrazolium bromide (MTT), human recombinant monoamine oxidase (MAO)
enzymes, kynuramine, and pargyline were purchased from Sigma-Aldrich. Uranyl
acetate and formvar-coated carbon-stabilized copper grid (400 mesh) were
purchased from Electron Microscopy Sciences (EMS). Dimethyl sulfoxide (DMSO)
and methanol were purchased from Fischer Scientific.
4.4.

In vitro αSN anti-aggregation study
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Selected novel multifunctional D2/D3 dopamine agonists were tested in an
in vitro assay to determine their ability to inhibit αSN aggregation. The plasmid
pET28 containing αSN expressing cDNA was used for recombinant synthesis
and purification of the protein by following the published procedure (Huang et al.
2005, Shevchik, Condemine, and Robertbaudouy 1994). The purified protein was
aliquoted, lyophilized, and then stored at −80 °C.
4.4.1. Shaking study
All the samples were prepared in sterilized PBS (pH = 7.4). The
lyophilized recombinant αSN was first dissolved in PBS and filtered through a
0.22 µm filter to remove preformed aggregates. Samples of αSN (60 µM) were
shaken (1,400 rpm) in the presence or absence of test compound (120 µM), (−)8a (D-593), in a Thermomixer R shaker (Eppendorf, Hamburg, Germany) at
37 °C for a period of 6 days. D-520 was used as the reference compound here.
Drugs were also tested alone (120 µM) to show any direct effect on assays.
Aliquots were collected at the beginning (0D) and at the endpoint (6D) of the
experiment, which were analyzed by transmission electron microscope (TEM),
circular dichroism (CD) spectra to gain information on the morphology and
protein structure of αSN. In addition, thioflavin T (ThT) assay and cell viability
assay were used to determine the effect of compounds on αSN fibrilization and
toxicity. Assays were carried out in three independent experiments.
4.4.2. Preparation of αSN preformed fibrils (PFF)
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The lyophilized recombinant αSN was dissolved in sterilized PBS (pH =
7.4). and filtered through a 0.22 µm filter to remove preformed aggregates. Then
a solution of αSN (5 mg/mL) was shaken (1,000 rpm) at 37ºC in a Thermomix R
shaker (Eppendorf, Hamburg, Germany) for a period of 5 days, which was
aliquoted and stored at -80ºC until use (Volpicelli-Daley et al. 2011).
4.4.3. Seeding study
All the samples were prepared in sterilized PBS (pH = 7.4). The
lyophilized recombinant αSN was first dissolved in PBS and filtered through a
0.22 µm filter to remove preformed aggregates. Monomeric αSN at 1.25 mg/mL
(86.45 μM) was seeded with 0.5% (v/v) of PFFs at 37ºC in the presence or
absence of test compounds (−)-8a (D-593), (−)-20 (D-618), and (−)-14 (D-644) at
172.9 μM without agitation. Monomeric αSN (86.45 μM) without seeding and
drugs alone (172.9 μM) were also tested. Aliquots were collected at 0D, 10D time
points. For compound (−)-49 (D-670), an extended seeding experiment was
carried out for 30 days in comparison to its parent compound D-520, and aliquots
were collected at 0D, 10D, 20D, and 30D time points. TEM and CD spectra were
used to characterize the morphology and structure of αSN in the seeded
aggregation. The aliquots were analyzed by ThT assay and cell viability assay to
determine the effect of compounds on αSN fibrilization and toxicity. Assays were
carried out in three independent experiments.
4.4.4. Transmission electron microscope (TEM)
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The aliquots obtained from the shaking and seeding studies were
characterized by TEM. Protein aliquots (4 μL) were applied to the formvar-coated
carbon-stabilized copper grids (400 mesh) and absorbed for 4 min. The grids
were then rinsed briefly with distilled water twice, negatively stained with 2%
aqueous uranyl acetate solution, air-dried, and examined with a JEOL (JEM 2010)
transmission electron microscope at an accelerating voltage of 200 kV and
80,000 magnification.
4.4.5. Circular dichroism (CD)
CD spectra were obtained using a Jasco J-1500 CD spectrophotometer to
characterize the secondary structure of collected αSN aliquots. αSN samples
were diluted to 20 µM by ultrapure water to minimize the absorption caused by
buffer for CD spectra measurements. Spectra were recorded in a 0.1 mm pathlength cuvette from 260 to 190 nm with a step size of 1 nm and a bandwidth of 1
or 3 nm. For all spectra, an average of five scans was obtained. CD spectra of
the appropriate buffer was recorded and subtracted from the protein spectra.
4.4.6. Thioflavin T (ThT) assay
The extent of fibrillization of αSN was evaluated with ThT fluorescence
assay (Narkiewicz, Giachin, and Legname 2014). The assay was carried out
following a published protocol (Modi et al. 2014). 10 μL of the aliquots were
mixed with 10 μL of ThT solution (40 μM in PBS) in a 384 well black plate (solid
bottom, Corning). ThT fluorescence level was measured in duplicates
immediately after addition by using the Synergy Hybrid H1 fluorescence
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microplate reader (BioTek) at 440/485 nm (excitation/emission) wavelength with
auto-sensitivity mode. Assays were carried out in three independent experiments.
4.4.7. Cell viability
PC12 cells were seeded at 17,000 cells/well density in a 96-well plate and
allowed to attach for 24 h. The collected αSN aliquots were diluted with cell
medium and treated to the cells for 24 h; the final concentration resulted from
dilution were 10 µM for αSN and 20 µM for the compounds. The cell viability was
measured by MTT assay, which will be described in details in the section 4.6.1.
4.5.

Human monoamine oxidase (hMAO) inhibition studies
To determine the ability of selected compounds in inhibiting MAO enzyme,

a fluorometric screening was carried out following published protocols with some
modifications (Yan et al. 2004, Novaroli et al. 2005, Chimenti et al. 2013). The
activity of enzyme was determined by measuring the fluorescence generated
from the MAO catalyzed oxidation of kynuramine to 4-hydroxyquinoline (4-HQ).
Commercially available microsomes from insect cells containing recombinant
hMAO-A and hMAO-B (Sigma-Aldrich) were used as the enzyme source in this
study. They were pre-aliquoted to avoid repeated freeze-thaw cycles and stored
at −80 °C. During experiment preparation, they were thawed rapidly in a 37 °C
water bath and kept on ice until use. Kynuramine was used as the substrate for
both MAO-A and MAO-B, and potassium phosphate buffer (0.1 M, pH 7.4, made
isotonic with KCl 20.2 mM) was used as the assay buffer. The final volume of the
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reaction was set to 200 µL. Pargyline, a potent MAO-B inhibitor, was included in
the assay as a reference compound.
4.5.1. Initial hMAO-B inhibition screening
Selected compounds were first examined at a dose of 25 µM for their
inhibitory activity against hMAO-B. The final concentration of enzyme and
substrate were set to 15 µg/mL and 25 µM, respectively. Stocks of compounds
(50 mM) were prepared in DMSO, whose percentage was kept at 0.05% in the
final assay reaction mixture. Substrate (50 µL/well) and compound solutions (100
µL/well) were added into a black 96-well plate and pre-incubated at 37 °C for 10
min. The control wells received assay buffer instead of compound solutions. The
enzymatic reaction was initiated by the addition of hMAO-B solution (50 µL/well).
The reaction mixture was then incubated at 37 °C for 20 min, and subsequently
2N NaOH aqueous solution (75 µL/well) was added to terminate the reaction.
The fluorescence of 4-HQ, was measured in triplicates using the Synergy Hybrid
H1 fluorescence microplate reader (BioTek) at the wavelength pair of 310/400
nm (excitation/emission), and the readings were averaged and normalized with
respect to the control. Assays were carried out in three independent experiments.
4.5.2. IC50 values determination
Compounds, which reduced the hMAO-B activity to near half in the initial
screening were considered hit molecules and were tested further for the IC50
values for both hMAO-A and hMAO-B to determine their selectivity index. Seven
doses of test compounds (0-250 µM) were used, and the final concentration of
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enzyme was set to 15 µg/mL. The final concentrations of substrate for measuring
either hMAO-A or hMAO-B activity were set to 40 µM and 25 µM, respectively.
The fluorescence was measured in either duplicates or triplicates, and the IC50
values were determined from non-linear regression of dose-response curves
using GraphPad Prism 6.0 (GraphPad Software, San Diego, CA, USA). Assays
were carried out in three independent experiments.
4.6.

Cell culture and treatments
PC12 Adh cells (ATCC® CRL1721.1TM, Manassas, VA, USA), a rat

adrenal pheochromocytoma cell line, were cultured in T-75 flasks (Greiner Bio
One, Frickenhausen, Germany) and maintained in RPMI 1640 medium
supplemented with 10% heat-inactivated horse serum, 5% fetal bovine serum,
100 units/mL penicillin, and 100 μg/mL streptomycin at 37 °C in 5% CO2
atmosphere. Stock solutions of compounds (−)-8a (D-593), (−)-20 (D-618), (−)-14
(D-644), (−)-49 (D-670), 76 (D-614), 62b (D-629) (100 mM) and rotenone (40 mM)
were prepared in DMSO and stored at −20 °C. Stock solution (1 M) of 6hydroxydopamine (6-OHDA) was prepared in DMSO and aliquots were stored at
−80 °C.
4.6.1. Cytotoxicity assay in PC12 cells
The effect of compounds (−)-8a (D-593), (−)-20 (D-618), (−)-14 (D-644),
(−)-49 (D-670), 76 (D-614), and 62b (D-629) on the viability of PC12 cells were
tested. 24 h after plating the cells at 17,000 cells/well density in a 96-well plate,
increasing doses of the selected compounds were added resulting the final
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concentrations to be 0.1-50 µM. Control cells received 0.01% DMSO containing
medium instead. After 24 h of treatment, MTT assay was performed. Following
the addition of 5 mg/mL MTT solution (prepared in Dulbecco’s phosphatebuffered saline) to the cells to a final concentration of 0.5 mg/mL, the plates were
further incubated at 37 °C in 5% CO2 atmosphere for 3−4 h to produce dark-blue
formazan crystals. Then the plates were centrifuged for 10 min at 450 rpm, and
the supernatants were carefully removed. Formazan crystals were then dissolved
in MeOH:DMSO (1:1) mixture and shaken gently at 400 rpm for 30 min at room
temperature on a Thermomix R shaker (Eppendorf, Hamburg, Germany). The
absorbance (A) was measured at a dual wavelength of 570 nm and 690 nm on a
microplate reader (Biotek Epoch, Winooski, VT, USA) and adjusted with a
background correction (A570-A690). Cell viability was normalized and plotted as
percentage of background corrected values compared to untreated controls.
Assays were carried out in three independent experiments.
4.6.2. Neuroprotection against 6-OHDA-induced toxicity in PC12 cells
For assessing the neuroprotective effects of test compounds (−)-8a (D593), (−)-20 (D-618), (−)-14 (D-644), (−)-49 (D-670), 76 (D-614), and 62b (D-629)
on 6-OHDA mediated cell death, a quantitative colorimetric MTT assay was used.
PC12 cells were seeded at 17,000 cells/well density in a 96-well plate and
allowed to adhere for 24 h. Increasing concentrations of compounds were added
to the cells to make the final concentration to be 0.1-50 µM. Control cells and 6OHDA control cells received 0.01% DMSO containing medium. After 24 h of pre-
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treatment, the drug containing medium was removed. Cells were exposed to 75
µM 6-OHDA and control cells were treated with 0.01% DMSO containing medium
for additional 24 h. Afterward, MTT assay was performed as described previously.
Assays were carried out in three independent experiments.
4.6.3. Neuroprotection against rotenone-induced toxicity in PC12 cells
Compound 76 (D-614) was also tested in another neurotoxin induced
cytotoxicity model in PC12 cells. PC12 cells were seeded at 10,000 cells/well
density in a 96-well plate and allowed to adhere for 24 h. Increasing doses of
compound 76 (D-614) was pre-treated to the cells for 1 h to make the final
concentrations to be 1-50 µM. Then 1 µM of rotenone was cotreated to the cells
for another 24 h. Afterward, MTT assay was performed as described previously.
Assays were carried out in three independent experiments.
4.7.

Animal experiments

4.7.1. Drugs and chemicals
The following commercially available drugs were used in the experiment:
reserpine hydrochloride (Alfa Aesar) and ropinirole (Sigma-Aldrich). Reserpine
was dissolved in 10−25 μL of glacial acetic acid and further diluted with 5.5%
glucose solution. The hydrochloride salts of compound (−)-8a (D-593), (−)-20 (D618), 76 (D-614), and ropinirole were dissolved in DI water. The hydrobromic salt
of compounds (−)-49 (D-670) and D-520 were dissolved in 3% and 5% (2hydroxypropyl)-β-cyclodextrin, respectively, due to low solubility in DI water. All
compounds for this study were administered in a volume of 0.1−0.2 mL for
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subcutaneous administration and 0.5−0.7 mL for intraperitoneal administration
into each rat.
4.7.2. Animals
In rodent studies, animals were male Sprague−Dawley rats from Harlan
(Indianapolis, IN) weighing 220−225 g unless otherwise noted. Animals were
maintained in sawdust-lined cages in a temperature and humidity controlled
environment at 22 ± 1 °C and 60 ± 5%, respectively. A 12 h light/dark cycle was
also maintained, with lights on from 6:00 a.m. to 6:00 p.m. They were grouphoused with unrestricted access to food and water. All experiments were
performed during the light component. All animal use procedures were in
compliance with the Wayne State University Investigation Committee consistent
with AALAC guidelines.
4.7.3. Reversal of reserpine-induced hypolocomotion in rats
Administrating reserpine, the irreversible inhibitor of the vesicular
monoamine transporter (VMAT), blocks the internalization of monoamines into
vesicles and leads to the loss of storage capacity. Unprotected monoamines in
the cytosol undergo metabolism, resulting in the depletion of monoamines in the
synapse of the peripheral sympathetic nerve terminals, which induces catalepsy
in rodents (Fernandes et al. 2012, Duty and Jenner 2011, Leao et al. 2015). The
effects of compounds (−)-8a (D-593), (−)-20 (D-618), 76 (D-614) and (−)-49 (D670) in reversing reserpine-induced hypolocomotion were tested following a
reported procedure (McCall et al. 2005). Ropinirole was used as a reference
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D2/D3 agonist in this study. Reserpine (5.0 mg/kg, s.c.) was administered to
isoflurane-anaesthetized rats 18 h before the injection of drugs or vehicle. Prior
to administration of test compounds, reference drug or vehicle, the rats were
placed individually in the chambers for 1 h for acclimatization. Immediately after
administration of either drugs or vehicle, animals were individually placed in an
Opto-Varimex-4 animal activity monitor chamber (Columbus Instruments, Ohio,
USA), and locomotor activity was monitored for 6 h. Horizontal activity (HACTV)
was recorded as consecutive interruption of two infrared beams, situated 50 cm
apart and 4 cm above the cage floor in the monitor chamber. The effect of drugs
on locomotor activity was compared with respect to saline treated controls
(means ± SEM).
4.8.

Statistical analysis
Statistical analyses were performed using GraphPad Prism 6.0 (GraphPad

Software, San Diego, CA, USA). For all the in vitro assays, the data were
analyzed by one-way analysis of variance (ANOVA) analysis followed by Tukey’s
multiple comparison post hoc test unless otherwise specified. And for the in vivo
assays, one-way ANOVA analysis followed by Dunnett’s analysis was used. The
effect was considered significant if the difference from control group was
observed at p < 0.05.
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CHAPTER 5 CONCLUSION
The pathogenesis of Parkinson’s disease (PD) has been found to be
multifactorial, and its complexity suggests that multifunctional therapeutics could
be beneficial for its treatment. Therefore, it is hypothesized that the incorporation
of pharmacological properties targeting α-synuclein (αSN) aggregation and
monoamine oxidase-B (MAO-B) activity into the dopamine D2/D3 agonistic
components may confer disease-modifying as well as symptom-relieving effects.
The first main objective was to generate a series of novel dopamine D2/D3
receptor agonists that can potentially modulate αSN aggregation by incorporating
the dihydroxy or hydroxy-methoxy component to the D2/D3 agonist fragments via
various linkers based on the hybrid molecular template. In this current structureactivity relationship (SAR) study, the effects of linker length and stereochemistry
on D2/D3 receptors binding were first assessed: compounds with elongated fiveor six-carbon linkers were found to considerably enhance the binding affinity
towards both D2/D3 receptors. Overall, it has been found that variation of linker
lengths and the changes in the stereochemistry at the linker region may either
increase or decrease the binding affinity. Afterwards, the influence of terminal
dihydroxy or hydroxy-methoxy component on D2/D3 receptors affinity was also
analyzed: the dihydroxy substitutions generally gave enhanced binding profiles
comparing to their corresponding hydroxy-methoxy analogs. Then, the effect of
agonist binding head group was briefly examined. In consistent to the previous
findings, all the (−)-isomers tested displayed higher binding affinities for both
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D2/D3 receptors, in comparison to their racemic counterparts. Furthermore, the
bioisosteric replacement of the 2-aminothiazole head group in compound (−)-8a
(D-593) with aminotetralin moiety in compound (−)-14 (D-644) was found to
produce a greater enhancement in the D2/D3 receptor binding. Five compounds
(−)-7a (D-591), (−)-8a (D-593), (−)-8b (D-601), (−)-14 (D-644), and (−)-20 (D-618)
with desirable binding profiles were further selected to test for their agonist
activity through in vitro functional assay, and these compounds were found to be
comparably potent and full agonist at both D2 and D3 receptors.
In addition, compound (−)-49 (D-670), which is the para-dihydroxy analog
of the previous lead compound D-520, was tested and compared with its parent
compound. Although a reduction in binding affinities was found in the binding
assay, compound (−)-49 (D-670) demonstrated an improved potency in the
functional assay. Moreover, while the efficacy of (−)-49 (D-670) to the D2 receptor
maintained, the compound was found to exhibit enhanced potency at the D3
receptor.
Following the characterization of receptors activities, selected compounds
were studied for their ability to modulate αSN aggregation through in vitro
shaking and seeding studies. During the process of either shaking or seeding,
changes in both morphology and secondary protein structure of αSN were
observed through transmission electron microscope (TEM) and circular dichroism
(CD) spectra, and the increased fibrilization and cytotoxicity of αSN were
observed through thioflavin T (ThT) assay and cell viability assay. In the shaking
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assay, test compound (−)-8a (D-593) was found to inhibit the fibrilization;
however, its ability to reverse αSN induced toxicity was not significant. In the
seeding assays, compounds (−)-8a (D-593), (−)-20 (D-618), and (−)-14 (D-644)
were able to inhibit the αSN aggregation and reversed αSN induced cytotoxicity
to various extents; the compounds (−)-14 (D-644) and (−)-8a (D-593) were found
to be more prominent. In addition, compound (−)-49 (D-670) displayed an antiaggregation activity comparable to its parent compound D-520 in the context of
fibrilization and cytotoxicity.
Furthermore, compounds (−)-8a (D-593), (−)-20 (D-618), (−)-14 (D-644),
and (−)-49 (D-670) were evaluated for their neuroprotective effect against the 6OHDA induced toxicity in PC12 cells. All the test compounds were able to
reverse the cytotoxicity induced by 6-OHDA. Thereafter, compounds (−)-8a (D593), (−)-20 (D-618), and (−)-49 (D-670) were selected for in vivo animal study.
The

compound

(−)-8a

(D-593)

was

found

to

effectively

reverse

the

hypolocomotion induced by reserpine treatment, whereas the compound (−)-20
(D-618) displayed only a slight effect. In contrast, compound (−)-49 (D-670) failed
to reverse the reserpine-induced akinesia. Thus, compounds (−)-8a (D-593) and
(−)-14 (D-644), which are promising D2/D3 agonists with neuroprotective activity,
were identified as the lead compounds in this SAR study and may have the
potential to provide symptom-relieving and disease-modifying effect for the
treatment of PD.

155

This work has provided a systematic evaluation on the effect of alkyl
linkers and hydroxyphenol or methoxyphenol components on dopamine D2/D3
receptor activities, which can guide in the design of future multifunctional D2/D3
agonist. In addition, through a line of biological assays, lead compounds were
successfully identified, which require further mechanistic study to investigate the
modulatory effect of compounds on αSN aggregation. Techniques such as size
exclusion high-performance liquid chromatograph (SEC-HPLC) in combination
with mass spectrometry could be applied to study the mode of interaction
between αSN protein and compounds.
The second main objective was to design and synthesize a series of novel
dopamine D2/D3 receptor agonists that may potentially selectively inhibit MAO-B
activity by replacing the propyl group with the propargyl group. In this SAR study,
the synthesized compounds were first compared in regards to their binding
activity towards D2/D3 receptors with their propyl parent compounds. A general
reduction in D2/D3 binding affinity was observed with most of the compounds
except for (−)-62c (D-676) and (−)-73 (D-635). In the case of functional activities,
while propargyl compounds generally became partial D2 agonists with reduced
potency due to the propargyl replacement, they remained full agonists at D3
receptor with reduced potency. However, (−)-73 (D-635) retained nearly full D2
agonistic activity and exerted a slight improvement in the potency at the D3
receptor. Moreover, a pentynyl analog (−)-62e (D-664) was also included in this
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SAR study. This replacement deprived the agonistic activity at both D2 and D3
receptors despite the its binding affinity at the receptors.
When tested in the in vitro enzymatic assays, compounds (−)-62b (D-629),
(−)-63 (D-649), and (−)-76 (D-614) were shown to be the most active compounds
and reduced the MAO-B activity by approximately half in the assay conditions.
This assay also revealed that substitutions on the phenyl ring in the accessory
binding site moiety may play a role in altering the MAO inhibitory effect. The
determination of IC50 values suggested that while compound (−)-62b (D-629) is
slightly selective for MAO-B, compound (−)-76 (D-614) is non-selective towards
both MAO isoforms.
Afterwards, compounds (−)-76 (D-614) and (−)-62b (D-629) were
evaluated for their neuroprotective ability in PC12 cells. In contrast to compound
(−)-62b (D-629), which failed in the 6-OHDA model, compound (−)-76 (D-614)
exerted a dose-dependent neuroprotective effect. However, this effect was not
replicated in the rotenone neuroprotection model.
Finally, compound (−)-76 (D-614) was tested in the PD animal model, and
it effectively reversed reserpine-induced hypolocomotion in rat. Thus, compound
(−)-76 (D-614), a promising D2/D3 agonist that exerted neuroprotective and MAOB inhibitory activity, was identified as the lead compound from this SAR study.
This initial SAR study explored the potential of incorporating additional
MAO-B inhibitory effect into D2/D3 agonist molecules via the replacement of the
propyl group by a propargyl group in the headgroup moiety. A relatively low
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compatibility of the structural preference and conformational requirements for
D2/D3 agonistic activity and MAO-B inhibitory activity has been observed in the
current molecular template. Thus, an expanded SAR study with further structural
modifications in the hybrid template is required to improve the receptor activities
and enzyme inhibition profile. Molecular modeling could also be applied to assist
with the drug design and compound screening. In addition, a mechanistic study
could be carried out to further characterize the identified MAO-B inhibitors.
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ABSTRACT
APPROACH TOWARDS THE DEVELOPMENT OF NOVEL DISEASE
MODIFYING THERAPEUTICS FOR PARKINSON'S DISEASE
by
DAN LUO
August 2017
Advisor: Dr. Aloke Dutta
Major: Pharmaceutical Sciences
Degree: Doctor of Philosophy
Parkinson’s disease (PD) is an age-related neurodegenerative disease,
which is characterized by the progressive loss of dopaminergic neurons in the
substantia nigra pars compacta (SNpc) and the presence of intraneuronal
proteinaceous deposits named Lewy bodies (LBs) or Lewy neurites (LNs). A
broad spectrum of motor and non-motor symptoms has been observed in PD,
with bradykinesia, resting tremor, rigidity, and postural instability as its key
clinical features. Although the etiology of PD is still not well-understood, multiple
pathological factors including oxidative stress, mitochondrial dysfunction, αsynuclein (αSN) protein aggregation, as well as genetic and environmental
aspects are strongly implicated in the disease progression. The present
treatments available for PD generally fall into four major categories, namely
levodopa/carbidopa, monoamine oxidase B (MAO-B) inhibitors, catechol-Omethyl transferase (COMT) inhibitors, and dopamine agonists. However, these
current clinical treatments are only able to provide symptomatic relief and fail to
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delay the disease progression. Furthermore, the long-term use of levodopa leads
to motor complications including the development of dyskinesia. Thus, there is
still a great unmet need for effective treatment of PD which should involve
disease modification. Due to the complexity observed in the disease
pathogenesis, treatments that incorporates the pathogenic factors involved in PD
might offer an advantage in combating the disease by modifying the disease
progression. The hypothesis of this project is that the incorporation of dopamine
D2/D3 agonistic binding component to accessory moieties targeting either αSN
aggregation or MAO-B enzyme may lead to multifunctional drugs with a potential
to provide both symptom-relieving and disease-modifying effects as a promising
approach for new generation PD treatment.
In this dissertation, two library of compounds have been developed based
on the previously established hybrid structure approach, and the initial structureactivity relationship (SAR) study has been perused to identify possible lead
compounds through in vitro and in vivo evaluations. The first main objective is to
design and develop a series of novel dopamine D2/D3 receptor agonists that can
potentially modulate α-synuclein (αSN) aggregation by combining the dihydroxy
or hydroxy-methoxy component with D2/D3 agonist fragment through various
linkers according to the hybrid molecular template. Based on the results of in
vitro receptor assays, compounds (−)-8a (D-593), (−)-20 (D-618), (−)-14 (D-644),
and (−)-49 (D-670) were selected and further evaluated to determine their
potential αSN aggregation modulatory properties and neuroprotective effect.
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Subsequently, compound (−)-8a (D-593) was identified as a lead compound by
using a well-established Parkinson’s disease (PD) animal model. The second
main objective is to design and synthesize a series of novel dopamine D2/D3
receptor agonists that may potentially inhibit monoamine oxidase B (MAO-B)
activity by introducing the propargyl group into the hybrid molecular template. An
initial SAR study was conducted based on the generated compound library
through in vitro receptor assays and enzymatic studies which led to the
identification of compounds (−)-62b (D-629) and (−)-76 (D-614) as potential
candidates. Moreover, in vitro neuroprotection models and a PD animal model
were used to further evaluate them, and (−)-76 (D-614) was identified as the lead
compound that requires further modification.
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